

Therapeutic drug monitoring of tacrolimus-personalized therapy: Second consensus report

Mercè Brunet, PharmD, PhD¹; Teun van Gelder, MD, PhD²; Anders Åsberg, PhD³; Vincent Haufroid, PharmD, PhD⁴; Dennis A. Hesselink, MD, PhD⁵; Loralie Langman, PhD⁶; Florian Lemaitre, PharmD, PhD⁷; Pierre Marquet, MD, PhD⁸; Christoph Seger, PhD⁹; Maria Shipkova, MD¹⁰; Alexander Vinks, PharmD, PhD¹¹; Pierre Wallemacq, PharmD, PhD¹²; Eberhard Wieland, MD¹⁰; Jean Baptiste Woillard, PharmD, PhD¹³; Markus J. Barten, MD¹⁴; Klemens Budde, MD, PhD¹⁵; Helena Colom, PharmD, PhD¹⁶; Maja-Theresa Dieterlen, MD¹⁷; Laure Elens, PhD¹⁸; Kamisha- L. Johnson-Davis, PhD¹⁹; Paweł K. Kunicki, PhD²⁰; Iain MacPhee, MD²¹; Satoshiro Masuda, PhD²²; Binu S Mathew, MD²³; Olga Millán, PhD¹; Tomoyuki Mizuno, MD¹¹; Dirk -Jan A.R. Moes, PharmD, PhD²⁴; Caroline Monchaud, PharmD, PhD¹³; Ofelia Noceti, PharmD, PhD²⁵; Tomasz Pawinski, PhD²⁶; Nicolas Picard, PharmD, PhD¹³; Ron van Schaik, MD²⁷; Claudia Sommerer, MD²⁸; Nils Tore Vetthe, PhD²⁹; Brenda de Winter, PharmD, PhD³⁰; Uwe Christians MD, PhD³¹; Stein Bergan PhD²⁹.

¹Pharmacology and Toxicology Laboratory. Biochemistry and Molecular Genetics Department. Biomedical Diagnostic Center, Hospital Clinic of Barcelona. University of Barcelona. IDIBAPS, CIBERehd. Spain.

²Department of Internal Medicine and Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.

³Department of Transplantation Medicine, Section of Nephrology, Oslo University Hospital-Rikshospitalet, Oslo, Norway.

⁴Louvain center for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Department of Clinical Chemistry, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

⁵Department of Internal Medicine, Division of Nephrology and Transplantation. Erasmus MC, University Medical Center Rotterdam. Rotterdam, the Netherlands.

⁶Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

⁷Rennes University Hospital & INSERM, Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmacoepidemiology and Drug Information Center & Clinical Investigation Center CIC-P 1414, Rennes, France.

⁸INSERM, Univ. Limoges, CHU Limoges, IPPRITT, U1248, F-87000 Limoges, France.

⁹Division of Mass Spectrometry and Chromatography, Institute of Medical and Chemical Laboratory Diagnostics (ZIMCL), University Hospital Innsbruck, Innsbruck, Austria.

¹⁰SYNLAB Holding Germany GmbH, Competence Center for Therapeutic Drug Monitoring, MVZ Leinfelden-Echterdingen GmbH. Germany.

¹¹Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

¹²Clinical Chemistry Department, Cliniques Universitaires Saint-Luc. Center for Toxicology and Applied Pharmacology, Université Catholique de Louvain, Brussels, Belgium

¹³Department of Pharmacology and Toxicology, CHU Limoges, F-87000, Limoges, France.

¹⁴University Heart Center Hamburg, Department of Cardiovascular Surgery, Hamburg Germany.

¹⁵Department of Nephrology and Medical Intensive Care Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin.

¹⁶Pharmacy and Pharmaceutical Technology and Physical- Chemistry Department. University of Barcelona, Spain.

¹⁷Department for Cardiac Surgery, Heart Center Leipzig, University of Leipzig, Leipzig, Germany.

¹⁸Louvain Drug Research Institute, Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics, Université catholique de Louvain, Brussels, Belgium.

¹⁹Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT.

²⁰Clinical Pharmacology Unit, Department of Medical Biology, Institute of Cardiology, Warsaw, Poland; AND Department of Drug Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.

²¹St George's Hospital, Blackshaw Rd, London SW17 0QT, UK.

²²Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan. Dr. Fukudo is now with the Department of Pharmacy and Pharmacology, Asahikawa Medical University, Japan. Dr. Masuda is now with the Department of Pharmacy, Kyushu University Hospital, Japan.

²³Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, Tamil Nadu, India.

²⁴Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

²⁵National Center for Liver Transplantation and Liver Diseases, Uruguay.

²⁶Department of Drug Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland.

²⁷Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.

²⁸Department of Nephrology, University of Heidelberg, Im Neuenheimer Feld 162, 69120, Heidelberg, Germany.

²⁹Department of Pharmacology, Oslo University Hospital, Oslo, Norway.

³⁰Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam.

³¹iC42 Clinical Research and Development, Department of Anesthesiology, University of Colorado
Denver Anschutz Medical Campus, Aurora, Colorado, USA.

Corresponding Author

Mercè Brunet, PharmD, PhD

Pharmacology and Toxicology Laboratory. Biochemistry and Molecular Genetics Department.

Biomedical Diagnostic Center, Hospital Clinic of Barcelona.

University of Barcelona, Villarroel 170, 08036 Barcelona, Spain

Email: mbrunet@clinic.cat

Disclosure: The authors report no conflicts of interest related to this work.

Abstract

Ten years ago, a consensus report on the optimization of tacrolimus was published in this journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicity (IATDMCT) decided to issue an updated consensus report considering the most relevant advances in tacrolimus pharmacokinetics, pharmacogenetics, pharmacodynamics and immunologic biomarkers, with the aim to provide analytical and drug-exposure recommendations to assist TDM professionals and clinicians to individualize tacrolimus TDM and treatment.

The Consensus is based on in-depth literature searches regarding each topic that is addressed in this document. Thirty-seven international experts in the field of TDM of tacrolimus as well as its pharmacogenetics and biomarkers contributed to the drafting of sections most relevant for their expertise. Whenever applicable, the quality of evidence as well as the strength of recommendations was graded according to a published grading guide. Following iterated editing, the final version of the complete document was approved by all authors.

For each category of solid organ and stem cell transplantation, the current state of pharmacokinetic monitoring is discussed and the specific targets of tacrolimus trough concentrations (pre-dose sample C_0) are presented for subgroups of patients along with the grading of these recommendations. In addition, tacrolimus AUC determination is proposed as the best TDM option early after transplantation, at the time of immunosuppression minimization, for special populations, and specific clinical situations. For indications other than transplantation, the potentially effective tacrolimus concentrations in systemic treatment are discussed without formal grading.

The importance of consistency, calibration, proficiency testing and the requirement for standardization and need for traceability and reference materials is highlighted. The status for alternative approaches for tacrolimus TDM is presented including dried blood spots (DBS), volumetric absorptive micro-sampling (VAMS) and the development of intracellular measurements of tacrolimus.

The association between *CYP3A5* genotype and tacrolimus dose requirement is consistent (Grading^{1,2} A I). So far, pharmacodynamic and immunologic biomarkers have not entered routine monitoring, but determination of residual NFAT-regulated gene expression supports the identification of renal transplant recipients at risk of rejection, infections and malignancy (B II).

In addition, monitoring intracellular T-cell IFN- γ production can help to identify kidney and liver transplant recipients at high risk of acute rejection (B II) and select good candidates for immunosuppression minimization (B II). Although cell-free DNA seems a promising biomarker of acute donor injury and to assess the minimally effective C_0 of tacrolimus, multicenter prospective interventional studies are required to better evaluate its clinical utility in solid organ transplantation.

Population pharmacokinetics (PopPK) models including *CYP3A5* and *CYP3A4* genotypes will be considered to guide initial tacrolimus dosing. Future studies should investigate the clinical benefit of time-to-event models to better evaluate biomarkers as predictive of personal response, the risk of rejection and graft outcome.

The Expert Committee concludes that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade. Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized pharmacokinetic approaches with pharmacogenetics, and valid biomarkers to further personalize tacrolimus therapy and to improve long-term outcomes for treated patients.

Keywords: Tacrolimus-personalized therapy, pharmacokinetics, biomarkers, pharmacogenetics, pharmacodynamics, Consensus, immunologic biomarkers, graft outcome, graft injury, tacrolimus target concentrations, methods standardization, new approaches in tacrolimus TDM, PopPK/PG modeling.

EXECUTIVE SUMMARY

This executive summary is an overview of the Consensus Report on TDM of Tacrolimus-personalized therapy that synthesizes the key points and the grading of recommendations regarding: tacrolimus exposure in different types of solid organ transplantation (SOT) and other indications; the influence of pharmacogenetic variables and pharmacodynamic biomarkers in achieving drug specific target concentrations, as well as the role of PK/PG and PK/PD models in personal drug adjustment.

The new recommendations and knowledge regarding the previous consensus report in 2009 are highlighted. During the last decade, there have been many changes regarding the clinical management and TDM of tacrolimus. The goal of these changes was to minimize the adverse effects, mainly nephrotoxicity, and improve its effectiveness. Several studies have evaluated new target concentrations for tacrolimus significantly lower than those of the previous decade. In addition, these therapeutic ranges for tacrolimus have been refined based on post-transplant time, concomitant immunosuppressive medication and according to immunological risk.

With the changes in tacrolimus monitoring, there is a requirement for highly standardized, specific, sensitive and robust methods that allow precise tacrolimus monitoring, even at low concentration ranges (2-4 ng/mL). In addition, during this last decade, we have developed a new approach from a pharmacological perspective of monitoring therapeutic drugs that includes not only the pharmacokinetics but also some pharmacogenetic and pharmacodynamic variables, since this combination can provide a more personalized treatment. Efforts have been made to evaluate the influence of genetic polymorphisms on the initial dosing of tacrolimus and the subsequent clinical effects such as the incidence of rejections in various populations in SOT. Considering that similar concentrations of tacrolimus may produce different degrees of

immunosuppression in treated patients, several groups have focused on evaluating the clinical usefulness of pharmacodynamic and immunological biomarkers predictive of the risk of graft rejection and clinical outcome.

Pharmacokinetic Monitoring

Drug exposure and within-patient variability of tacrolimus concentrations as a biomarker for therapeutic drug monitoring

Previous studies in SOT have shown a relationship between tacrolimus exposure and the risk of acute rejection and drug-related adverse events. The AUC is considered the pharmacokinetic exposure parameter best associated with clinical effects. Unfortunately, no prospective studies of clinical outcomes have been conducted in adult and pediatric transplant recipients to investigate properly the potential benefits of AUC₀₋₁₂ monitoring compared to C₀ guided therapy. However, C₀ is used in most transplant centers for routine TDM of tacrolimus. The monitoring of tacrolimus-AUC has been proposed especially in the early period post-transplantation, from time to time to check the overall exposure, and when clinically indicated. Furthermore, the rather poor correlation between C₀ and AUC translates into very variable AUC/C₀ ratios, which means that patients with identical C₀ may have very different AUC_{0-12h}. Therefore, the authors suggest evaluating this ratio at least once in the early period and once in the stable period, for each transplant recipient.

Recent reports indicate that the within-patient variability of tacrolimus concentrations could be a useful tool for optimizing the immunosuppressive therapy in SOT. Most of the time, the within-patient variability is simply evaluated using the coefficient of variation (CV) of trough

concentrations (C_0). The hypothesis is that significant variability of tacrolimus concentrations may lead alternatively to underexposure and overexposure periods resulting in immune activations with sub-clinical rejections accumulation favoring organ lesions and drug toxicity associated with adverse events and organ damages. Furthermore, the intra-patient variability may identify patients with low adherence and patients with particular pharmacokinetic profiles. To date, none of the different tacrolimus formulations (immediate release, prolonged or extended release) has been clearly reported to decrease pharmacokinetic variability of the drug when compared to the other.

In this Consensus Report, it is explained for the first time that the intra-patient variability must be evaluated; likewise, the monitoring of the C_0 / AUC ratio is proposed, to identify those patients that are good candidates to analyze AUC-Tac instead of C_0 .

Recommended tacrolimus target concentration ranges in solid organ transplantation.

Executive summary on tacrolimus exposure recommendations

In kidney Transplant recipients:

1. In immunological low-risk patients, tacrolimus may be targeted to: a C_0 of 4-12 ng/mL (and preferably to $C_0 > 7$ ng/mL) when prescribed in combination with IL-2 receptor (IL-2R) blocker induction therapy, mycophenolate and glucocorticoids (A I); or a C_0 of 4-7 (month 0-2) and 2-4 (> month 2) ng/mL when combined with everolimus and glucocorticoids and induction therapy (either Thymoglobuline or IL-2R blockers) (B II).
2. Tacrolimus C_0 targets may be higher in adult patients at higher immunological risks. (B II).

3. Although only supported by clinical experience, a C_0 target range of 10-20 ng/mL may be proposed for pediatric patients (C1 II).

4. A minimal AUC_{0-12h} threshold of 150 ng.h/mL may be proposed for the twice daily formulation in adults (B II). AUC targets corresponding to different C_0 ranges were derived from AUC- C_0 correlation studies in large adult patient populations, for the twice daily and once-daily (Advagraf) formulations.

In liver transplant recipients:

Adults:

1. When prescribed in combination with mycophenolate or everolimus and corticosteroids, tacrolimus may be targeted to a C_0 of 6–10 ng/mL during the first 4 weeks post-transplantation and 5–8 ng/mL thereafter (A I).

2. Tacrolimus as a monotherapy, or when only associated with induction treatment, may require a higher C_0 target (10-15 ng/mL during the first 3 months after transplantation and 5-10 ng/mL afterwards) (C1 II).

3. A tacrolimus C_0 of 10-15 ng/mL may also be aimed for in patients on a corticosteroid-free regimen (even beyond the 4th month after surgery) (C1 II).

For pediatric patients, there is not enough clinical evidence to make recommendations.

In heart and lung transplantation:

The C_0 ranges recommended almost 20 years ago must be revised (and probably lowered), as they encompassed values between 15 and 20 ng/mL in the first weeks post-transplantation, whereas recent studies have shown that the risk of acute kidney injury within the first two weeks post-transplantation was significantly increased for $C_0 > 15$ ng/mL (B II).

In bone marrow transplantation:

A C_0 of 10–20 ng/mL may be targeted when tacrolimus is prescribed orally in combination with methotrexate, in adults (B II) as well as in children (B II).

For the use of tacrolimus on other indications, there is not strong enough evidence to make recommendations (C2).

MEASUREMENT OF TACROLIMUS CONCENTRATIONS

This Consensus Report encompasses the advances made in the field of the analysis of tacrolimus concentrations, with a critical discussion of pros and cons for each method, including new monitoring strategies such as dried blood spots (DBS) and intracellular tacrolimus concentrations. Stability of tacrolimus has been investigated using both patient blood samples and spiked whole-blood samples. The stability of tacrolimus concentrations was proven for samples stored up to 14 days at 22°C or 4°C, as well as at least 1 month at -20°C and 1 year at -70°C.

The use of commercial whole blood-based tacrolimus calibrators is recommended to ensure accurate measurements and to support the harmonization of results between laboratories.

Analytical methods to determine tacrolimus in whole blood

Analysis of tacrolimus in whole blood is performed either by immunoassays or by liquid chromatography-tandem mass spectrometry (LC-MS/MS), with both techniques being represented in nearly equal proportions at measurement service providers worldwide.

Chromatographic methods

The majority of the LC-MS/MS assays (~75%) were multianalyte methods that allowed for the simultaneous quantification of tacrolimus and other immunosuppressive drugs within one analytical batch using whole blood samples.

High analytical selectivity and sensitivity, and the possibility for high throughput multianalyte assays are important benefits of LC-MS/MS. Thus, this technique has met the evolving clinical requirements for fast, accurate, and precise tacrolimus assays performing well at low concentrations. Nevertheless, skilled laboratory management and trained staff are necessary to establish and operate LC-MS/MS assays for routine TDM.

Sample preparation: Tacrolimus is measured in whole blood. Protein precipitation, solid-phase extraction (SPE), and liquid-liquid extraction (LLE) have been reported as sample preparation strategies prior to chromatography in LC-MS/MS assays including tacrolimus. Precipitation of whole blood samples can be performed by either a stepwise or simultaneous addition of zinc sulfate solution and organic solvent.

Chromatography: Chromatographic separation is commonly based on C18 (or C8) stationary phases combined with mobile phases of water and methanol to which an acidified ammonium buffer is added. The mobile phase constituents should be of LC-MS quality.

Mass-spectrometry: The majority of tacrolimus LC-MS/MS assays apply electrospray ionization (ESI) as the interface to get the sample compounds ionized and into gas phase. The conditions for spraying, evaporation, ionization, and acceleration of tacrolimus ions into the mass-spectrometer have to be optimized with respect to the specific instrument type. Several of the ion source parameters are global in a multianalyte assay and, consequently, optimization of these parameters may have to be prioritized for compounds yielding the lowest instrument response at the lower limit of quantification (LLOQ) (usually sirolimus and everolimus when included in a multianalyte assay for immunosuppressive drugs).

Immunoassays

First generation assays have been replaced by improved tests. Currently a choice of immunoassays is available (EMIT, ECLIA, others) and the Chemiluminescent Microparticle Immunoassay (CMIA) has rapidly become a leader of immunoassay methodology for tacrolimus due to low *bias* vs. chromatography, imprecision even better than LC-MS/MS and close agreement of results for clinical samples in proficiency tests.

Evaluation of the CMIA tacrolimus assay showed no interference with hematocrit, bilirubin or total protein, but cross-reactivity yielding 94% with 31-O-desmethyl (M-II) and 45% with 15-O-desmethyl (M-III) tacrolimus metabolites. The cross-reactivity with 13-O-desmethyl (M-I) and 12-hydroxy (M-IV) tacrolimus metabolites was negligible.

NEW MONITORING STRATEGIES

Microsample based tacrolimus concentration monitoring

The use of DBS on filter cards and other microsampling are innovative, minimal-invasive sample methods, which can replace traditional blood sampling for TDM of tacrolimus. This approach is patient-friendly and can be implemented at home by the patient themselves, collecting very small amounts of blood (typically 10-20 μ L). The procedure is both cost and time saving, and it also allows for multiple sampling within a dose interval, simplifying the determination of AUC.

Current challenges in microsample implementation include: extraction recovery, the hematocrit effect, correlation between venous and capillary blood measurements, the quality of the blood spot, risk of contamination, and sample stability.

New generation micro-sampling such as volumetric absorptive micro-sampling (VAMS) can possibly mitigate some of the usual bias encountered with these methods, particularly the hematocrit effect.

Intracellular and tissue tacrolimus concentration monitoring

Determining tacrolimus drug concentrations where it exerts its immunosuppressive effect might be particularly relevant to achieve personalized therapy. Several groups have contributed to the development of analytical methods to measure tacrolimus concentrations in peripheral blood mononuclear cells (PBMC) of kidney, liver and heart transplant recipients. The large variability reported in these studies highlighted the critical importance of pre-analytical and analytical steps for intracellular concentration assays. Most analytical methods employed liquid chromatography with tandem mass-spectrometric detection, but there are several analytical issues that have not

yet been fully addressed. These methods must be appropriately standardized, harmonized, and validated following international guidelines.

PHARMACOGENETICS

The association between *CYP3A5* genotype and tacrolimus dose requirement is consistent and has been observed among kidney, liver, heart and lung transplant recipients, both adult and pediatric. Although genotyping has proven effective in predicting the starting dose of tacrolimus, this has not influenced outcome of transplanted patients, provided appropriate use of TDM. As the clinical benefit of popPK models is being investigated, the value of including *CYP3A* genotypes and potentially other genetic markers in such models may be re-evaluated.

Executive summary and practical recommendations

1. Patients expressing *CYP3A5* require approximately 50% higher tacrolimus dose to reach the target therapeutic range compared with non-expressors (A I).

Although there is evidence from a randomized-controlled clinical trial that basing the tacrolimus starting dose on the *CYP3A5* genotype may facilitate tacrolimus dosing, this has not been a universal finding and there is currently no convincing clinical evidence that a pharmacogenetics-based approach to tacrolimus dosing improves clinical outcomes after solid organ transplantation.

2. Of the many other candidate single nucleotide polymorphisms that have been studied, *CYP3A4*22* appears to be the most promising as it explains residual variability in tacrolimus pharmacokinetics (B II, and C2 II, for Caucasians, Asiatic and African origin populations).

PHARMACODYNAMIC BIOMARKERS FOR TACROLIMUS MONITORING

Drug specific pharmacodynamic biomarkers

Calcineurin phosphatase (CaN) activity

The activity of CaN is determined in PBMC which requires cell isolation before the assay can be performed. An inverse relationship between CaN activity in PBMC and CNI concentrations in whole blood has been observed in patients after liver and kidney transplantation. Results from *in vitro* experiments indicate that, in contrast to cyclosporine, tacrolimus had a relatively high EC₅₀, above the upper limit of the therapeutic range (20 ng/mL). This questions the relevance of CaN activity as a pharmacodynamic marker for tacrolimus' immunosuppressive effects.

NFAT regulated gene expression

The quantitative analysis of IL-2, IFN- γ and GM-CSF gene expression in whole blood is established to quantify the inhibition of the transcription of NFAT-regulated genes, based on samples collected at tacrolimus C₀ and peak concentrations (1.5 hour post-dose) after oral administration of tacrolimus.

NFAT-regulated gene expression has been performed in solid organ transplantation such as kidney (adults and children), liver, heart, and lung transplant recipients, showing that monitoring the residual NFAT-regulated gene expression could identify allograft recipients at higher risk of infections or acute rejection.

The real-time polymerase chain reaction (RT-PCR) technique provides a highly reproducible, and sensitive tool and can be set up with satisfactory analytical performance in a routine molecular biological laboratory to be used in larger patient cohorts and in multicenter clinical studies. NFAT-regulated gene expression has the potential to develop into a monitoring tool complementing pharmacokinetics, especially in long-term renal allograft recipients.

Drug non-specific pharmacodynamic biomarkers

Intracellular cytokines

Several studies have focused on the utility of intracellular expression of IL-2 and IFN γ as prognostic biomarkers for the risk of acute rejection, as diagnostic biomarkers at the time of rejection and as markers reflecting the efficacy and the safety of tacrolimus. Flow cytometry and the enzyme-linked immunosorbent spot (ELISPOT) are the two mainly used methodologies. An ongoing randomized multicenter European study (Biodrim; Health F2-2012-305147) is currently evaluating the ELISPOT assay during tacrolimus minimization therapy in order to stratify renal transplant patients into low and high responders. In stable liver transplant recipients IFN- γ expressing CD4⁺ and CD8⁺ T-cells has been identified as surrogate markers for the risk of rejection after withdrawal of long-term immunosuppressive treatment.

For the validation of these biomarkers as early predictive biomarkers of the risk of rejection and graft clinical outcome it is crucial to improve some methodological aspects and harmonize these functional assays.

Donor-specific anti-HLA antibodies

Today, donor-specific anti-HLA antibodies (DSA) and the subsequent development of ABMR are considered to be leading causes for graft loss. The development of standardized highly sensitive solid-phase assays for detecting anti-HLA antibodies has significantly improved the clinical utility. In kidney and heart transplantation, DSA is a biomarker of under-immunosuppression, which may be caused by non-adherence but may also occur in both CNIfree and CNIfree minimization clinical protocols. Most physicians agree that tacrolimus (with levels > 5ng/ml) is the CNIfree of choice in case of dnDSA, although no data from prospective controlled multicenter studies are available.

Graft-derived cell-free DNA

Quantification of donor-derived cell-free DNA (dd-cfDNA) in recipient blood or urine has been evaluated as a potential surrogate biomarker of acute injury in the donor organ but lacks the specificity to distinguish between acute rejection and BK virus nephropathy injury. Plasma levels of dd-cfDNA have been correlated with allograft rejection and outcome in renal transplant recipients. In liver transplant recipients it has been demonstrated that Graft-derived cell-free DNA (GcfDNA or d-cfDNA) quantification could be used to assess the minimally effective trough concentrations of tacrolimus.

Although dcfDNA seems to be a promising biomarker for monitoring graft health after transplantation, multicenter, prospective, observational and interventional studies will be required to better define how it can be used and evaluate its clinical utility before considering it a valid biomarker in solid organ transplantation.

Executive summary and practical recommendations

1. Determination of residual NFAT-regulated gene expression supports the identification of renal transplant recipients at higher risk of acute rejection, opportunistic infections, malignancy, and cardiovascular risk (B II).
2. Monitoring residual NFAT-regulated gene expression complements CNI pharmacokinetics as an adjunct to guiding CNI therapy (B III).
3. Monitoring intracellular T-cell IFN- γ production (particularly by the enzyme-linked immune-spot, ELISPOT, assay) before and early after transplantation can help to identify kidney and liver transplant recipients at high risk of acute rejection (B II) and select good candidates for immunosuppression minimization (B II).

Pharmacodynamic monitoring of tacrolimus therapy has not entered routine monitoring yet. To advance in the process of validation of pharmacodynamic and immunologic biomarkers it is crucial to improve and standardize methods. The clinical implementation of these biomarkers as a complement to tacrolimus-TDM may have impact on patient and graft care.

PK/PGx/PD modeling

Executive summary and practical recommendations

1. The utilization of popPK model based Bayesian estimators has shown improved target achievement compared to standard TDM. While trough concentration is used in most transplant centers for TDM of tacrolimus there is some evidence that C_0 correlates poorly with AUC_{0-12} .
2. The use of popPK model derived Bayesian estimators based on limited sampling strategies however provides AUC predictions with bias <5% and an imprecision <20%. This seems to be an applicable way to improve future tacrolimus TDM as compared to continue with standard trough concentration based TDM, especially when considering home sampling with micro sampling devices that currently are under validation (as presented above).
3. The authors recommend the integration of *CYP3A5**3 and *CYP3A4**22 genotype information, when available, in future tacrolimus popPK models, primarily for the opportunity to optimize initial dosing.
4. More pharmacokinetic-pharmacodynamic and PB/PK modeling activities are required to enhance the understanding of factors influencing clinical outcomes in transplantation.

INTRODUCTION

Tacrolimus is among the most frequently used immunosuppressive drug in solid organ transplantation. Building on three decades of experience and a large number of clinical trials, we have arrived at the current principles for the optimal use of this drug.³⁻⁶ These include personalization of the dosing by frequent measurements of whole blood concentrations, in order to apply target concentration ranges which have gradually been set at lower levels, based on the

results from multicenter trials that investigated various combinations of immunosuppressants.⁷⁻⁹

Although these immunosuppressive protocols have reduced the first-year incidence of biopsy proven acute rejections (BPAR) in renal and liver transplant recipients to respectively 15% and 25% or lower, there is still room for improvement. Importantly, there is a range of adverse events which affect the quality of life and life expectancy of transplant patients who need lifelong immunosuppression. At the same time, we are faced with large numbers of patients who lost their grafts due to antibody-mediated rejections, most likely due to under-immunosuppression. Therefore, the search for methods that may reflect personal drug response, to further optimize and personalize tacrolimus dosing to obtain the lowest possible individual exposure, is still warranted.

In September 2017, the Immunosuppressive Drugs Scientific Committee (ISDs SC) of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) decided to prepare an updated Consensus Report and to discuss the most recent advances in therapeutic drug monitoring (TDM) of tacrolimus-personalized therapy. The aim was to improve the standards of practice, and to highlight the potential of new methods and principles that may provide individualized therapy and improve patient care.

Ten years ago a consensus report on the optimization of tacrolimus was presented in this journal.¹⁰ This report pointed to the rather poor correlation between tacrolimus trough concentrations and outcome, especially with acute rejection, and recommended area under the concentration-time curve (AUC) measurements for more precise monitoring. Furthermore, due to a high degree of pharmacokinetic and pharmacodynamic between-patient variability, the use of pharmacogenetic and immunologic biomarkers should be considered and properly evaluated in prospective, multicenter clinical trials. To support pharmacokinetic dose individualization,

limited-sampling strategies have been introduced, accompanied by population pharmacokinetic models or calculations using Bayesian forecasting.^{11, 12} In the meantime, the use of mass-spectrometry in assays to measure tacrolimus has taken over in routine clinical monitoring in many centers. This has led to a modification of practice for efficient processing of large numbers of samples¹³ whereas some problems related to analytical specificity have also been eliminated.¹⁴ Furthermore, new assays have provided opportunities for measurement in other matrices, such as peripheral blood mononuclear cells and dried blood spots. It should be noted that to improve the prediction efficacy of monitoring, pharmacodynamic and specific immunological biomarkers strongly associated with the mechanism of action of tacrolimus have been assessed in several clinical trials.¹⁵

In this new document, the Expert Committee, consisting of thirty-seven international experts in the fields of TDM of tacrolimus and its pharmacogenetics and biomarkers, present a broad consensus on the current recommendations to achieve optimal personalization of tacrolimus therapy. The consensus is based on in-depth literature research and detailed Expert Committee discussions about pharmacology, pharmacokinetic monitoring (for once daily and twice daily formulations), analytical methods, standardization and new TDM approaches. Calcineurin (CaN) phosphatase activity measurement and a new concept for pharmacodynamic monitoring of calcineurin inhibitors (CNI), nuclear factor of activated T-cells (NFAT)-regulated gene expression as well as non-specific pharmacodynamic-biomarkers (intracellular cytokines and chemokines production) have also been introduced and documented for tacrolimus, and their potential as a supplement to blood concentration measurements is discussed. With respect to pharmacogenetics, the significance of *CYP3A5* variants has been investigated in detail in kidney, liver, heart and lung transplant recipients and several population pharmacokinetic (popPK)

models including *CYP3A5* genotype have been developed for tacrolimus. The potential contribution of other genetic factors, such as *CYP3A4**22 and the efflux transporter adenosine triphosphate-binding cassette subfamily B member 1 (*ABCB1* gene), is summarized.

These recommendations and evaluations are outlined for all discussed topics. Of note, recommended tacrolimus target concentrations are defined for each type of organ transplant. Moreover, for pharmacodynamic biomarkers and pharmacogenetics, a systematic weighing of the quality of evidence and strength of recommendations according to the Grading of Recommendations Assessment Development and Evaluation was done (**Table 1**)^{1, 2}.

Furthermore, this Consensus Document will incorporate the recommendations concerning the clinical utility of combining tacrolimus pharmacokinetic TDM with pharmacogenetic and pharmacodynamic biomarkers to better prevent acute rejection, subclinical rejection, drug-related adverse events and graft dysfunction.

This Consensus Report will support all professionals involved in the management of patients treated with tacrolimus in transplantation and other clinical settings and aims to improve both standards of practice in pharmacological tacrolimus TDM (pharmacokinetic/pharmacogenetic/pharmacodynamic) and personalized patient care.

TACROLIMUS PHARMACOLOGY

Mechanism of action

Tacrolimus (known also as FK-506) binds to an immunophilin FK506 binding protein (FKBP) which constitutes the main therapeutic mechanism.¹⁶ The tacrolimus-FKBP complex inhibits the activity of CaN, a serine threonine phosphatase, which plays an important role in interleukin 2 (IL-2) promoter induction after T-cell activation.^{17, 18} This process inhibits the translocation of a

family of transcription factors of activated T-cells. It leads to reduced transcriptional activation of cytokine genes for interleukins (IL-2, IL-3, IL-4, IL-5), tumor necrosis factor α (TNF- α), interferon-gamma (IFN- γ), and granulocyte-macrophage colony-stimulating factor ((GM-CSF). Finally, proliferation of T lymphocytes is reduced.^{19, 20}

Indications (registered and off-label)

The approved indications for tacrolimus vary by country and formulation. With regards to organ transplantation in adult and pediatric patients, the originator's immediate release or intravenous formulations obtained market approval in the USA for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants. In Europe, it is approved also for the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products. In Japan, where the drug was developed, additional approvals were granted for lung, pancreas, allogeneic small bowel transplants, as well as for the prophylaxis of graft rejection and graft vs host disease (GVHD) in bone marrow transplantation. In Latin America, it is also approved for the treatment of severe and mild acute rejection and the prevention of GVHD.

The indications for prolonged or modified release formulations are somewhat more restrictive (except Graceptor in Japan): in the USA, Astagraf is only approved for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants. Envarsus has the additional restriction that patients should be converted from tacrolimus immediate-release formulations. In Europe, Advagraf and Envarsus are approved for kidney and liver transplantation but not for heart transplantation, as well as for the treatment of allograft rejection, but only in adults.

Tacrolimus has also been registered for a variety of other non-transplant indications across countries. In Europe, Protopic is registered for the treatment of eczema by topical administration on the skin. In Japan, oral tacrolimus is approved for the treatment of interstitial pneumonia associated with polymyositis and dermatomyositis. In Uruguay, it is indicated for refractory rheumatoid arthritis, refractory atopic dermatitis and refractory uveitis.

Interestingly, regional indications become off-label use in the other parts of the world, such as: hematopoietic stem cell, lung or small bowel transplantation, to which one can add rare composite tissue transplantations (face, hand, arm *etc.*); or refractory auto-immune diseases, not only those approved in Uruguay or Japan, but also the more common psoriasis, lupus nephritis, inflammatory bowel diseases, *etc.*

Pharmacokinetics of tacrolimus

Oral tacrolimus is rapidly absorbed, with a peak concentration attained within 0.5-1 hour, but it has a flat absorption profile in some liver transplant recipients with absorption that seems to be independent of bile.^{21, 22} The poor dissolution of tacrolimus in gastric juices, administration with food, erratic gastrointestinal motility, extensive pre-systemic metabolism by CYP3A enzymes in the gut wall and liver and activity of the efflux-pump P-glycoprotein (P-gp, encoded by, *ABCB1* gene) are relevant factors that contribute to the variability in absorption. The mean oral bioavailability is 25%.²²

Binding of tacrolimus to red blood cells (RBC, about 95%) is concentration-dependent.²³ In plasma, it is approximately 99% bound to plasma proteins such as α_1 -acid glycoprotein, albumin and for a very small part to lipoproteins. Blood: plasma tacrolimus concentration ratios range from 13-114 (mean =15) and are dependent on hematocrit, plasma protein and tacrolimus concentration.²³

Tacrolimus is metabolized mainly by CYP3A4 and CYP3A5 in liver and gut wall, with a minimal contribution of CYP3A7.²⁴ Up to 15 metabolites are formed by mono and di demethylation, hydroxylation and to some degree a combination of demethylation and hydroxylation. The major metabolites of tacrolimus are the 13-O-desmethyl tacrolimus (M-I) and the 15-O-desmethyl tacrolimus (M-III). 13-O-desmethyl tacrolimus (M-I) has 10% of the activity of tacrolimus while the 31-O-desmethyl tacrolimus (M-II) has similar activity to the parent drug but the concentrations are low-to-not-detectable in patients.^{25, 26} Tacrolimus is highly lipophilic, has a low clearance and approximately 95% of its metabolites are eliminated by the biliary route. Less than 1% of unchanged tacrolimus is eliminated by urinary and biliary routes.²⁷ The terminal elimination half-life of tacrolimus has a range between 4-41 hours.²²

Using PK modeling as described in a separate section later in this paper, apparent clearance and central volume of distribution as 24.0-28.5 L/h and 70.6-158.2 L, respectively, have been reported for adult kidney transplant recipients.²⁸ CYP3A5 genotype, weight, hematocrit and post-operative day were identified to affect tacrolimus clearance. The between-individual variability for clearance and central volume of distribution was 54% and 110%.²⁸ In another study, the mean between-occasion variability in tacrolimus clearance was 17% at 6-12 months post renal transplantation.²⁹ Circadian variation with tacrolimus pharmacokinetics was reported, with a lower bioavailability at night³⁰; but a lack of circadian variability, either with early or maintenance tacrolimus therapy, has also been reported.³¹

Clearance is two-fold higher following pediatric liver transplantation, with a shorter terminal half-life (11.5+/-3.8 hours).³² In pediatric liver transplantation, a linear increase of tacrolimus clearance up to 21 days post-surgery was reported.³³ Thereafter, tacrolimus clearance decreased up to a period of one year after transplantation.³⁴ The apparent clearance decreased with time

after transplantation due to an increase in hematocrit and albumin.³⁵ In pregnancy, an apparent decrease in α_1 -acid-glycoprotein, albumin and RBC resulted in a 39% increase in the total tacrolimus clearance and 100% increase of the unbound fraction of tacrolimus, compared to the postpartum period.³⁶

Temporary elevation of tacrolimus trough concentrations (about 2-fold and more) has been observed in patients with diarrhea.^{37, 38} This may be because intestinal Pgp activity is impaired in patients with persistent diarrhea, leading to increased bioavailability.³⁹

Reduction in the dose of corticosteroids, from the early post-transplant months to one year after transplantation, contributes to a decrease in tacrolimus clearance, facilitating a reduction in the tacrolimus dose.^{35, 40} Variability of tacrolimus exposure in African American patients compared to Caucasian and Asian patients has been reported, and is attributed to ethnic differences in CYP3A5 and P-gp.⁴¹ In the section on Pharmacogenetics in this review, the past, present and future of pharmacogenetic testing for tacrolimus will be discussed.

Drug-drug and drug-food interactions

Compounds which affect CYP3A enzyme activity or P-gp-mediated transport may influence tacrolimus concentrations in blood. Drug-drug interactions of clinical importance are summarized in **Table 2**, based on reviews.^{42, 43} Drugs that are known inhibitors of CYP3A4/5/7 include calcium antagonists, macrolide antibiotics and others as listed in **Table 2**. One group of drugs that have demonstrated profound inhibition of CYP3A enzymes is the triazole antifungals.^{44, 45} In individual cases large increases in tacrolimus exposure have been reported, as exemplified by voriconazole.⁴⁶ At initiation of therapy with these drugs, an immediate tacrolimus dose reduction is recommended, as maintaining the tacrolimus dose and waiting for a tacrolimus concentration after a couple of days is likely to cause significant toxicity.

More recent reviews have focused on potent interactions between tacrolimus and the antiretroviral agents used for the treatment of HIV-infected transplant recipients. Among these drugs are classes that inhibit and induce, respectively, the CYP3A enzymes and the P-gp transporter. This knowledge is also important for the selection of the most appropriate anti-HIV regimen to combine with immunosuppressive treatment.⁴⁷

The direct-acting antiviral agents for HCV infection can also produce drug interactions with tacrolimus.⁴⁸⁻⁵¹ Considerable modifications of tacrolimus dose have been recommended for combination with other regimens of the direct acting antivirals against HCV.

In contrast, as listed in Table 2, drugs that are known inducers of CYP3A include rifampin, antiepileptic drugs, some HIV antivirals and importantly also the glucocorticoids.^{40, 52} These drugs enhance CYP3A activity, increase the rate of tacrolimus metabolism and lead to a decrease of tacrolimus concentration that if passing unnoticed may fall below the recommended therapeutic range, which would put a patient at risk for graft rejection. If in the first months after kidney transplantation the prednisolone dose is gradually tapered, this affect tacrolimus exposure. In this setting, a rise in serum creatinine as a result of increasing tacrolimus concentrations may be misinterpreted as a rejection following corticosteroid tapering.

The consumption of solid food when taking oral doses of tacrolimus can decrease both the rate and extent of drug absorption from the GI tract.⁵³ This food-effect is most pronounced after a high-fat meal.⁵⁴ Therefore, the drug label recommends taking tacrolimus on an empty stomach, or at least 1 hour before or 2 to 3 hours after a meal. Food-drug interactions with tacrolimus include grapefruit and grapefruit juice.⁵⁵ St. John's wort is a known inducer of the CYP3A.⁵⁶ and has been shown to decrease tacrolimus exposure in renal transplant recipients.⁵⁷

Consequently, foods and drugs that are known to alter the activity of drug metabolizing enzymes should be used with caution during tacrolimus therapy, and the use of herbal medications should be avoided. The use of concomitant medications with tacrolimus may put a patient at risk of toxicity or sub-therapeutic blood concentrations.⁴³

Galenic formulations & generics

Tacrolimus is now also available in immediate or modified release pharmaceutical forms for oral administration (tablet or capsule). The Advagraf prolonged release once daily formulation was developed to increase treatment adherence, ultimately leading to better prevention of graft rejection. Recently, a new prolonged-release tacrolimus formulation named Envarsus was developed utilizing so called "solid solution" delivery technology. Envarsus presents higher bioavailability and as a consequence needs to be administered in comparably lower doses based on 0.75 mg, 1 mg and 4 mg tablets (correction factor of 0.7). A potential benefit of this formulation is that less-fluctuating tacrolimus concentrations have been observed.⁵⁸

Tacrolimus is a narrow therapeutic index drug (NTID). Several generic formulations for Prograf have been registered since patent protection expired. A list of tacrolimus brand names worldwide is currently counting 258 products, all formulations included and mostly due to the large number of immediate release generics.⁵⁹ The lack of worldwide harmonization in the registration of generic drugs, especially with respect to the criteria for bioequivalence, has resulted in regional differences in the availability of tacrolimus generics. For the once daily tacrolimus formulations patent protection was still in place at the time when the present document was written, and generic formulations based on these technologies had not entered the market yet.

Part of the transplant community has been, and still is, concerned that the pharmacokinetic properties of generic tacrolimus formulations may be too different from those of the innovator product, in all or in subgroups of special populations such as patients with cystic fibrosis or elderly patients.⁶⁰ Various national or international transplant societies have published recommendations regarding the implementation of generic immunosuppressive drugs in the transplant field.^{61, 62} Typically they recommended caution with the use of generic immunosuppressive drugs until more robust clinical data are available and adequate regulatory safeguards are instituted. One of the main concerns was that bioequivalence demonstrated in healthy volunteers may not be representative of all transplant recipients. In the literature there are a large number of published studies on comparisons between one or more generic formulation and the Prograf formulation.⁶³ Endpoints of these studies often include pharmacokinetic parameters, including bioequivalence. Some studies also include clinical endpoints, such as acute rejection or renal function. For the latter endpoints the sample size is often too small and the confidence intervals are too wide to conclude whether the substitution to generic formulations is safe or unsafe. For studies that focused on pharmacokinetic endpoints, a major problem is the higher variability in transplanted patients compared to healthy volunteers. In registration studies using healthy volunteers, standardized conditions in a specialized research unit are the norm. However, studies in transplant patients are typically subject to a less controlled research environment with ensuing variability. One of the clear exceptions is the prospective, replicate dosing, partially blinded, randomized, 3-treatment, 6-period crossover bioequivalence study that was conducted at the University of Cincinnati in patients with kidney (n = 35) or liver transplant (n = 36). In this study it was concluded that the bioequivalence demonstrated for tacrolimus in healthy volunteers also translates to those receiving a kidney or liver transplant.⁶⁴ In contrast to

this population with a median age of 52 years for kidney and 57 years for liver transplant recipients, another study included 28 Norwegian renal transplant recipients with median age 69 years (range 60-78 years); In this study bioequivalence criteria were not met.⁶⁵ Another example is the immediate release generic Tacrolimus which in one study including pediatric renal transplant recipients demonstrated very low bioavailability compared to the originator formulation (Prograf).⁶⁶ Further experiments by these authors showed that the pharmaceutical characteristics of this generic was dissimilar to the original and likely explained the reduced tacrolimus exposure in children.

It is unlikely that large prospective trials comparing generic and innovator tacrolimus formulations in newly transplanted patients will be conducted.⁶⁷ We consider generic tacrolimus as an attractive therapeutic option, especially in *de novo* transplant patients. As a standard of practice, the treatment should be guided by TDM, and simultaneously controlled for safety and efficacy. Conversions from innovator drug to generic or from one generic to another generic version need to be performed under careful monitoring of drug exposure and only after adequate instructions to the patient. In view of the risk of mistakes caused by patient confusion, it is important to limit the number of conversions from one formulation to another as much as possible.

PHARMACOKINETIC MONITORING

Evidence-based pharmacokinetic monitoring for tacrolimus in specific clinical situations

Relationships between tacrolimus exposure and treatment outcomes have been amply reported. The AUC can be regarded as the exposure metrics best associated with tacrolimus clinical effects, but no prospective study has been conducted in adult or pediatric transplantation to investigate the potential benefits on clinical outcomes of between-dose AUC monitoring over

therapy guided by trough concentrations, C_0 (i.e. concentration in samples drawn immediately before dose). C_0 is much easier to obtain and used in most transplant centers for routine TDM. The monitoring of tacrolimus AUC has been proposed especially in the early period post-transplantation to check the time evolution of the overall exposure and when clinically indicated (e.g. to investigate suspected tacrolimus adverse effects, or to guide immunosuppression minimization). Furthermore, in different conditions, the AUC/ C_0 ratio is influenced by the post-transplantation time-period, the CYP3A5*3 genotype,⁶⁸ and can be drastically modified in patients with decreased intestinal motility or decreased absorption (e.g. diabetes mellitus, ileus, cystic fibrosis, bariatric surgery, gastrectomy, colectomy), in patients exposed to strong pharmacokinetic drug-drug interactions (e.g. on anti-HIV, azole antifungal drugs) or in patients with other sources of tacrolimus metabolism deficiency. The rather poor correlation between C_0 and AUC⁶⁹ translates into very variable AUC/ C_0 ratios, which means that patients with identical C_0 may have very different between-dose AUC. Interestingly, tacrolimus AUC_{0-24h} correlated better with C_{24h} than C_0 for both twice-daily and once-daily tacrolimus, and AUC_{0-12h} correlated better with C_{12h} than C_0 for twice daily tacrolimus. The authors concluded that C_0 can only be a correct proxy of the overall exposure if blood sampling is perfectly timed.⁶⁸ However, this ratio was found to be very stable with time in individuals and the authors suggested evaluating this ratio at least once in the early period (first month) and once in the stable period (after three months) for each transplant recipient.⁷⁰

This section summarizes the updated recommendations for tacrolimus exposure in each type of solid organ transplantation as well as in other clinical applications.

Pharmacokinetic monitoring in kidney transplantation

Tacrolimus exposure, efficacy and toxicity

Since the previous consensus paper on tacrolimus TDM,¹⁰ only a few studies have investigated the relationships between tacrolimus exposure and the risk of acute rejection or toxicity. In the large Genomics of Deterioration of Kidney Allograft Failure (DeKAF) study in adult patients over the first 6 months after transplantation, each 1 ng/mL decrease in tacrolimus C_0 was associated with a 7.2% increased risk of acute rejection ($p = 0.03$).⁷¹ A smaller study in low-immunological risk patients without steroids and with a moderate dose of mycophenolic acid concluded that C_0 should be maintained >7 ng/mL during the first year post-transplantation.⁷² However, a pooled analysis of three other randomized, controlled clinical trials found no relationship between tacrolimus C_0 and biopsy proven acute rejection (BPAR).⁷³ Two rather old and small observational studies respectively showed: a significant association between tacrolimus AUC_{0-12h} and acute rejection, with mean values of 157 ng.h/mL in patient with AR and 215 ng.h/mL in patients without⁷⁴; and efficacy thresholds to avoid BPAR of 150 ng.h/mL for tacrolimus AUC_{0-12h} and 45 mg.h/L for mycophenolic acid AUC_{0-12h} .⁷⁵

Evidence is even more limited in pediatric patients. A retrospective study of 58 children showed that a lower frequency of chronic kidney disease and decreased graft function was observed when C_0 was maintained at ≥ 10 ng/mL in the first three months after transplantation.⁷⁶

Tacrolimus exposure has been more consistently associated with the incidence of adverse events,^{77, 78} but overall, the studies which investigated the relationship between tacrolimus exposure and the risk of AR and toxicity were often retrospective and/or included limited numbers of patients and/or involved co-medications different from those used nowadays.

Recommended tacrolimus target concentration ranges

Based on the current evidence, it is not possible to recommend a single target tacrolimus concentration range.⁴ Rather, the tacrolimus target exposure has been defined empirically and depends on the perceived risk of acute rejection, the time after transplantation and the co-medication used. In the United States and in Europe, tacrolimus combined with mycophenolate is the backbone of immunosuppressive drug protocols. In most centers, patients also receive induction therapy (either T-cell-depleting antibody therapy or interleukin (IL)-2 receptor blockers) and glucocorticoids.⁷⁹ The best evidence for such regimens was provided by the SYMPHONY randomized, controlled clinical trial,³ which showed that 75% of the low-immunological risk patients in the tacrolimus arm (which performed best) had a tacrolimus C_0 between 4 and 11 ng/mL in the first month after transplantation, between 4 and 10 ng/mL later on, and between 4 and 9 ng/mL between 6 and 12 months.⁹ Still, as mentioned above, a more recent study advised against $C_0 < 7$ ng/mL in a similar low-risk population.⁷² Also, different targets may be aimed for when tacrolimus is combined with T lymphocyte-depleting antibody therapy or in higher risk patients.

Tacrolimus in combination with everolimus therapy was investigated in the TRANSFORM randomized, controlled clinical trial.⁸⁰ It showed that in transplant recipients at mild to moderate immunological risk, everolimus plus low-exposure tacrolimus (target C_0 of 4-7 ng/mL (months 0-2), 2-5 ng/mL (months 3-6) and 2-4 ng/mL thereafter) is non-inferior to mycophenolate plus standard-exposure tacrolimus (target C_0 of 8-12 ng/mL, 6-10 ng/mL and 5-8 ng/mL, respectively) for a binary composite end point assessing immunosuppressive efficacy and preservation of graft function.⁸⁰

There has been no new study in support of tacrolimus exposure targets in pediatric kidney transplant recipients. As a reminder, the recommendations are to start with an initial tacrolimus dose of 0.15 mg/kg twice a day, to achieve C_0 concentrations between 10 and 20 ng/mL during the first 2 months after transplantation and between 5 and 10 ng/mL thereafter.¹⁰

Concerning between-dose AUC targets, a minimal threshold of approximately 150 ng.h/mL in adult kidney transplant recipients emerges from the only two studies published.^{74, 75} However, based on exposure measurement in very large numbers of patients on twice-daily⁶⁹ or once-daily⁷⁰ tacrolimus formulations, between-dose AUC target ranges were derived from the different C_0 targets proposed for low-, standard- and high-risk patients. For twice daily tacrolimus, the corresponding AUC_{0-12h} / C_0 -ranges proposed were: 75-140 ng.h/mL for 3-7 ng/mL; 100-190 ng.h/mL for 5-10 ng/mL; 140-210 ng.h/mL for 8-12 ng/mL; and 180-270 ng.h/mL for 10-15 ng/mL.⁶⁹ For once-daily tacrolimus (Advagraf), the corresponding AUC_{0-24h} target ranges proposed were: 150-275 ng.h/mL for C_0 3-7 ng/mL; 180-350 ng.h/mL for 5-10 ng/mL; 260-400 ng.h/mL for 8-12 ng/mL; and 310-475 ng.h/mL for 10-15 ng/mL.⁷⁰ Importantly, for a given C_0 range, 3 tighter time-adjusted AUC ranges were proposed (for 0-3 months, 3-12 months and > 12 months post-transplantation), because the correlation between AUC and C_0 changes over the first 12 months post-transplantation for both formulations, owing to the natural decrease in tacrolimus apparent clearance over this time period. The AUC ranges proposed above correspond to the combination of the 3 time-adjusted ranges.

Pharmacokinetic monitoring in liver transplantation

Tacrolimus exposure, efficacy and toxicity

AUC is considered to be the pharmacokinetic exposure index best associated with clinical effects. Therefore, the monitoring of tacrolimus AUC has been proposed, when clinically

indicated, but routine monitoring of tacrolimus C_0 concentrations is usual practice for outpatients.⁶ In case of combination therapy of tacrolimus with corticosteroids and either mycophenolate or everolimus, a tacrolimus C_0 of 6 to 10 ng/mL should be targeted from day-1 and over the first 4 weeks of treatment, followed by a target of 5 to 8 ng/mL.^{7, 8, 81-86} Waiting 6 weeks before targeting 5 to 8 ng/mL in combination with mycophenolic acid may be considered as an alternative, as the evidence in favor of the target change at 4 weeks is weak. With such immunosuppressive regimen, $C_0 > 10$ ng/mL seem to offer little additional advantage in terms of reduced allograft rejection, but result in a higher rate of renal dysfunction.⁸⁵ Also, $C_0 < 5$ ng/mL should be avoided, mainly during the first month, as they may lead to worse long-term outcomes.⁸² Tacrolimus given as monotherapy or only associated with induction treatment may require higher C_0 targets (10-15 ng/mL during the first 3 months after transplantation and 5-10 ng/mL afterwards), although there is some evidence in favor of minimized targets with such regimens too.⁸⁷⁻⁹⁰ Similarly, higher targets (10-15 ng/mL even beyond the 4th month after surgery) may be aimed for in case of corticosteroid-free treatment. In general, though, C_0 value > 15 ng/mL should be avoided.⁹¹ Liver function usually becomes stable 3 weeks post-transplantation. TDM after this period may therefore be reduced in frequency beyond this point in time, if patient condition and C_0 levels are stable.

Although there are limited data regarding optimal C_0 target range(s) in pediatric liver transplant patients, a retrospective study of 72 pediatric patients aged 0.5-17.6 years indicated that adverse events such as nephrotoxicity were associated with higher tacrolimus C_0 during maintenance therapy (median tacrolimus C_0 in patients with or without adverse events: 8.2 and 4.8 ng/mL, respectively).⁹²

Pharmacokinetic monitoring in thoracic transplantation

Tacrolimus exposure, efficacy and toxicity

Data on tacrolimus pharmacokinetics and TDM in thoracic transplantation are limited. All studies were conducted in <25 adult patients, except for one in 45 heart transplant⁹³ and another in 78 lung transplant recipients.⁹⁴

Tacrolimus dose after thoracic transplantation is usually adjusted based on C_0 levels, mainly targeting the ranges proposed almost 20 years ago for kidney and liver transplant recipients: 15-20 ng/mL for the first 2 months, 10-15 ng/mL from months 3-6, and 8-10 ng/mL after 6 months following heart transplantation⁵; and 10-25 ng/mL for the first 2 weeks, 10-20 ng/mL for the next 6 to 10 weeks, and 10-15 ng/mL thereafter in lung transplantation.⁹⁵ These C_0 targets were never formally revised. Moreover, as these targets have not been associated with any type of assay for blood concentration measurement, they should be interpreted and implemented in routine clinical practice with caution, and further research is needed to refine them.⁹⁶ Two recent studies explored the relationship between tacrolimus C_0 and acute kidney injury, in heart⁹⁷ and in lung⁹⁸ transplantation, respectively, and showed that the risk of acute kidney injury within the first two weeks post-transplantation was significantly increased for $C_0 > 15$ ng/mL.

As in other solid organ transplantations, tacrolimus AUC rather than single concentrations may be used for TDM. A wide range of correlation coefficient values between C_0 and AUC_{0-12} have been reported.⁹⁹⁻¹⁰² Only one study in heart transplantation has evaluated the relationship between AUC and outcome.¹⁰¹ The AUC_{0-12} after the first oral dose was significantly lower in patients who experienced acute rejection compared to those who did not (71 vs. 168 h.ng/mL, $p = 0.012$), but no information was provided on when acute rejection occurred. Unfortunately, no

prospective studies have been conducted so far in thoracic transplantation to compared different AUC₀₋₁₂ targets, or to compare AUC monitoring with C₀ monitoring.⁹⁶

Pharmacokinetic monitoring in bone marrow transplantation

Tacrolimus exposure, efficacy and toxicity

Graft-versus-host disease (GVHD) remains one of the main causes of treatment-related mortality after allo-hematopoietic stem cell transplantation (HSCT). The concomitant administration of a CNI (tacrolimus or cyclosporine) and short-term methotrexate is one of the standard regimens used to prevent GVHD.

Randomized controlled trials in both adult and pediatric patients have suggested that the combination of methotrexate and tacrolimus may be superior to methotrexate and cyclosporine to reduce acute-GVHD (aGVHD).¹⁰³⁻¹⁰⁶ Tacrolimus is generally administered by continuous IV infusion beginning on the day prior to allogeneic transplantation at a dose of 0.03 mg/kg/d.¹⁰⁷⁻¹⁰⁹

When patients are able to tolerate oral administration, the factor used for tacrolimus dose conversion from intravenous to oral administration varies between 1:3 and 1:5.¹⁰⁹ In most clinical trials and retrospective studies, the C₀ target concentration was between 10 and 20 ng/mL.^{108, 110, 111} A retrospective cohort study of 120 consecutive adult patients undergoing first allogeneic HSCT found a lower risk of grade 2-4 aGvHD in patients with tacrolimus mean C₀ of >12 ng/mL over the first week post-grafting, while lower tacrolimus concentrations at weeks 2, 3 and 4 were not associated with a higher incidence of aGvHD.¹¹² Tacrolimus C₀ target ranges of 10-30 or 10-40 ng/mL have also been reported^{113, 114}, but the incidence of nephrotoxicity was very high¹¹³ and significantly increased for C₀ >20 ng/mL.¹¹⁴

Few studies have evaluated tacrolimus concentration targets in children undergoing HSCT. A Japanese retrospective study of tacrolimus combined with methotrexate (97 children aged 0.4-18 years) found that mean tacrolimus concentrations ≤ 7 ng/mL during continuous infusion over the first 4 weeks (i.e., not really representative of the steady-state concentration) were associated with an increased risk of aGVHD and poorer survival.¹¹⁵ Another retrospective study, where tacrolimus was combined with mycophenolic acid (60 children aged 0.4-21 years) found that a mean tacrolimus concentration < 10 ng/mL during week 3 was associated with increased incidence of aGVHD.¹¹⁶

Pharmacokinetic monitoring in other diseases where tacrolimus is prescribed.

Tacrolimus is also prescribed (off-label in most cases) for several auto-immune diseases.

Atopic dermatitis

A topical tacrolimus ointment is effective against atopic dermatitis (or atopic eczema).¹¹⁷ It did not lead to relevant systemic tacrolimus exposure in adults,¹¹⁸ in children aged 2-17 years old,¹¹⁹ or in infants aged < 2 years.¹²⁰ In adults, 94% of tacrolimus blood concentrations were < 1 ng/mL and the highest value at any time point in any patient was 1.38 ng/mL.¹¹⁸

A small proof-of-concept, non-comparative study investigated the safety and efficacy of sequential therapy with short term oral tacrolimus to achieve rapid disease control followed by maintenance with topical tacrolimus 0.1% ointment in the treatment of severe atopic dermatitis.¹²¹ Over the first 3 weeks of the study, all patients received oral tacrolimus as monotherapy. Topical tacrolimus was then added to the oral treatment in weeks 4 to 6. After week 6, patients were treated with only topical tacrolimus. Clinical improvement was noted in

about 2/3 of the patients. The average whole blood tacrolimus levels were 8.1 ng/mL at week 1, 7.7 ng/mL at week 3, and 5.5 ng/mL at week 6.

Psoriasis

In patients treated with tacrolimus following renal transplantation, remarkable improvements in incidental psoriasis have been noted.¹²² Tacrolimus may be more suited than cyclosporine to a patient population with increased cardiovascular risk.¹²³ However, there is no evidence in favor of a tacrolimus concentration target range for this indication. Topical tacrolimus has been suggested as a suitable treatment for more localized psoriasis, such as facial, genital, and intertriginous psoriasis¹²⁴, requiring no TDM since systemic drug exposure has been shown to be low.

Lupus nephritis

The standard of care for the induction treatment of proliferative lupus nephritis remains mycophenolate mofetil and cyclophosphamide. CNIs are only recommended as a second line alternative given their side effects, especially in Asian populations.¹²⁵ However, a Bayesian network meta-analysis found that a maintenance treatment with tacrolimus in patients with biopsy-proven lupus nephritis class III, IV, or V yielded the best chance of preventing renal relapse as well as the lowest risk of withdrawals due to adverse events and leukopenia, as compared to mycophenolate mofetil, azathioprine and cyclophosphamide.¹²⁶ Tacrolimus dose was titrated to achieve a C_0 of 4-6 ng/mL in 34 Chinese patients,¹²⁷ and a C_0 of 6-10 ng/ml in the first and second month and 4-8 ng/ml thereafter in a Thai study.¹²⁸

In pediatric patients, a single center clinical study found that once daily tacrolimus at 3 mg/day, resulting in C_0 between 1.5 and 7.5 ng/mL, improved the serological parameters, the lupus

activity index and reduced the need for steroids in patients aged 9-25 years. However, no significant relationship between treatment effect and blood concentration was noted over the 2-year study period.¹²⁹

A meta-analysis of 23 clinical studies, all performed in Asian populations, showed that in most studies, tacrolimus dose was titrated to achieve a C_0 values of 5-10 ng/ml in the first and second months, and 4-7 ng/ml thereafter.¹³⁰ Still, the 'optimal' tacrolimus blood trough concentration has yet to be determined, and the targets used have largely been chosen to avoid toxic effects.¹³¹ Finally, the positive results of tacrolimus in Asian patients cannot be extrapolated to other ethnicities.

Inflammatory bowel disease

In a recent review, tacrolimus and infliximab appeared to be equally safe and effective in the short-term treatment of active ulcerative colitis.¹³² Tacrolimus oral dose was generally adjusted to achieve C_0 levels of 5-10 ng/mL thereafter. In a study of 65 patients with moderate to severe active ulcerative colitis two target tacrolimus concentrations (5-10 and 10-15 ng/mL) and a control group on placebo were compared double-blindly.¹³³ Clinical improvement was observed significantly more often in the tacrolimus high target range group. Bruns *et al.*¹³⁴ recommended frequent monitoring of whole blood tacrolimus concentrations, since efficacy and toxicity are dose-dependent.

Tacrolimus has also been investigated in pediatric patients with inflammatory bowel disease. A prospective multicenter trial including 13 pediatric patients aged 6-20 years with oral tacrolimus started at a dose of 0.1 mg/kg twice daily and subsequently adjusted to achieve C_0 concentrations between 10 and 15 ng/mL found that 69% of patients responded to oral tacrolimus within 14 days.¹³⁵ A single center, retrospective study of 18 pediatric patients aged 1-16 years, given

tacrolimus at a starting dose of 0.1 mg/kg/dose twice daily and subsequently adjusted to a target C_0 of 10-15 ng/mL for the first 2 weeks and 7-12 ng/mL thereafter, concluded that in patients with steroid-resistant colitis, tacrolimus was capable of inducing short- to medium-term remission but yielded no long-term benefit.¹³⁶

Executive summary on tacrolimus exposure recommendations

In kidney Transplant recipients

1. In low-immunological risk patients, tacrolimus may be targeted to: a C_0 of 4-12 ng/mL (and preferably to $C_0 > 7$ ng/mL) when prescribed in combination with IL-2 receptor (IL-2R) blocker induction therapy, mycophenolate and glucocorticoids (A I); or a C_0 of 4-7 (month 0-2) and 2-4 (> month 2) ng/mL when combined with everolimus and glucocorticoids and induction therapy (either Thymoglobuline or IL-2R blockers) (B II).
2. Tacrolimus C_0 targets may be higher in adult patients at higher immunological risks. (B II)
3. Although only supported by clinical experience, a C_0 target range of 10-20 ng/mL may be proposed for pediatric patients (C1 II)
4. A minimal AUC_{0-12h} threshold of 150 ng.h/mL may be proposed for the twice daily formulation in adults (B II). AUC targets corresponding to different C_0 ranges were derived from AUC- C_0 correlation studies in large adult patient populations, for the twice daily and once-daily (Advagraf) formulations.

In liver transplant recipients

For adult patients:

1. When prescribed in combination with mycophenolate or everolimus and corticosteroids, tacrolimus may be targeted to a C_0 of 6–10 ng/mL during the first 4 weeks post-transplantation and 5-8 ng/mL thereafter (A I).
2. Tacrolimus as a monotherapy, or when only associated with induction treatment may require a higher C_0 target (10-15 ng/mL during the first 3 months after transplantation and 5-10 ng/mL afterwards) (C1 II).
3. A tacrolimus C_0 of 10-15 ng/mL may also be aimed for in patients on a corticosteroid-free regimen (even beyond the 4th month after surgery) (C1 II).

For pediatric patients, there is not enough clinical evidence to make recommendations.

Heart and lung transplantation: the C_0 ranges recommended almost 20 years ago must be revised (and probably lowered), as they encompassed values between 15 and 20 ng/mL in the first weeks post-transplantation, whereas recent studies have shown that the risk of acute kidney injury within the first two weeks post-transplantation was significantly increased for $C_0 > 15$ ng/mL (B II).

Bone marrow transplantation: C_0 of 10-20 ng/mL may be targeted when tacrolimus is prescribed orally in combination with methotrexate, in adults (B II) as well as in children (B II).

In the other conditions in which tacrolimus is sometimes employed, there is not strong enough evidence to make recommendations (C2).

Within-patient variability of tacrolimus exposure as a biomarker for therapeutic drug monitoring

In addition to the tacrolimus blood concentration itself, its within-patient (between-occasion) variability might also be a valuable tool for optimizing immunosuppressive therapy in solid organ transplantation.¹³⁷⁻¹³⁹ Within-patient variability can be simply evaluated using the coefficient of variation (CV) of at least three consecutive C_0 measurements in a given time period. To date, none of the different tacrolimus formulations (immediate release, prolonged or extended release) clearly shows lower within-patient pharmacokinetic variability than the others.^{140, 141} Significant variability of tacrolimus concentrations during immunosuppressive treatment may lead alternatively to underexposure and overexposure periods and represent a risk of treatment failure.

The first suggestions to consider the within-patient variability as a potential biomarker of treatment outcome were reported in kidney transplantation.²⁹ The CV of tacrolimus C_0 beyond 6 months post-transplantation was found to be a more relevant biomarker of tacrolimus toxicity and immunosuppressive efficacy than the sole C_0 .^{142, 143} Patients with high exposure variability were confirmed to be at higher risk of developing histologic kidney lesions,¹⁴³ graft loss,¹⁴² and of poorer long term outcomes.^{29, 144-146} Most of the studies conducted in kidney transplantation included patients with stable treatment (at least 6 months after transplantation), in a period when adherence may be regarded as a strong determinant of within-patient variability.

In liver transplantation, whether in the early post-operative period (days 8 to 30) or at mid-term (after 6 months), the within-patient variability of tacrolimus concentrations was related to patient outcome.^{147, 148} In adult patients, early within-patient variability (between day 8 and day 30) was associated with long term graft and patient survival and with complications such as

nephrotoxicity, cardiotoxicity and neurological adverse events, meaning that early interventions may be undertaken to reduce variability.¹⁴⁸ In pediatric patients, the link between within-patient variability, calculated from month 6 of tacrolimus initiation, and biopsy-proven acute rejection was first found in retrospective studies and later confirmed prospectively, whereas there was no relationship with graft or patient survival.^{147, 149}

Very recently, similar results have been reported in heart transplantation. The within-patient variability was calculated retrospectively between month 3 and month 12 and a high CV turned out to be an important risk factor for the onset of rejection.¹³⁹

Evaluating the within-patient variability of C_0 values during tacrolimus treatment should be further considered in the clinical management of solid organ recipients. Early identification of at-risk patients, with higher within-patient variability, may allow implementing actions aimed at reducing this variability and preventing its clinical consequences.

Executive summary on within-patient variability of tacrolimus exposure

Within-patient variability of tacrolimus concentrations has emerged as a potential tool to predict adverse events during follow-up of kidney, liver and heart transplant recipients, but has not entered routine monitoring yet (B II). Evaluation of within-patient variability can easily be implemented to improve therapeutic drug monitoring (B II). The use of within-patient variability has not been validated prospectively and the timing of determination has to be defined.

MEASUREMENT OF TACROLIMUS CONCENTRATIONS

Sample stability

Short and long-term stability of tacrolimus and its major metabolites (MI, MII, MIII) have been investigated using both patient blood samples and whole-blood samples spiked with these

substances. Stability of the measured tacrolimus concentration was proven for samples stored up to 14 days at 22°C or 4°C, as well as at least 1 month at -20°C and 1 year at -70°C.^{25, 150} MI, MII and MIII were found to be stable for at least 3 days at ambient temperature, 1 month at -20°C and 12 months at -80°C.^{25, 151} Three freeze-thaw cycles were possible without compromising the quantitative results.^{25, 151} These cycles also had no effect on the unbound tacrolimus concentration, but this fraction increased by > 30% in samples stored for 6 months at -80°C.¹⁵² The authors concluded that samples should be ultrafiltrated when fresh to study the unbound tacrolimus concentration. For long-term storage the prepared ultrafiltrates can be frozen at -80°C. Stability of tacrolimus concentrations was also investigated in some alternative sample matrices. For example in peripheral blood mononuclear cells (CD4⁺ T- and CD19⁺ B-cells), stability was demonstrated for up to 3 months at both ambient temperature and -30°C;¹⁵³ in oral fluid ambient temperature (no exact time was mentioned) and for up to 1 month at -80°C;¹⁵⁴ and in human bile samples over 20 hours at ambient temperature and 6 months at -80°C.¹⁵⁵ After 3 freeze and thaw cycles no loss of tacrolimus concentration was observed in oral fluid or bile.

Extended stability of tacrolimus in DBS samples using different grades of Whatman® paper (Whatman, Kent, UK) has been reported. For example on Whatman 31 ET CHR paper tacrolimus concentrations were consistent over 28 days when stored at either 22 °C or 37 °C¹⁵⁶, over 30 days on Whatman 903 Protein Saver Cards at temperatures ranging between -20 °C and 25 °C and at least 5 days at 60 °C.¹⁵⁷

Analytical methods to determine tacrolimus in whole blood

More than 60% of the requests for measurement of immunosuppressive drug concentrations in clinical laboratories concerns this drug. Because TDM was recommended with the introduction of tacrolimus in the early 1990s, many analytical methods determining tacrolimus concentrations

have been developed and established for clinical services.¹⁴ These methods offer different advantages but may also suffer a variety of disadvantages.¹⁵⁸ Analytical laboratories face a number of alternatives when choosing the method that is most appropriate for their local circumstances. Analysis of tacrolimus in whole blood is performed either by immunoassays or by liquid chromatography-tandem mass spectrometry (LC-MS/MS), with both techniques being represented in nearly equal proportions at measurement service providers worldwide.¹⁵⁹

Chromatographic methods

In a 2013 international survey, 53 % of TDM laboratories reported that LC-MS/MS was used as their routine tacrolimus method.¹⁵⁹ About 60% of the LC-MS/MS procedures was laboratory developed tests (LDT), whilst the remainder was based on kits launched on the market by the diagnostic industry. The majority of the LC-MS/MS assays (~75%) was multianalyte methods that allowed for the simultaneous quantification of tacrolimus and other immunosuppressive drugs within one analytical batch, using a whole blood sample.¹⁵⁹

High analytical selectivity and sensitivity, and the possibility for high throughput multianalyte assays are important benefits of LC-MS/MS. Thus, this technique has met the evolving clinical requirements for fast, accurate, and precise tacrolimus assays performing well at low concentrations. The ease of use and robustness of LC-MS/MS instruments and also the combination with automated or semi-automated sample preparation have gradually been improved and further facilitated the widespread implementation in clinical laboratories. Nevertheless, skilled laboratory management and specially trained staff are necessary to establish and operate LC-MS/MS assays for routine TDM. Furthermore, for LC-MS/MS, a rather large upfront financial investment is necessary.

The design, validation and continuous quality assurance of immunosuppressive drug LC-MS/MS assays are critical for routine performance and these aspects have recently been reviewed by the IATDMCT Immunosuppressive Drugs Scientific Committee.¹⁴ The process of LC-MS/MS-based quantification of tacrolimus in clinical samples can be divided into sample preparation, chromatographic separation, mass-spectrometric selection as well as detection, data processing and validation, finally leading to reportable results.

Sample preparation: Tacrolimus is extensively distributed into red blood cells and so it is measured in whole blood. Ethylenediaminetetraacetic acid (EDTA) is the preferred anticoagulant.¹⁴ Protein precipitation, solid-phase extraction (SPE), and liquid-liquid extraction (LLE) have been reported as sample preparation strategies prior to chromatography in LC-MS/MS assays including tacrolimus.¹⁶⁰ The sample preparation and chromatography should be designed to balance each other: clean extracts may allow simple and fast chromatography, whereas crude extracts should be compensated for by more thorough chromatographic clean-up and separation to avoid impairment of the MS/MS response.

Precipitation of whole blood samples can be performed by either a stepwise or simultaneous addition of zinc sulfate solution and organic solvent. Annesley and Clayton developed a protocol in which five volumes deionized water was added to whole blood before step-wise addition of zinc sulfate 0.1 mol/L and methanol. Apparently, the water hemolysis step improved the extraction efficiency and lowered the imprecision of the tacrolimus measurements in clinical samples.¹⁶¹ This extraction protocol was further validated by Seger *et al.* as part of a standardized multianalyte LC-MS/MS assay: 50 μ L EDTA whole blood was added to 250 μ L water and 750 μ L methanol:zinc sulfate 0.1 mol/L (2:1), then vortex mixed at room temperature and centrifuged at 4 °C.¹⁶² The water hemolysis step and subsequent precipitation with methanol:

zinc sulfate may be regarded as state-of-the art for this type of sample preparation. However, visual inspection of the precipitate is recommended.

Chromatography: The hydrophobic nature of tacrolimus makes it suitable for reversed-phase chromatography. Conditions for chromatographic separation are commonly based on C18 (or C8) stationary phases combined with mobile phases of water and methanol to which an acidified ammonium buffer (*e.g.* formic acid plus ammonium acetate) is added.¹⁶⁰ The mobile phase constituents should be of LC-MS quality. Tacrolimus is retained on a C8/C18 analytical column with methanol content up to approximately 50 % in the mobile phase, thereby allowing the separation of less hydrophobic compounds. Further on, tacrolimus can be eluted with adequate peak symmetry by increasing the methanol content to ≥ 90 %.^{13, 162} Some chromatographic compromises may be necessary when cyclosporine is included in the assay, because the latter demands highly optimized conditions to obtain acceptable peak shapes. Column temperatures, in the range 35 °C to 75 °C, may be used to facilitate peak narrowing, also allowing a higher flow rate due to reduced back-pressure.

Online extraction with two-dimensional chromatography is a widely used strategy for clean-up before directing the extracts into the mass-spectrometer. The prepared matrix is then injected on an extraction column with large particles and a low-organic mobile phase is pumped at a high rate (turbulent flow). Subsequently, the system switches to a high-organic mobile phase which back-flushes tacrolimus from the extraction column and through an analytical column.¹⁶⁰ Such online clean-up techniques may be applied to avoid potential ion suppression effects on the signal intensity and also to minimize contamination of the mass spectrometer.

The chromatography of tacrolimus should be designed to minimize co-elution with compounds causing ion suppression/ ion enhancement. Tracking of the time intervals with potential signal

suppression/ enhancement (post-column infusion) and monitoring the retention times for glycerophosphocholines will guide such achievements during assay development.^{163, 164}

Mass-spectrometry: The majority of tacrolimus LC-MS/MS assays apply electrospray ionization (ESI) as the interface to get the mobile phase solvent and sample compounds into gas phase.¹⁶⁵ The conditions for spraying, evaporation, ionization, and acceleration of tacrolimus ions into the mass-spectrometer have to be optimized with respect to the specific instrument. Several of the ion source parameters are global in a multianalyte assay and, consequently, optimization of these parameters may have to be prioritized for compounds yielding the lowest instrument response at the lower limit of quantification (LLOQ) (usually sirolimus and everolimus when included in an multianalyte immunosuppressive drugs assay).

Sample matrix components will potentially influence the evaporation and ionization efficiency of tacrolimus (ion suppression or enhancement). Proper sample preparation and chromatographic separation is mandatory to minimize such matrix effects on the analyte response. Highly sensitive mass-spectrometers enable less impact of matrix effects since they allow less biological matrix per sample to be loaded into the system. It is generally recommended to use a stable isotope-labeled internal standard (SIL-IS) to correct variations throughout the assay procedure, including compensation of matrix effects. There are commercially available SIL-IS for tacrolimus (*e.g.* ¹³C, D₂-TAC).

Selective reaction monitoring (SRM) is applied for tacrolimus quantification, usually with the positively charged ammonium adduct as precursor ion (*m/z* 821.5) and product ion set at *m/z* 768.5.¹⁶⁰ The corresponding mass transitions should be used for the IS.

Assuring adequate quality of clinical tacrolimus LC-MS/MS assays: The use of commercial whole blood-based tacrolimus calibrators is recommended to ensure accurate measurements and

to support the harmonization of results between laboratories. Indeed, 78% of TDM laboratories have reported the usage of commercial tacrolimus calibrators.¹⁵⁹ Preferably the quality control samples should be sourced independently from the calibrators. Tacrolimus measurements should be based on a multilevel calibration curve and a proper calibration model with adequate weighting should be applied. Natural tacrolimus isotopes may contribute to the IS response when a SIL-IS is used and a nonlinear calibration curve should be considered in such cases. Also, there may be tacrolimus impurities in the IS solution generating an analyte response in tacrolimus-free samples. Impurity interferences like this should be balanced against requirements for the LLOQ. Reproducibility of the peak integration can be ensured with automated data processing using custom-adjusted algorithms in the instrument software. Manual integration should generally be avoided but, if necessary, it should be justified and documented in each case. Since the MS/MS signal intensity may fluctuate over time on an instrument, it is useful to include daily testing of the absolute assay response to verify that requirements for the LLOQ are fulfilled.

Hospital TDM laboratories may receive tacrolimus samples from both in-house and outpatient clinics and the requirements for the turnaround time will often be different depending on the clinical setting. LC-MS/MS assays should be designed to meet a turnaround time of approximately 3 hours for in-house tacrolimus samples. Alternating injections into two LC-channels coupled to a single MS/MS allow overlapping chromatography and can be used as a strategy to obtain a reduced batch run-time.¹³ Laboratories performing therapeutic monitoring of tacrolimus should perform adequate assay validation or verification before implementation of the assay as a routine service. They should adhere to pre-defined acceptance criteria for analytical performance of their routine runs and participate in external proficiency testing (PT).¹⁴

Immunoassays

Tacrolimus TDM has benefited extensively from immunochemical methods since the drug was introduced into clinical practice. First generation assays including the PRO-Trac II ELISA (DiaSorin), the Microparticle Enzyme Immunoassay (MEIA) produced by Abbott and the Cloned Enzyme Donor Immunoassay (CEDIA) originally produced by Microgenics, subsequently Thermo Fisher, were replaced by improved tests. Currently a choice of immunoassay is available.

EMIT: The Enzyme Multiplied Immunoassay Technique (EMIT) is offered by Siemens (formerly Dade-Behring) from the early 2000s. The assay may be performed on several analyzers (*e.g.* Vital Viva - different models, Roche Cobas Mira - different models and Integra, Beckman Synchron LX20, Bayer Advia 1650, Abbott Architect c8000, Hitachi 902 *etc.*). The EMIT reagents suffer from cross-reactivity with tacrolimus metabolites, resulting in significant overestimation of tacrolimus concentrations in patient samples as compared to LC-MS/MS, reaching up to 30-36%.^{25, 166} It has also been noted that another factor contributing to the bias could be nonspecific cross-reactivity.²⁵ Poor LLOQ ranging between 2.8 ng/mL and 4.6 ng/mL has been reported,¹⁶⁷⁻¹⁶⁸ suggesting that EMIT is not reliable for monitoring tacrolimus concentrations below about 3.0-5.0 ng/mL. LeGatt *et al.* reported total imprecision of 13.7% and 6.0% for tacrolimus concentrations of 3.4 and 19.1 ng/mL, respectively.¹⁶⁷ Commonly observed poor repeatability of determinations between analytical runs, as well as a wide dispersion of the results by EMIT seen in proficiency testing^{14, 168} were partially related to reagent instability after opening and method calibration at a particular laboratory. Currently, use of EMIT for tacrolimus monitoring is steadily diminishing.

ACMIA: Another assay from Siemens is the Antibody-Conjugated Magnetic Immunoassay (ACMIA) developed for the Dimension analyzer family. This application, which has been available since 2007 for general biochemistry analyzers, had the advantage of no manual pretreatment step.

The LLOQ for ACMIA was reported as 2.5-5.36 ng/mL¹⁶⁸⁻¹⁷¹

A mean positive bias of 1.78 ± 1.51 ng/mL vs. LC-MS/MS was found in patient samples by Tempestilli *et al.*¹⁷⁰ and practically no bias (+1.7%) by Cangemi *et al.*¹⁷² Total imprecision of $\leq 12.9\%$ ^{173, 174} was reported. Tempestilli *et al.* observed the influence of albumin on tacrolimus concentrations and suggested the risk of inappropriately low tacrolimus dosage in low albumin patients.¹⁷⁰ However, ACMIA results were not affected by hematocrit values.^{175, 176}

Interestingly, the method's main asset became its primary disadvantage. No pretreatment could lead to lower accuracy and to an overestimation of the results in as many as 1% of patient samples.^{170, 177} In some patients the assay was affected by endogenous blood constituents (incl. heterophilic or anti β -galactosidase antibodies) giving falsely elevated results.^{172, 177}

Recently, the manufacturer has made modifications,¹⁷⁸ which are expected to resolve the problem. The “new” ACMIA for tacrolimus is characterized by an improved LLOQ of 0.86 ng/mL, fitting well with recent TDM requirements¹⁴, negligible bias of 1.7% to LC-MS/MS and total imprecision of $\leq 5.5\%$.¹⁷⁸ If the modified ACMIA proves resistant to erroneous results, it could be an attractive tool for tacrolimus TDM.¹⁷⁹

CMIA: The Chemiluminescent Microparticle Immunoassay (CMIA) was developed by Abbott for a family of Architect analyzers. After receiving FDA approval, the CMIA can be used for routine tacrolimus TDM in US clinical laboratories.¹⁸⁰ The first analytical step is a manual

pretreatment of a whole blood sample in order to precipitate proteins and extract tacrolimus into a supernatant, followed by immunoassay. Evaluation of the CMIA tacrolimus assay showed no interference with hematocrit, bilirubin or total protein^{169, 171, 181} but cross-reactivity yielding 94% with 31-O-desmethyl tacrolimus (M-II), and 45% with 15-O-desmethyl tacrolimus (M-III) tacrolimus metabolites. The cross-reactivity with 13-O-desmethyl tacrolimus (M-I) and 12-hydroxy tacrolimus (M-IV) metabolites was negligible.¹⁷¹

Functional sensitivity (CV = 20% of the fitted curve) of 0.5 ng/mL,^{169, 181, 182} even lower than the manufacturer's claim (0.8 ng/mL) was reported. However, CV <10% was noted only beyond 1 ng/mL tacrolimus concentration.¹⁶⁹ In Wallemacq's multicenter study, the total CMIA imprecision was $\leq 8.2\%$ using QC materials¹⁷¹ and it was $\leq 8.8\%$ using samples of Chinese renal transplant patients as reported by Li et al.¹⁸³ Saint-Marcoux *et al.* noted $4.4 \pm 0.2\%$ bias vs. LC-MS/MS in pooled clinical samples, whereas in 2 analytical sites involved in Wallemacq's comparison, the bias was reported as +0.51 and +1.63 ng/mL.^{171, 184} The assay rapidly became a leader of immunoassay methodology for tacrolimus due to a comparatively low bias vs. chromatography, imprecision even better than LC-MS/MS and close agreement of results for clinical samples in proficiency testing data.

ECLIA: The Electrochemiluminescence Immunoassay (ECLIA, Elecsys) is a semi-automated diagnostic assay developed by Roche for use in a family of Cobas e analyzers to monitor tacrolimus in whole blood samples. A comprehensive study has been conducted in five centers in Europe to evaluate the performance of ECLIA for tacrolimus determination. Three different models of Cobas analyzers (e 411, e 601, e 602) were used.¹⁸⁵ The manufacturer declares that the assay shows no interference from bilirubin, hematocrit, or total protein, and that cross-reactivity is 70% for metabolite M-II but no detectable cross-reactivity with tacrolimus metabolites: M-I,

M-III and M-IV. A study by Shipkova showed method linearity between 0.5 and 40 ng/mL, functional sensitivity (CV $\leq$ 20%) was 0.3 ng/mL, and CV $\leq$ 10% was at 0.8 ng/mL;¹⁸⁵ Within-run imprecision was $\leq$ 8.9%; laboratory-to-laboratory imprecision $\leq$ 12.1%. This performance was confirmed in more recently published studies.^{180, 186} Fung *et al.* reported total imprecision of 3.9-9.4%.¹⁸⁷ Whilst the ECLIA tacrolimus assay has a shorter analysis time (18 vs. 30 min) than the CMIA, it uses a higher sample volume (300 vs. 200 μ L), a factor to be considered when choosing the assay best suited for a particular laboratory.^{185, 187, 188}

Immunoassays under evaluation: A new test for tacrolimus monitoring, the Quantitative Microsphere System (QMS) Tacrolimus Immunoassay, has been introduced recently by Thermo Scientific (Fremont, CA, USA). Method description as well as its clinical evaluation is available in a publication by Leung *et al.*¹⁸⁹ They found that the assay is free from interference from bilirubin, hemolysis and lipemia. The method was reported as linear up to 30 ng/mL with a LLOQ at 0.7 ng/mL (CV = 14.4%). Imprecision was stated as 3.9-8.1% and 4.7-10.0% (within-run and between-run, respectively). A comparison made between QMS and LC-MS/MS measures in 145 patient samples showed a bias of +1.6 ng/mL.¹⁸⁹

A similar type of assay, latex agglutination turbidimetric immunoassay (LTIA, Nanopia TDM Tacrolimus assay kit) from Sekisui Medical has been tested in Japan. LTIA was compared to three other IAs (CMIA, ECLIA and ACMIA) by Akamine *et al.*¹⁹⁰ In this evaluation, LTIA had the best profile for cross-reactivity with three major tacrolimus metabolites (M-I, M-II and M-III), and yet LTIA presented the highest bias (+1.88 ng/mL) which was additionally influenced by CYP3A5 genotype and hematocrit value.¹⁹⁰ Further investigations are necessary to judge whether the LTIA tacrolimus assay is suitable for tacrolimus TDM.

The evolution observed over more than 20 years for tacrolimus immunoassays shows improved specificity, precision, limit of quantification, as well as time of analysis and automation. Thus, the new generation of immunoassays is increasingly an alternative to LC-MS/MS methods in tacrolimus monitoring.

Consistency of tacrolimus results generated by different analytical methods

Method inconsistency may have an impact on patient care for several reasons including but not limited to its effect on clinical decisions and drug dosing. It also has an impact on long-term outcomes for patients and on the correctness of retrospective analysis of clinical data or the interpretation of pooled data from clinical trials, since these analyses may be used for regulatory purposes or to establish clinical decision points. The range of immunoassays available for tacrolimus each shows a different spectrum of cross-reactivity to tacrolimus metabolites and different susceptibilities to interactions with heterophilic antibodies and endogenous factors such as hematocrit or albumin.¹⁴ Therefore, dealing with the issue of consistency of results generated with different methods is not easy. A recent study of the performance of current tacrolimus immunoassays among Japanese hospitals demonstrated large between-laboratory variability even when using samples spiked with the drug.¹⁶⁸ The very low level of method harmonization with laboratory developed tests (LDTs, *e.g.* the majority of LC-MS/MS methods) presents further obstacles. According to data from the Analytical Services International (ASI) Proficiency Testing (PT) program collected between 2014 and 2017 (**Figures 1A and 2A**) the ratio between the maximum and minimum averages of the concentrations determined by different methods when analyzing the same samples was about 1.3-fold. This was true both for spiked and pooled patient samples. However, considering the within-method CV (%) found for each of the different peer groups (**Figures 1B and 2B**) a much greater difference between minimum and maximum

reported results can be anticipated. Recently Agrawal *et al.*¹⁹¹ evaluated, under “real-world” clinical conditions, the effect of a change in analytical methodology from CMIA (run on an Abbott Architect system) to a kit based LC-MS/MS method (Waters TQD Acquity mass-spectrometer with Mass Trak) on patient classification according to the tacrolimus concentration. Although a good analytical performance has been demonstrated for both of these methods in the past,^{192, 193} the results of this study demonstrated that 40% of patient samples were discordantly classified by the two methods when the applied therapeutic ranges were 2 ng/mL wide. The discordance rate improved to 3% when the width of the target range was increased to 4 ng/mL. A change in patient classification due to lack of comparability between methods might lead to the patient receiving either an insufficient dose and rejecting the organ, or receiving a high, potentially toxic dose. Although introducing laboratory- (or method-)specific target ranges may be a helpful approach to attenuate the impact of between-method differences on patient classification, this approach may pose a hidden danger, particularly when laboratories need to change the methodology at short notice (*e.g.* due to problems with reagent supply) or when transplant physicians have to simultaneously interpret results provided by different laboratories. The narrow therapeutic index of tacrolimus sets stringent requirements for the performance of analytical methods. For instance, estimation by different approaches that try to take into account the within-individual biological variability of pre-dose tacrolimus concentrations shows that an adequate application of a 4-5 ng/mL wide target concentration range would require analytical imprecision and bias of $\leq 6\%$ each.^{14, 194} As discussed in recently published IATDMCT recommendations for proper analytical performance¹⁴ and demonstrated in **Figures 1 and 2**, such goals are hardly achievable in current routine TDM services. Targeting of even more narrow therapeutic ranges for clinical purposes seems, with reference to current analytical

practices, unrealistic.¹⁵⁹ The recommended achievement of between run imprecision of at least $\leq$ 10% with a total error of $\leq$ 15% (among other performance characteristics) should be considered obligatory for tacrolimus analytical methods to rate them as acceptable.¹⁴

Furthermore, to properly deal with patient non-adherence issues that are particularly critical in transplantation not only method precision but also the ability to measure very low concentrations is important. The recommended LLOQ for tacrolimus is $\leq$ 1 ng/mL, and can be achieved currently by LC-MS/MS methods, the ECLIA, and CMIA techniques,¹⁴ as well as the newest generation of ACMIA. The measurement range of the QMS method as reported by the manufacturer can theoretically also cover such low concentrations, but the imprecision observed in PT programs is broader than those of the latter methods (**Figure 1B**). Hence, between-method consistency in analytical sensitivity is lacking too.

Last but not least, the fact that tacrolimus is prescribed as a long-term therapy clearly highlights the importance of consistent analytical performance of methods and laboratories over long periods of time. However, as can be seen in **Figure 1**, long-term inconsistency with analytical methods over time is still an issue, and the within-method variability of the bias to the same spiked concentrations frequently reached 15% and even more when looking at the interquartile ranges.

In summary, when looking back to the early years of tacrolimus TDM, a continuous improvement of method performance can be seen. However, the analytical performance of currently available methods still varies broadly which needs critical consideration when implementing or changing TDM services for tacrolimus.

Method calibration and proficiency testing

In the case of tacrolimus analytics, there are multiple PT programs available (both national and international) with the College of American Pathologists (CAP) scheme and the programs formerly run by ASI (now provided by LGC) being most popular. Results from these programs have been used in the past to reveal analytical problems and their causes.¹⁹⁵ When choosing a PT program it is important to consider whether specimens based on human whole-blood spiked with tacrolimus metabolites, real patient material from transplant recipients and blank samples without tacrolimus and metabolites are part of the distributions by the program. Such samples are important to check for matrix effects on the accuracy of the measurement.¹⁴

In general, users can check on accuracy using third party prepared calibrators or controls or compare their results with those given by PT data. Fortunately, since 2013, a higher order whole blood reference material for tacrolimus has been available commercially (ERM-DA110a) and listed in the database of the Joint Committee for Traceability in Laboratory Medicine (JCTLM). Because commercially available calibrators and controls are in general traceable to this material their use in routine services is preferable to reduce the risk of calibration bias. Participation in PT is particularly supportive if own results can be compared not only to the peers but also to results traceable to a higher order reference method, however unfortunately this possibility is still not available for tacrolimus. In this situation, comparison to results generated with the LC-MS/MS technique (the LC-MS/MS participant group) can provide some helpful information when evaluating immunoassays. However, the drawback here is that the LC-MS/MS group is not consistent.¹⁹³ and the level of validation as well as the overall quality performance management at the participating analytical sites are unknown. Therefore, for the evaluation and verification of immunoassays accuracy, confirmation of their results using a fully validated LC-MS/MS as a reference and real (not pooled) patient samples is advised before application to routine services.

Acceptance criteria for such between-method comparisons have been recommended by the IATDMCT Immunosuppressive Drugs Scientific Committee:¹⁴

- a. A linear regression slope within $\pm 10\%$ of the theoretical value of 1.0.
- b. A linear regression intercept not significantly different from zero.
- c. A standard error for the estimate, $S_{yx} \leq 10\%$ of the average of the therapeutic concentrations.

Figures 1 and 2 summarize data regarding the performance of currently used tacrolimus methods as collected between 2014 and 2017 (after the introduction of ERM-DA110a) from the ASI PT program. They show that, although, the bias of method means when compared to spiked target concentrations (4, 8 and 12 ng/mL, **Figure 1A**) lies with few exceptions (EMIT at 4 ng/mL) within a range of $\pm 10\%$, it varies broadly between distributions. When comparing the performance of immunoassays with pooled patient samples (**Figure 2A**) versus the LC-MS/MS group, all of them showed some overestimation, in agreement with published data generated with non-pooled patient samples.^{169, 185} In contrast to the EMIT and QMS assays, the median overestimation with the CMIA, ECLIA, and ACMIA was $<10\%$.

Looking at the long-term method-specific percentage CVs (both for spiked and pooled patient samples), they clearly favor LC-MS/MS, CMIA, and ECLIA methods compared to ACMIA, QMS and EMIT (**Figures 1B and 2B**). Moreover, the percentage CVs of the first group of methods seems not to be concentration-dependent, in contrast to the methods of the second group, for which much broader within-group variability at the lowest concentration (4 ng/mL) compared to 8 and 12 ng/mL was identified. During the observation period the CMIA and ECLIA methods demonstrated better long-term precision than the very heterogeneous LC-MS/MS group.

All these results underline the strengths of PT and demonstrate that there is without doubt a high potential for improvement of tacrolimus analytics to further standardize method and laboratory performance.

Standardization of tacrolimus TDM

The applicability and reliability of analytical figures generated by laboratories is strongly linked with data quality, particularly their accuracy. This general remark holds true for any kind of measurement service and is not limited to clinically relevant entities such as tacrolimus.

Laboratory medicine adopted relatively early the general metrological concept of traceability,^{196, 197} and established a close relationship with national metrological institutes. By founding the Joint Committee for Traceability in Laboratory Medicine (JCTLM) located at the International Bureau of Weights and Measures,¹⁹⁸ chemical and biological entities in laboratory medicine have been raised to the same level of international consistency and used classical SI units for measuring time, weight, and length.

Measurement procedure accuracy is achieved through ensuring specificity of the applied methods. These methods are the responsibility of individual laboratory units offering defined measurement services. Total error or measurement uncertainty calculations¹⁹⁹⁻²⁰¹ can be used to investigate the error components associated with the processes of measuring, namely bias and precision which do combine up to the accuracy of a measurement system.²⁰² Error budgets may be used to estimate the expected total error (TE) which combines systematic error components (associated with bias) and stochastic (random) error components (associated with precision). They can be either calculated by “top-down” or “bottom-up” approaches. Whereas bottom-up approaches are used in the assessment of reference measurement systems,²⁰¹ top-down approaches allow the monitoring of systems in routine use; *e.g.* either individual users or global

measurement services. For tacrolimus, a recent top-down investigation showed that this approach, either using single laboratory validation data or proficiency testing data, gave identical results.²⁰³ Different top-down approaches to estimate measurement uncertainty of whole blood tacrolimus mass concentration values meet the assay quality criteria set up by a recent IATDMCT guidance paper.¹⁴

If individual laboratories use the same test principle, *e.g.* an automated immunoassay, traceability of locally applied calibrators to an “industrial master calibration” is usually assured and guaranteed by the assay vendor. The vendor (*e.g.* operating under FDA clearance or within the framework of an obtained IVD-CE certification) has responsibility for the trueness, *i.e.* lack of *bias* of the local calibration to this master calibration. The expected assay precision is also stated by the assay producer, local deviations to the given numbers must be carefully monitored, since they increase the total error of an assay. If such deviations exceed (definable) thresholds, the local laboratory should ensure the assay vendor takes corrective actions (*e.g.* running an additional service, changing a pipetting unit *etc.*) to prevent the occurrence of irregular analytical errors.²⁰⁴ If a laboratory has decided to develop an “in house assay” (LDT), the responsibility for maintaining the trueness and precision of a measurement service is entirely the responsibility of the individual laboratory.²⁰⁵ Failure can be minimized if the trueness of the assay is kept under control by using commercial calibrator materials. In the past it has been impressively shown that this approach minimizes the risk of between-laboratory imprecision for both 25-OH vitamin D²⁰⁶ and tacrolimus,¹⁹² which improves the comparability of patient results obtained by individual laboratories.

In the current global situation, with several FDA approved / IVD-CE certified tacrolimus measurement systems on the market and at least two additional calibrator material vendors

serving the LTD community, one has to assume that the trueness between this tacrolimus TDM measurement platform realizations is limited. Proficiency data (**Figures 1A and 2A**) supports this assumption,¹⁴ emphasizing the need for traceability of individual tacrolimus measurement services beyond the industrial or commercial calibrator systems.

LGC, a National Measurement Institutes of the United Kingdom, took up this challenge some years ago and presented two certified reference materials to the public: ERM-DA110a, a whole blood matrix containing tacrolimus in 2014 (secondary higher order reference material) and, in 2017, ERM-AC022a, which is pure tacrolimus (neat substance, primary higher order reference material). ERM-AC022a was characterized by quantitative NMR but it is not clear which reference method was applied for value assignment, since the primary reference method has not been disclosed, as has been done in other fields, e.g. for steroid hormone measurements.^{207, 208} However, ERM-AC022a and ERM-DA110a are both listed by the JCTLM, implying that the responsible JCTLM working group has reviewed the reports associated with both, and concluded that they are in accordance with the JCTLM regulations.²⁰⁹ Nevertheless, the availability of peer reviewed reference methods for tacrolimus is long overdue. Unfortunately, in the whole field of ISD-TDM, only one such method has been presented and it was for cyclosporine.²¹⁰ Within the Scientific Division (SD) of the IFCC (International Federation of Clinical Chemistry), a work group (WG-ID) was founded in 2018 to focus on activities in this field, including the generation of reference materials and the placement of appropriate reference procedures for immunosuppressive drugs including tacrolimus.²¹¹

New TDM approaches

It should be noted that all of these new TDM approaches were made possible by important analytical improvements developed during the last decade (*i.e.* sensitive and precise liquid chromatography with tandem mass-spectrometry).

Microsample based tacrolimus concentration monitoring (DBS and others)

DBSs on filter cards and volumetric absorptive micro-sampling are innovative, minimal-invasive sample methods, which can replace traditional blood sampling for the TDM of immunosuppressive drugs but can also be used for a number of other applications. This approach is patient-friendly and can be implemented at home by the patient themselves, collecting very small amounts of blood (typically 10-20 μ L). The procedure is both cost and time saving, and it also allows for multiple sampling within a dose interval, enabling the determination of a patient's AUC. The AUC reflects patient's systemic drug exposure. Micro sampled AUC determinations have advantages in special populations such as neonates, pediatric and older patients, in whom venipunctures are difficult and the blood volume that can safely be collected is limited. Furthermore, in a busy out-patient clinic it is logistically difficult to draw multiple blood samples throughout a 12-24 hours dosing-interval. Thus, for tacrolimus TDM, a microsample approach is particularly appealing.

Preanalytical and analytical requirements and pitfalls: Microsample methods require extensive validation with some criteria beyond the usual recommendations for analytical method validation.^{212, 213} This approach also requires sufficient analytical sensitivity because of the low volume of blood collected. The use of microsamples with dried blood is a destructive method meaning that the complete sample is used for the analysis and no confirmation of drug measurement can be conducted using the same sample, only using parallel samples. Current challenges in microsample implementation include but are not limited to: extraction recovery,

matrix effect on blood volume (hematocrit effect), correlation between venous and capillary blood measurements, the quality of the blood spot, risk of contamination, and sample stability. These issues require additional validation steps and have to be properly addressed during method validation.²¹⁴ New generation microsampling such as volumetric absorptive microsampling (VAMS) can possibly mitigate some of the usual bias encountered with these methods, particularly hematocrit effect.²¹⁵ Several DBS methods for tacrolimus TDM have been published. These methods are often multiplexed with other immunosuppressive drugs and may include creatinine determination, which is of particular relevance in kidney transplantation.²¹⁶⁻²¹⁸ To date, microsample validation is only addressed in a few guidelines.^{219, 220}

Future developments and clinical perspective: The use of micro-sampling for tacrolimus TDM needs to be cross-validated with established TDM strategies based on venous EDTA whole blood, to determine whether this approach is suitable for clinical purposes. One of the main advantages over established sampling procedures for tacrolimus TDM is the potential to improve the patient's quality of life. One study has been conducted recently in transplanted children. In parents and children completing the satisfaction survey, all but one reported preference for DBS sampling over venous blood sampling.²²¹ Clinical performance of microsampling in routine practice should also be evaluated in various transplant settings. Analytical performance together with patient training to ensure appropriate sample quality and motivation will be key factors for the implementation of micro-sampling in clinical practice.

Intracellular and tissue tacrolimus concentration monitoring

TDM of immunosuppressive drugs results in a decrease in acute cellular rejection (ACR) rates as well as a decrease in treatment-related toxicity, particularly the nephrotoxic effects of the CNI.⁹¹ However, despite intensive use of TDM, the global outcomes of transplantation appear to be only

marginally improved.¹⁰ This has led pharmacologists to develop newer ways to optimize drug treatment, including measuring the concentration of immunosuppressive drugs directly at their site of action. Currently, standard TDM of tacrolimus is based on the measurement of drug concentrations in whole-blood. Determining tacrolimus drug concentrations where it exerts its immunosuppressive effect, in the T-cell or, for practical reasons, in peripheral blood mononuclear cells (PBMC), might be particularly relevant. Moreover, measuring tacrolimus directly in graft tissue may be of interest as it is reasonable to expect that local concentrations better reflect drug effect. Interest in such approaches has been strengthened by observations of the weak relationship between intracellular and whole blood tacrolimus concentrations in patients following various types of transplantation, suggesting potential added value.²²²⁻²²⁵ A study confirming the link between intracellular tacrolimus concentrations and patient outcomes following liver transplantation suggested that this new TDM approach was a valuable option,²²⁶ but definitive clinical verification and validation remain to be generated. The work conducted on this topic has been reviewed recently.^{227, 228}

Preanalytical and analytical requirements and pitfalls: The first investigations evaluating intracellular concentrations of tacrolimus were conducted in the 1990s. Several groups have contributed to the development of analytical methods to measure tacrolimus concentrations in PBMC of kidney, liver and heart transplant recipients.^{153, 222, 224, 225, 229, 230} The large variability reported in these studies highlighted the critical importance of pre-analytical and analytical steps for intracellular concentration assays. These methods must be appropriately validated following international guidelines and be sufficiently sensitive to quantify low intracellular concentrations, especially in the setting of immunosuppressant minimization protocols. Most analytical methods have involved liquid chromatography with tandem mass-spectrometry detection. Normalization

of the concentrations measured is also needed and can be achieved based on the number of cells, on the mean corpuscular volume of cells for PBMC, or based on the sample weight for tissues. There are several potential issues that have not yet been fully addressed, such as tacrolimus passive or active transport across the cell membrane before cell separation, equilibrium modifications during cell separation or washing steps and the risk of sample contamination with red blood cells. Proper evaluation of the impact of each of these potential issues has to be conducted as these may cause measurement bias. There is a crucial need for practice harmonization for the TDM of intracellular tacrolimus concentrations. Moreover, to date, no quality control programs exist.

Relationship with whole blood concentrations: Early studies to evaluate the relationship between whole blood and cellular concentrations of tacrolimus have reported a lack of correlation.²²⁴⁻²²⁶ However, as the approach is further refined, a trend to better correlations has emerged. Notably, a recent study conducted in a large population of stable kidney transplant recipients (n = 213) showed a linear relationship between whole blood and intracellular tacrolimus concentrations, although agreement between the two concentrations remained modest (r = 0.67).²³¹ Among factors influencing tacrolimus compartmentalization in cells, the role of P-gp (or ABCB1) has already been identified as a determinant of tacrolimus efflux and *ABCB1* genotype relates to intracellular tacrolimus exposure.²²⁴ Other factors may include the circulating free-fraction (influenced by protein binding and hematocrit), and the intracellular expression of CYP3A5/4.²²⁴ More research must be carried out to further explore the role of these factors in the high variability of immunosuppressive efficacy of tacrolimus. A more detailed knowledge of such factors may also allow the identification of sub-populations of patients who may benefit from alternative TDM strategies, such as intracellular measurement of tacrolimus.

Clinical evidences and future perspectives: To date, the most convincing proof of concept study was reported by Wallemacq's group in Belgium.²²⁶ In a study conducted in 90 liver transplant recipients treated with tacrolimus monotherapy, they reported a relationship between tacrolimus concentrations in PBMC as well as in liver biopsy samples and histological rejection grade determined at day-7 post-transplantation, whereas whole blood concentrations were not associated with the severity of rejection.²²⁶ The results of this study suggested that intracellular tacrolimus concentrations early after liver transplantation seem to be related to rejection risk and severity. The lack of a relationship between whole blood tacrolimus concentrations and clinical outcome during this early period may be a good argument for using intracellular tacrolimus concentrations as a biomarker of immunosuppressive drug effect. Another observational study highlighted the case of a liver transplant recipient experiencing an ACR while having the lowest intracellular tacrolimus exposure among study participants.²³² However, the definitive evidence for the relevance of intracellular tacrolimus concentrations as a longitudinal biomarker usable for clinical practice with standard immunosuppressive regimens is still lacking. The time-consuming pre-analytical sample work up makes this approach complex and still requires extensive validation. Another perspective could be obtained by multi-variate mathematical modeling predicting intracellular concentrations, based on increasing experience in genetic polymorphism, together with a better understanding and identification of covariates influencing intracellular tacrolimus concentrations. Besides intracellular measurement, determining the tacrolimus free-fraction also appears to be an appealing approach. This unbound (*i.e.* the pharmacologically active moiety) fraction of the drug might be of interest in reflecting immunosuppressive drug effect. This newer way of TDM should also be investigated but is still at an early stage of development.^{152, 233} Finally, it should be mentioned that the analysis of tacrolimus in oral fluid

samples has been investigated. One study concluded that the correlation with whole blood concentrations was poor and due to several problematic methodological problems could not be recommended.²³⁴ A more recent report indicated that some of these problems could be overcome, however, blood contamination may still pose a problem²³⁵ and this kind of sampling seems to not have gained any further interest so far.

PHARMACOGENETICS

After oral administration, tacrolimus is metabolized by gastrointestinal and hepatic cytochrome P450 (CYP) 3A isoenzymes, predominantly CYP3A4 and CYP3A5 (other members of the CYP3A family are CYP3A7 and CYP3A43). The main enzyme involved in tacrolimus biotransformation is CYP3A5, with CYP3A4 having a lower efficiency for catalysis.²³⁶

The expression of CYP3A5 is largely determined by genetic polymorphisms, with only 15-25% of Caucasians expressing CYP3A5 at a detectable level. The main genetic factor responsible for this is an intron 3 single-nucleotide polymorphism (SNP; *CYP3A5**3, rs776746, g.6986A>G) which causes aberrant splicing, resulting in the absence of protein and, thus, CYP3A5 activity.^{237, 238} Individuals with at least one *CYP3A5**1 allele (defined as the “wild-type” allele) are classified as CYP3A5 expressors (*CYP3A5**1/*1 or *CYP3A5**1/*3). The minor allele frequency (MAF) of *CYP3A5**3 varies widely across different ethnicities, resulting in significant differences in CYP3A5 expression (**Table 3**). Another rare SNP located in exon 7 (*CYP3A5**6, rs10264272, g.14690G>A) has also been shown to result in loss of functional CYP3A5 activity.²³⁷

Until recently, and in contrast to CYP3A5, no common SNP in the *CYP3A4* gene could be related to CYP3A4 activity and to explain the significant between-individual variability in CYP3A4 activity. However, in 2011, Wang et al., demonstrated that an intron 6 SNP

(*CYP3A4**22, rs35599367, C>T) significantly influenced *CYP3A4* hepatic expression, suggesting that this SNP may be a biomarker for the prediction of the response to drugs metabolized by *CYP3A4*.²³⁹

In addition to *CYP3A4* and *CYP3A5*, the efflux transporter *ABCB1* also plays a role in tacrolimus pharmacokinetics.^{240, 241} Over the last decade, more than 50 SNPs have been identified in *ABCB1*.^{242, 243} The three most common SNPs in the protein-encoding region are rs1128503 (1236C>T, Gly412Gly), rs2032582 (2677G>T/A, Ala893Ser/Thr), and rs1045642 (3435C>T, Ile1145Ile).^{244, 245} These three SNPs (with a MAF of around 50% in Caucasians) are in strong linkage disequilibrium (LD) and have been investigated extensively. Other less frequent SNPs have been described and, potentially, can explain part of the between-individual variability observed in the expression and/or function of *ABCB1*. Of particular interest, the *ABCB1* 1199G>A coding SNP located in exon 11 (rs2229109) is relatively frequent, with a reported allelic frequency of about 6% in the Caucasian population. This SNP is associated with a serine to asparagine substitution at position 400 in a cytoplasmic loop of *ABCB1* which is involved in substrate recognition and with intracellular accumulation of tacrolimus in HEK293 and K562 recombinant T-cell lines.²⁴⁶

A SNP in the gene encoding P450 oxidoreductase (*POR**28; rs1057868, C>T, Ala503Val) has been associated with an increased *in vivo* *CYP3A* activity using midazolam as a drug probe.²⁴⁷ Because tacrolimus is metabolized by *CYP3A* isoenzymes, this SNP might affect tacrolimus pharmacokinetics.

Finally, two different SNPs in peroxisome proliferator-activated receptor alpha (*PPAR*α) (rs4253728 G>A and rs4823613 A>G) have been shown to influence *CYP3A4* activity both *in vitro* and *in vivo*.²⁴⁸

Pharmacokinetic-Pharmacogenetic relationships in kidney transplantation

In relation to pharmacokinetic parameters and TDM, it has been clearly demonstrated that the *CYP3A5**3 variant is the main genetic factor influencing tacrolimus dose requirement (defined as the dose-adjusted, whole blood pre-dose concentration or C_0) in stable renal transplant recipients, both in the early and late phase after transplantation (*i.e.* several weeks to months after transplantation).²⁴⁹⁻²⁵¹ Since the original publication, this genetic association has been confirmed in a large number of studies²⁵² and meta-analysis.^{253, 254} Based on these observations, dose adjustments have been proposed for the first tacrolimus dose after kidney transplantation, according to the *CYP3A5* genotype of the recipient, with a doubling of the tacrolimus starting dose in patients who are *CYP3A5* expressors (carrying at least one wild-type *CYP3A5**1 allele).²⁵⁵ Indeed, genotype-based adjustment of the initial tacrolimus dose has already proven useful, with a greater proportion of patients reaching the therapeutic concentration range shortly after transplantation.²⁵⁶ Such a pre-emptive strategy, without additional dose adaptation (only based on *CYP3A5* genotype) during the first four days after transplantation, has been proven to be safe and easy to implement.²⁵⁷ The level of evidence of this pharmacogenetic-pharmacokinetic association justified a specific guideline from the Clinical Pharmacogenetics Implementation Consortium (CPIC).²⁵⁸ However, the benefit in terms of reaching the targeted tacrolimus exposure earlier with the use of *CYP3A5* genotype-based dosing has not been a universal finding²⁵⁹ and no trials have so far demonstrated improved clinical outcomes.

Besides *CYP3A5**3, *CYP3A4* activity has also been shown to be an important factor influencing tacrolimus dose requirement and clearance in renal transplant patients.²⁶⁰ To a lesser extent than *CYP3A5**3, *CYP3A4**22 has been shown to influence tacrolimus dose-adjusted pre-dose concentrations and dose requirements in stable renal transplant patients.^{261, 262} A similar approach

to genotype-based dose adjustment has been proposed with the advice that both *CYP3A5**3 and *CYP3A4**22 should be taken into consideration.²⁶³ Updated guidelines for the tacrolimus starting dose based on the recipient's *CYP3A5* and *CYP3A4* combined genotype (**Table 4**) have been validated through popPK modelling.^{264, 265} However, the clinical utility of this approach still remains to be proven in prospective studies before it can be included in a future revised version of the CPIC guidelines.

Although numerous studies have shown no influence of *ABCB1* genotype on tacrolimus pharmacokinetic parameters^{249, 251, 266, 267}, some studies and/or meta-analyses have reported weak but significant associations,^{268, 269} mainly during the first month after transplantation.²⁷⁰ In those, latter publications, *ABCB1* 3435 CC patients were reported to have a lower tacrolimus concentration-to-dose ratio and a higher dose requirement for tacrolimus compared with patients having the CT and TT genotype, although no genotype-based dose adjustments have been proposed according to *ABCB1* genotype of the recipient. An explanation for the lack of the anticipated correlation between *ABCB1* variants and tacrolimus pharmacokinetics could be that the expression and the function of *ABCB1* is highly variable and is influenced by several factors, including non-genetic factors.²⁷¹

It is interesting to note that *ABCB1* genotype has been shown to influence intracellular tacrolimus concentrations, particularly in PBMCs. Indeed, 3435T and 1199A carriers had a significantly higher intracellular tacrolimus concentration compared with homozygous wild-type patients, suggesting a reduced *ABCB1* activity towards tacrolimus in PBMCs of patients with these *ABCB1* variants.²⁷² Theoretically, such effects of *ABCB1* genotype on PBMC concentrations could influence pharmacodynamics without any significant impact on whole-blood pharmacokinetic parameters.²⁷³

In addition, in relation to pharmacokinetic parameters and TDM, it has been demonstrated that patients carrying at least one *POR*28* allele have a higher tacrolimus dose requirement than those not carrying this allele (*POR*1/*1*), but this association was only found in CYP3A5 expressors.²⁷⁴⁻²⁷⁷ Only one study reported no association between *POR* genotype and tacrolimus pharmacokinetic parameters.²⁷⁸ Going one step further, another study, which confirmed that the *POR*28* allele was associated with increased *in vivo* CYP3A5 activity towards tacrolimus in CYP3A5 expressors, also showed that *POR*28* homozygosity (*POR*28/*28*) was associated with a significantly higher CYP3A4 activity towards tacrolimus in CYP3A5 non-expressors.²⁷⁹ Up until now, no specific genotype-based dose adjustments have been proposed according to recipient's *POR* genotype but, based on the consistency of the available data, future recommendations could include *CYP3A5*3*, *CYP3A4*22* and *POR*28* genetic information. Finally, tacrolimus dose-adjusted pre-dose concentrations were not different depending on peroxisome proliferator-activated receptor alpha *PPARA* genotype in a cohort of 241 Caucasian kidney transplant patients.²⁷⁸ In another study (n = 177), a limited effect (15% higher tacrolimus concentration) was observed in the *PPARA* variant allele carriers.²⁷⁴

Pharmacogenetic-Pharmacodynamic relationships in kidney transplantation

FK-binding protein-12 (FKBP-12), the principal binding protein for tacrolimus, is polymorphically expressed. The same holds true for CaN and the nuclear factor of activated T-cells (NFAT), which is the main downstream target of CaN (reviewed in Pouche *et al.*²⁸⁰). In an *in vitro* study, it was demonstrated that genetic polymorphisms in the genes encoding proteins of the CaN pathway were associated with the inhibitory effects of tacrolimus.²⁸¹ However, in a study including 160 kidney transplant recipients, no statistically significant associations between

these genetic variants and tacrolimus pharmacodynamics was demonstrated.²⁸² Taken together, the limited available data do not suggest a clinically relevant effect of genetic polymorphisms in FKBP-12, CaN and NFAT and tacrolimus pharmacodynamics.

Pharmacogenetics in liver transplantation

CYP3A isoenzymes are expressed in both the liver and the intestine. Both organs contribute to the pre-systemic metabolism of tacrolimus but, unlike other forms of solid organ transplantation, the hepatic enzyme content is determined by the donor genome in liver transplantation whereas the intestinal content is determined by the genome of the recipient.

The association between tacrolimus pharmacokinetics and the *CYP3A5* genotype of both the intestine (recipient) and the liver (donor) has been assessed in living-donor liver transplantation (LDLT) and in deceased-donor liver transplantation. Some studies have demonstrated that donor and recipient *CYP3A5**3 genotypes are of major influence for tacrolimus blood concentration to dose ratio (C/D) which serves as an index of clearance and tacrolimus dose requirement²⁸³⁻²⁸⁵, whereas other authors have suggested that donor *CYP3A5**3 seems to contribute more than the recipient.^{286, 287} Of note, the lowest (C/D) ratio values were seen when both donor and recipient were *CYP3A5* expressors.^{285, 288, 289} A meta-analysis combining data from living- and deceased-donor liver transplantation (694 donor & recipient genotypes) confirmed that both the genotype of the donor and recipient are important in determining the C/D ratio. The *CYP3A5* genotype of the recipient, the determinant of intestinal genotype, has the greatest influence on tacrolimus dose requirement in the immediate post-transplant period, whereas the donor genotype, affecting hepatic expression, becomes more important after the first few weeks.²⁹⁰

Another study, which included more than 400 LDLT cases from Japan suggested that the *CYP3A5* genotype of the recipient was more important than that of the grafted liver as an

indicator of systemic tacrolimus exposure for at least 5 weeks after transplantation.²⁹¹ The increasing role of the donor *CYP3A5* genotype with time is compatible with the progressive liver graft recovery and growth. Of note, in this study there was a higher frequency of acute cellular rejection among patients receiving a liver with at least one *CYP3A5**1 allele compared to those receiving a liver with the *CYP3A5**3/*3 genotype, suggesting an association between local (intrahepatic) concentration of unmetabolized tacrolimus and rejection. This effect of donor and recipient *CYP3A5* genotype is apparently independent of the tacrolimus formulation. This association was reported in two studies in stable liver transplant recipients treated with the once-daily tacrolimus formulation.^{283, 292}

Opinion is divided on the association of the *CYP3A5* genotype with the nephrotoxicity of tacrolimus. In both liver and heart transplantation, it was reported that *CYP3A5* expression in the kidneys could play a role in the individual susceptibility to the nephrotoxic effects of tacrolimus.²⁹³⁻²⁹⁵ Another report suggested that expression of *CYP3A5* (in both the graft liver and the intestine of the recipient) may result in a higher incidence of infectious complications in LDLT recipients. The exact mechanism for these complications related to excessive immunosuppression is unclear but it was postulated that these may relate to differences in tacrolimus metabolism.^{296, 297}

Only a few studies have been conducted on *CYP3A4**22 in liver transplantation. In stable liver transplant recipients, Moes *et al.* found no association between this SNP and the pharmacokinetics of the once-daily formulation of tacrolimus (considering both the donor and the recipient genotypes).²⁹² The *CYP3A4**22 SNP was also investigated among Asian patients but was not identified in this population.²⁹⁸ Results from adult liver transplant recipients receiving a twice-daily formulation of tacrolimus have shown that donor *CYP3A4**22 genotype

influences tacrolimus pharmacokinetics; a substantial reduction in tacrolimus dose was required in the first weeks after transplantation to achieve target concentrations.^{299, 300} In addition, donor and recipient *CYP3A4**22 genotypes seem to have opposite effects, with absence of effect of the combined recipient and donor statuses on tacrolimus C/D ratio value.²⁸⁹ In pediatric liver transplantation, a popPK study suggested that the apparent clearance of tacrolimus decreased by 29% when a graft carried a *CYP3A4**22 allele (with no effect of the recipient genotype). This effect was quantitatively similar to that observed in the case a donor liver expressing *CYP3A5* (*i.e.* an increase of 30% for apparent clearance).³⁰¹ However, comparison between pediatric and adult liver transplant patients is difficult since young transplant recipients have a higher liver graft to body weight ratio, leading to a higher tacrolimus apparent clearance and dose requirement.

Results from these studies revealed controversial data, so further studies are needed to better evaluate the apparently limited influence of *CYP3A4**22 that might be masked by the more dominant effect of *CYP3A5**3 on tacrolimus pharmacokinetics.

Regarding *CYP2C19* status and its influence on tacrolimus exposure, liver transplant patients with a *CYP2C19* defect genotype have a higher risk of clinically significant drug-drug interactions between tacrolimus and drugs whose major metabolic pathway involves *CYP2C19*, such as omeprazole and lansoprazole³⁰² and voriconazole.⁴⁵

As for other types of transplantation, the association between various *ABCB1* SNPs and tacrolimus pharmacokinetics and pharmacodynamics in liver transplantation is debated. The mean tacrolimus C_0 correlated significantly with *ABCB1* messenger ribonucleic acid (mRNA) expression in PBMC and the *ABCB1* messenger ribonucleic acid (mRNA) expression level in the small intestine was associated with acute rejection risk and one-year graft survival.³⁰³

Pharmacogenetics in heart transplantation

As in other solid organ transplant populations the effect of the defective *CYP3A5**3 allele on tacrolimus dose-requirement is also well established in heart transplant recipients. In fact, 7 different candidate-gene association studies related this SNP to differential tacrolimus exposure regardless of the period after transplantation or the design of the study (*i.e.* longitudinal or cross-sectional).³⁰⁴⁻³¹⁰ It has also been consistently reported that the tacrolimus dose required by *CYP3A5* expressors to achieve the target therapeutic range is approximately 2-fold higher when compared to *CYP3A5* non-expressors. However, it is estimated that only about 25% of the variability in tacrolimus dose requirement is explained by a patient's *CYP3A5* genotype, which is slightly lower than the value observed among the renal transplant population. This observation suggests that other pharmacogenetic markers may explain part of this residual variability.

So far, only two studies have assessed the effect of the *CYP3A4**22 allele on tacrolimus dose requirement in adult heart transplant recipients. The first of these studies was characterized by a cross-sectional design with a relatively small number of patients ($n = 76$).³⁰⁸ In contrast to observations made in kidney and liver transplantation, no significant association was found between the *CYP3A4**22 SNP and tacrolimus dose requirement, even if the combined *CYP3A4* and *CYP3A5* genotype was studied. In the second study no association between *CYP3A4* genotype and tacrolimus dose requirements was observed. However, only one *CYP3A4**22 carrier was detected among the 52 tacrolimus-treated heart transplant recipients.³¹⁰ In contrast, in a cohort of 60 pediatric heart transplant recipients, it was observed that *CYP3A4**22 carriers needed a 30% lower tacrolimus dose to reach similar exposure compared with *CYP3A4**1/*1 patients.³⁰⁷ This study was characterized by a longitudinal design in which 13 time-points were analyzed during the first 2 weeks after transplantation. This more rigorous design might explain

why the difference was significant despite the low number of patients included in the analysis. The differences were even more significant when patients were categorized into the different *CYP3A* genotype clusters. It was demonstrated that *CYP3A* poor metabolizers required 17% less tacrolimus compared with intermediate metabolizers and 48% less than extensive metabolizers. These findings suggest that the combined *CYP3A4* and *CYP3A5* genotype can provide useful information to guide tacrolimus immunosuppressive therapy after heart transplantation.

As for other solid organ transplantation populations the majority of studies have not reported a clear association between *ABCB1* genotype and tacrolimus pharmacokinetics or dose requirement among heart transplant recipients.^{304, 306, 309, 310} A minor association between the *ABCB1* 1236C>T SNP and tacrolimus dose requirement was observed in a mixed cohort of 60 heart transplant recipients³¹¹ in which 36 SNPs were investigated in relation to the efficacy, safety and pharmacokinetics of immunosuppressive drugs, including tacrolimus (n = 23). In this small study, it was shown that patients homozygous for the 1236C allele had a lower tacrolimus C₀/D than carriers of the 1236T variant allele, although this difference was not statistically significant.

Only one study in heart transplantation has evaluated the association between *POR*28* and tacrolimus pharmacokinetics.³¹⁰ In this study, associations between 7 SNPs and dose-adjusted tacrolimus C₀ at 1, 3, 6, and 12 months after heart transplantation were evaluated in 52 patients. Carriers of the *POR*28* variant had a higher dose-adjusted tacrolimus C₀ at all-time points but the differences were only significant at months 3 (p = 0.025) and 6 (p = 0.047) after transplantation. Interestingly, this *POR*28* effect was observed without consideration of the *CYP3A5*3* allelic status, whereas in other forms of solid organ transplant the defect caused by the *POR*28* allele was only apparent among *CYP3A5* expressors.

Pharmacogenetics in lung transplantation

As expected, among lung transplant recipients, *CYP3A5**1 carriers require higher doses of tacrolimus to reach the target therapeutic range throughout the first post-transplant year, suggesting that doubling the dose in *CYP3A5* expressors might also be an option in lung transplantation.³¹² This was confirmed in a popPK study in which the tacrolimus clearance was found to be 40% higher compared with non-expressors.⁹⁴ With regard to the influence of *ABCB1* genotype, available data are limited but 2 studies suggested that *ABCB1* haplotypes associated with high *ABCB1* pump function are characterized by a lower exposure to tacrolimus in adult lung transplant recipients. The magnitude and the variation over time post-transplant of the influence of *ABCB1* haplotypes on tacrolimus dose requirements were not definitely characterized in these two studies since the cohorts were relatively small and a combined analysis of all *CYP3A5* and *ABCB1* variants was not performed.^{312, 313} No study on the association between *CYP3A4**22 and tacrolimus pharmacokinetics / dose requirement after lung transplantation has been reported.

Executive summary and practical recommendations

The association between *CYP3A5* genotype and tacrolimus dose requirements is consistent and has been observed among kidney, liver, heart and lung transplant recipients, both adult and pediatric. Patients expressing *CYP3A5* require an at least 50% higher tacrolimus dose to reach the target therapeutic range compared with non-expressors (A I). Although there is evidence from a randomized-controlled clinical trial that basing the tacrolimus starting dose on an individual's *CYP3A5* genotype may facilitate tacrolimus dosing, this has not been a universal finding and there is currently no convincing clinical evidence that a pharmacogenetics-based approach to tacrolimus dosing improves clinical outcomes after solid organ transplantation. Of

the many other candidate SNPs that have been studied, *CYP3A4**22 appears to be the most promising as it explains residual variability in tacrolimus pharmacokinetics (B II, and C2 II, for Caucasians, Asiatic and African origin populations, respectively). We believe that future studies should investigate the clinical benefit of popPK models including *CYP3A5* and *CYP3A4* genotype (and possibly other genetic markers), to guide tacrolimus dosing.

PHARMACODYNAMIC BIOMARKERS FOR TACROLIMUS MONITORING

Pharmacodynamic biomarkers for the action of tacrolimus

Pharmacodynamic biomarkers can be either drug-specific or non-drug specific.³¹⁴ In the case of tacrolimus, drug-specific biomarkers are related to the signal transduction pathways and enzyme activities inhibited by the drug, whereas non-specific biomarkers reflect the inhibition of T-cell activation and proliferation in general, including cytokine production. Pharmacodynamic biomarkers can be determined either directly in whole blood, in whole blood stimulated with mitogens, antibodies, in donor leucocytes or third-party cells and in isolated lymphocytes, either quiescent or stimulated. Pharmacodynamic biomarkers used to monitor tacrolimus pharmacodynamic effects and activities are listed in **Table 5** and illustrated in Figure 3.

Drug specific pharmacodynamic biomarkers

Calcineurin phosphatase activity

Attempts to measure CaN activity to monitor the effect of tacrolimus have been pursued since very early after the release of the drug. One of the earliest approaches was to follow the dephosphorylation of a radioactively labeled peptide substrate by measuring the ³²P released.³¹⁵ To avoid radio isotopes, a phosphorylated peptide substrate R II has been synthesized which can be measured in its dephosphorylated state by HPLC.³¹⁶ However, it turned out that this approach

is less sensitive compared to the radiometric method and recently an LC-MS/MS-based method was published by Carr *et al.*³¹⁷ All methods to measure CaN activity using a synthetic substrate suffer from non-specificity because other intracellular phosphatases besides CaN also dephosphorylate the peptide. Therefore, this non-specific activity must either be measured separately or subtracted from the assay readout, or specific inhibitors and CaN activators must be added to the incubation mixtures to achieve a CaN specific result.³¹⁸ CaN activity is determined in peripheral blood mononuclear cells (PBMC) which requires cell isolation before the assay can be performed. Unfortunately, results from different assays are reported in method specific units, which make the comparison of data difficult. Several groups have measured CaN activity in patients after liver and kidney transplantation and, in general, observed an inverse relationship between CNI concentrations in whole blood and CaN activity in PBMC, but with a high between-individual variability.³¹⁹⁻³²¹ A common observation with *in vitro* experiments is that, in contrast to the CNI cyclosporine, tacrolimus does not attain 100% inhibition of the enzyme even at very high concentrations.^{317, 320, 321} In one study, the EC₅₀ of tacrolimus was 26.4 ng/mL above the accepted upper limit of the therapeutic range (20 ng/mL).³²⁰ In line with this observation, tacrolimus C₀ have been shown to be without effect on the CaN activity.³¹⁷ This questions the measurement of CaN activity as a pharmacodynamic marker of tacrolimus effect, particularly in blood samples which are drawn as trough samples immediately before the next dose. However, several groups observed an association between CaN activity and clinical events such as nephrotoxicity in liver transplant patients³²⁰ or rejection in kidney graft recipients.³²² Surprisingly, CaN measured by HPLC did not correlate at all with intracellular tacrolimus concentrations in PBMCs.²³²

There are contradicting results about the appropriate time point for PBMC isolation after tacrolimus administration. Some authors observed better effects 2 hours after dosing, which reflects tacrolimus peak concentrations, whereas others noted a greater inhibition of enzyme activity after 4 hours.³¹⁶ An intrinsic drawback of all pharmacodynamic assays to measure enzyme activities in isolated PBMC is the fact that the drug is lost during the isolation and washing steps and that the cells are incubated in a non-physiological environment. Furthermore, CaN assays are not standardized and are, except for the LC-MS/MS method, barely validated in terms of their analytical performance.³¹⁷

Nuclear translocation of NFAT by flow cytometry

A downstream event of CaN is the translocation of the dephosphorylated NFAT to the nucleus. NFAT is a family of transcription factors and NFAT has been reported to be particularly sensitive to inhibition by tacrolimus.³²³ Intra-nuclear translocation of NFAT1 can be followed by flow cytometry image stream (AMNIS).^{324, 325} For this purpose, whole blood is stimulated *ex vivo* with phorbol myristate acetate (PMA)/ionomycin for 30 minutes and the nuclear localization of NFAT1 is visualized in stimulated and non-stimulated CD4⁺ and CD8⁺ T cells using an anti-NFAT1 antibody and 4',6-Diamidino-2-Phenylindole (DAPI) staining.³²⁵ Maguire *et al.* observed in a small study with 3 renal transplant patients an inverse correlation between tacrolimus concentrations and nuclear translocation of NFAT1.³²⁵ The assay is time consuming, requires special equipment and fresh blood samples. Furthermore, it has yet to be thoroughly validated.

Using multi-parametric flow cytometry, Noceti *et al.* investigated the effect of tacrolimus along the CaN pathway in lymphocytes in healthy human participants (n=35)³²⁶ and in patients on the waiting list for liver transplantation (n = 19).²⁸¹ As described by $I/I_{\max}$ models, increasing doses

of tacrolimus proportionally inhibit NFAT1 translocation as well as IL-2 and CD25 expression. Moreover, IL-2 and CD25 response to the inhibition of NFAT1 expression in PBMC nuclei follow allosteric sigmoidal models, suggesting tight signal translation along the CaN pathway.³²⁶ Between-individual variability was higher under non-stimulated than under stimulated conditions, as well as in the presence of tacrolimus.³²⁷ IL-2⁺CD8⁺ cells at tacrolimus I_{max} showed the highest tacrolimus between-individual variability, suggesting its usefulness as a biomarker of individual effects integrating many different sources of regulation and variability. Multivariate statistical analysis showed the influence of pharmacogenetic polymorphisms on tacrolimus pharmacodynamics.^{281, 326}

The aforementioned study also demonstrated the feasibility of using non-stimulated PBMCs to explore the CaN pathway under more physiologic conditions while integrating more variability than in the equivalent stimulated status.²⁸¹ The largest variability was observed at tacrolimus IC₅₀, which is in line with the large between-individual differences observed in clinical drug effects among patients. NFAT1 translocation might reflect the degree of individual immunological capacity, as Sommerer et al. and Zhan *et al.*, reported a correlation between lower NFAT-regulated gene expression and increased frequency of infection episodes in transplant patients.^{328, 329}

NFAT1 translocation to PBMC nuclei promises to be a suitable candidate biomarker to monitor tacrolimus pharmacodynamics after transplantation. However, further evidence in terms of potential associations of the extent of NFAT1 translocation with clinical outcomes is still needed.

NFAT regulated gene expression

As CNI trough or peak concentrations are only marginally associated with clinical outcome, if at all, several approaches to measure the biologic effects of CNI-based immunosuppression have been developed, including the assessment of CaN phosphatase activity, cytokine release and gene expression.^{315, 330-336}

Quantitative analysis of gene expression has been established to calculate the functional effects of CaN inhibition, specifically the inhibition of the transcription of NFAT-regulated genes in peripheral blood.^{315, 328, 337, 338} This assay is based on the quantitative analysis of IL-2, IFN- γ and GM-CSF gene expression in whole blood samples collected at cyclosporine / tacrolimus C₀, and peak concentrations (2 hours for cyclosporine and 1.5 hours for tacrolimus) after oral administration.

The real-time polymerase chain reaction (RT-PCR) technique provides a rapid, highly reproducible, and sensitive tool for the quantitative analysis of gene expression.³³⁷ This method can be semi-automated and standardized and performed in specialized laboratories. Whole blood samples are stable for 24 hours at 20 °C. Although overall gene expression is reduced upon storage, the relative degree of NFAT inhibition remains stable during this period. NFAT-regulated gene expression has shown low analytical variability (less than 10%) in repeated measurements. Whereas between-patient variability is high, within-individual variability is low in patients on stable CNI doses and stable immunosuppressive co-medication.^{336, 337}

This assay can be set up with satisfactory analytical performance in a routine molecular biological laboratory.^{328, 339-341} Linearity, imprecision, and limit of quantification, as well as sample stability were investigated. A between-laboratory comparison showed comparable results.³³⁹ The reproducibility of the NFAT-regulated gene expression assay across laboratories could facilitate the implementation of this assay for the pharmacodynamic routine monitoring of

CNI in different centers. Therefore, this monitoring technique could be used in larger patient cohorts and in multicenter clinical studies.

NFAT-regulated gene expression has been performed in solid organ transplantation such as kidney (adults and children), liver, heart, and lung transplant recipients.^{318, 333, 339} Beneficial effects in the early post-transplant period were confirmed, as well as in the long-term follow-up after transplantation.^{318, 340, 342} However, most of the evaluations included maintenance allograft recipients.^{318, 328, 343-350} These results summarized data on acute rejection, opportunistic infections, malignancy (*e.g.* non-melanoma skin cancer), and cardiovascular risk or outcome. In observational, cross-sectional and prospective clinical trials, including one prospective case-control study, monitoring of residual NFAT-regulated gene expression has been proven as a tool to reduce cyclosporin A therapy in stable renal allograft recipients.^{318, 333} In one prospective randomized controlled clinical study, the novel approach of monitoring residual NFAT-regulated gene expression led to a significantly reduced cardiovascular risk and improved allograft function in stable renal transplant recipients compared to the standard monitoring by cyclosporine trough concentrations.³⁵¹

In a considerable proportion of patients treated with tacrolimus, the inhibition of NFAT-regulated gene expression is lower compared to cyclosporine treatment, possibly partially due to a low relative increase of tacrolimus concentrations from C_0 to C_{max} .³⁴⁸ The lack of CaN inhibition in patients treated with tacrolimus has been described previously by direct quantification of the enzyme activity,^{317, 320, 321} suggesting additional, as yet unidentified targets of the drug. Nevertheless, several studies on tacrolimus treatment showed that monitoring residual NFAT-regulated gene expression could identify allograft recipients at higher risk of infections or acute rejection.^{340, 345, 348, 349}

NFAT-regulated gene expression is a promising biomarker in CNJ therapy in regard to infectious complications, malignancies, acute rejection and cardiovascular risk. Within the last years, an assay which detects NFAT-regulated gene expression was introduced in clinical studies in several transplant centers in Europe and USA with encouraging results. The assessment of residual expression of NFAT-regulated genes is a minimally-invasive, rapid, robust, and reliable assay system, which has proven its validity and practicality in clinical and research settings. In patients treated with cyclosporine or tacrolimus, NFAT-regulated gene expression has the potential to develop into a monitoring tool complementing pharmacokinetics, especially in long-term renal allograft recipients.

Dephosphorylated proteins

The inhibitory effect of tacrolimus on the phosphorylation of intracellular signaling molecules can be measured by phospho-specific flow cytometry in T-cells and their subsets. There are scarce examples in which this approach has been used. One recent study by Kannegieter *et al.* followed the phosphorylation of p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) and Protein kinase B (AKT) in CD3⁺, CD4⁺ and CD8⁺ T-cells.³⁵² In non-stimulated whole blood samples, p38 MAPK and AKT were inhibited after kidney transplantation in CD4⁺ and ERK in CD8⁺ cells in patients treated with a tacrolimus-based immunosuppressive therapy. Stimulation of whole blood samples with PMA/ionomycin revealed lower phosphorylation of p38 MAPK and AKT in CD4⁺ and CD8⁺ cells compared to samples obtained before initiation of immunosuppressive therapy. Patients experiencing acute rejection episodes, but on therapy with belatacept, showed higher phosphorylation of ERK in both CD4⁺ and CD8⁺ cells compared to patients without rejection. Authors from the same group expanded monitoring of p38 MAPK, ERK, and AKT phosphorylation to CD14⁺ monocytes in 20 kidney

transplant recipients receiving a tacrolimus-based immunosuppressive regimen. However, no association with clinical outcome or tacrolimus dose adjustments was reported.³⁵³ A small conversion study of a twice-daily to a once-daily formulation of tacrolimus with 12 stable kidney graft recipients was accompanied by the monitoring of p38 MAPK phosphorylation. After conversion to the once daily formulation, a higher phosphorylation of 11.4% in CD4⁺ T-cells and 15.6% in CD8⁺ T-cells was observed despite comparable tacrolimus C₀. The authors considered phosphoflow as a sensitive approach to assess the pharmacodynamic effects of tacrolimus.³⁵⁴ An advantage of phosphoflow cytometry is that no cell isolation is required. However, samples should be freshly analyzed and experience with the technique as well appropriate instruments are required, which currently precludes a wider application.

IL-2 mRNA expression and production in leukocytes

The terminal downstream effector of the CaN pathway is the cytokine IL-2, which can be followed as a pharmacodynamic read-out of tacrolimus action by studying its mRNA expression. Alternatively, the intracellular formation can be followed in T-cells by flow cytometry or the release from leukocytes into cell culture media.³⁵⁵ In a study with 8 renal transplant patients treated with tacrolimus, mycophenolic acid and steroids, PBMC were isolated and stimulated with an anti-CD3 mouse monoclonal antibody.³⁵⁵ The authors observed an inverse association between tacrolimus whole blood concentrations and IL-2 mRNA expression, the number of IL-2 producing CD4⁺ T-cells and the extracellular IL-2 concentration.³⁵⁵ Vadafari *et al.* showed an effect of the *ABCB1* genotype on intracellular IL-2 expression as a pharmacodynamic read-out of the tacrolimus effect on T-cells from kidney transplant recipients.²⁷³ The *ABCB1* 3435CT SNP has been shown to affect transporter activity, whereby the CC genotype has been associated with

a higher activity compared to the *TT* genotype. In turn, this leads to lower tacrolimus concentrations inside the cells, which are associated with less IL-2 expression.

Drug non-specific pharmacodynamic biomarkers

ATP release from CD4⁺ T-cells

T-cell activation can be assessed by a commercial assay (ImmuKnow, Viracor-IBT Laboratories, Lee's Summit, MO, USA) to follow ATP release from stimulated CD4⁺ T-cells. The assay has been used to assess the pharmacodynamic effect of switching from a twice daily formulation of tacrolimus (Prograf) to a once daily formulation (Advagraf) in simultaneous pancreas-kidney graft recipients.³⁵⁶ Unlike the effects observed in kidney transplant patients on p38 MAPK phosphorylation,³⁵² no significant effect was seen on the ATP production, suggesting an equal pharmacodynamic effect of both formulations.³⁵⁶ Similar results have been reported before in living donor liver transplant recipients.³⁵⁷ In a recent study involving liver transplant patients, the tacrolimus dose was individualized in 102 of 202 patients on the basis of the ImmuKnow assay results. Tacrolimus doses were either reduced or increased by 25% when ATP concentrations were <130 ng/mL (strong immune response) or >450 ng/mL (low immune response), respectively. Patient survival was higher, and the incidence of infections lower in the interventional arm compared to the 200 controls who were dosed according to trough blood level results only. Patients without adverse events had, in general, a lower tacrolimus dose and trough concentrations.³⁵⁸

T-cell proliferation and surface activation markers

The impact of tacrolimus on inhibition of T-cell proliferation was measured *ex vivo* by flow cytometric quantification of the proliferation cell nuclear antigen (PCNA) in peripheral blood of

heart transplant recipients.³⁵⁹ Furthermore, in patients with chronic kidney disease, *ex vivo* peripheral blood analysis by flow cytometry showed inhibitory effects of tacrolimus on T-cell proliferation after labelling with carboxylfluorescein diacetate succinimidyl ester (CFSE).³⁶⁰

Regarding early T-cell activation markers, investigations involving renal transplant patients have demonstrated that CD40L and CD69 are suppressed during tacrolimus immunosuppression³³⁰, which was even more evident after conversion from cyclosporine to tacrolimus.³⁶¹ In general, tacrolimus treatment suppresses T-cell markers (CD25, CD95, CD154), co-stimulatory molecules (CD28, ICOS) and adhesion molecules (CD54) in patients after solid organ transplantation (**Supplementary Table 1**, <http://links.lww.com/TDM/A321>).^{330, 359, 361-364}

Tacrolimus immunosuppression also affects T-cell differentiation into distinct effector cell types like CD4⁺, CD8⁺ and Th17 cells. While the percentage of CD4⁺ and CD8⁺ T-cells has been reported to be reduced^{361, 365, 366} without changing the CD4⁺/CD8⁺ T-cell ratio³⁶⁷, the CD4 suppressor activity was enhanced.³⁶¹ The percentage of natural killer (NK) cells was not affected by tacrolimus treatment; however the NK cell proliferation, NK cytotoxicity and cytokine secretion in response to IL-2 were inhibited following tacrolimus treatment.³⁶⁸ In addition, tacrolimus impaired IL-2 receptor and signal transducer and activator of transcription 3 (STAT3) signaling and induced a downregulation of NK receptors, which in turn induced proliferative and functional defects of NK-cells³⁶⁸ resulting in an impaired innate immunity.³⁶⁵

Investigation of the effects of T-cell activation has its limitations. For example, the immunosuppressive effects of tacrolimus are rapidly lost once dosing is briefly interrupted,³⁶⁶ and it is unknown to what extent tacrolimus-impaired T-cell function may be altered by infection or rejection of a transplanted organ.³⁵⁹ Furthermore, the effects of tacrolimus, which has a 10- to 100-fold greater immunosuppressive potency than cyclosporine,³³⁰ could be influenced by

genetic variations. For example, a strong association between tacrolimus pharmacodynamics and polymorphisms in the genes encoding cyclophilin A, CaN catalytic subunit and CD25 has been reported.³²⁶ Moreover, the pharmaceutical formulation of tacrolimus may result in different concentration-time curves, which may impact T-cell activation. A study based on liver transplant patients suggested that the originator formulation of tacrolimus may affect regulatory T-cell (Tregs) differently than generic tacrolimus formulations.³⁶⁸ Furthermore, switching between once and twice daily tacrolimus formulations may influence drug efficacy.^{354, 369} The fact that T-cell proliferation and activation measured by CD25 and CD71 expression trended higher after conversion from mycophenolate mofetil to enteric coated mycophenolate sodium,³⁷⁰ suggests that investigating the effects of tacrolimus on immune function also needs to consider immunosuppressive co-medication.

Intracellular cytokines

Based on its mechanism of action, the clinical utility of analyzing the expression of different cytokines in lymphocytes, with a notable role on T-cell response (CD4⁺ and CD8⁺ T-cells), has been evaluated to assess the individual effects of tacrolimus on the immune response after solid organ transplantation.^{15, 371-373} Most studies published so far focused on the intracellular expression of IL-2 and IFN- γ , two cytokines that play a key role in the activation of the alloresponse.^{15, 372, 374}

From an analytical point of view, two methodologies are mainly used: flow cytometry and the enzyme-linked immunosorbent spot (ELISPOT).

Several studies have focused on the utility of intracellular expression of IL-2 and IFN γ as prognostic biomarkers for the risk of acute rejection, as diagnostic biomarkers at the time of rejection and as markers reflecting the efficacy and the safety of tacrolimus. Until now, only a

few multicentre prospective trials have been reported. Millán *et al.*³⁷⁵ evaluated the ability of these biomarkers to predict the risk of acute rejection in 142 transplant recipients (63 liver/79 kidney) recruited from four Spanish centers. Changes in the percentage expression of IL-2 in CD8⁺CD69⁺, IFN- γ in CD4⁺CD69⁺ and IFN- γ in CD8⁺CD69⁺ were evaluated using flow cytometry before transplantation and during one year after transplantation. The results demonstrated that, in those patients who suffered acute rejection, a significant increase of the intracellular expression of these cytokines was observed.

An ongoing randomized multicenter European study (Biodrim; Health F2-2012-305147) is currently evaluating the utility of IFN- γ and IL-2 ELISPOT assay during tacrolimus minimization therapy in order to stratify renal transplant patients into low and high responders. The CTOT-01, a prospective, multicenter, observational study designed to determine the diagnostic and prognostic utility of a panel of non-invasive biomarkers for transplant outcomes in renal recipients included IFN- γ ELISPOT analysis before and after transplantation. The same group recently evaluated the adverse outcomes of tacrolimus withdrawal in a cohort of non-sensitized primary renal transplant recipients. Analysis of donor-reactive IFN- γ ELISPOT correlated with the development of donor-specific antibodies (DSA) and/or acute humoral rejection in the tacrolimus withdrawal group.³⁷⁶

Results from Boleslawski *et al.*³⁷⁷ showed that percentage of CD3⁺CD8⁺IL-2⁺ expression (measured pre and post-transplantation) could be a surrogate marker to identify patients treated with tacrolimus or cyclosporine at high risk for acute rejection. In line with these results, Akoglu *et al.*³⁷⁸ found that IL-2 production in CD8⁺ T-cells correlated with Banff score (Spearman's rho = 0.81; p = 0.027) in adult liver transplant recipients treated with CNI. Ahmed *et al.*³⁷⁹ demonstrated that the frequency of CD8⁺ and CD8⁻ cells that synthesized IL-2 and IFN- γ

correlated with the biologic effect of tacrolimus in kidney and liver transplant patients. In stable liver transplant recipients undergoing weaning from immunosuppressive therapy, Millan *et al.*³⁸⁰,³⁸¹ identified the percentage of IFN- γ expressing CD4⁺ and CD8⁺ T-cells as surrogate markers for the risk of rejection in stable liver transplant recipients after withdrawal of long-term immunosuppressive treatment, using flow cytometry³⁸⁰ and also in *de novo* adult liver transplant recipients receiving tacrolimus, mycophenolic acid and prednisone.³⁸¹ Furthermore, the latter study³⁸¹ demonstrated that the analysis of the degree of inhibition of IFN- γ and IL-2 expression in CD8⁺ T-cells could be useful in identifying those patients with a high susceptibility to tacrolimus, avoiding unnecessarily high levels of immunosuppression in this group. Patients with an inhibition of these biomarkers lower than 40% during the 1st week post-transplantation developed acute rejection. Moreover the capacity to inhibit IFN- γ during the 1st week post-transplantation was related to the severity of acute rejection, in agreement with the results reported by Akoglu *et al.*³⁷⁸ All together, these results suggest that measuring expression of IL-2 and IFN- γ in lymphocytes may reflect the individual response to tacrolimus and may be useful for dose adjustment. Recently, Noceti *et al.*³²⁶ investigated the CaN/NFAT pathway in a new model of non-stimulated PBMC and its response to increasing tacrolimus concentrations. This group reported that intracellular IL-2 expression in CD4⁺ T-cells correlated with tacrolimus concentrations and, in agreement with other groups, a large between-individual variability was found, especially for IL-2 producing CD8⁺ cells.

Another intracellular cytokine that has been explored to evaluate tacrolimus effect on T-cell activation is IL-17. This proinflammatory cytokine is produced by the third subset of effector T-cells named Th17.³⁸² To date, only a few studies have assessed the effect of tacrolimus on Th17 responses. First, Abadja *et al.*³⁸³ evaluated by ELISPOT how tacrolimus and mycophenolic acid

interfere with IL-17 production. The main finding of this study was that both drugs are capable of inhibiting Th17-related response. Mycophenolic acid seems to lead to an even stronger IL-17 suppression than tacrolimus. The combination of mycophenolic acid with low doses of tacrolimus tends to produce lower circulating IL-17 levels than after treatment with a conventional dose tacrolimus given alone. Thus, tacrolimus minimization strategies might help to better control Th17 immunity when mycophenolic acid is part of the immunosuppressive therapy. Second, in a prospective sequential study including renal allograft recipients receiving tacrolimus-based therapy, Chung *et al.*³⁸⁴ showed that Th1 effector T-cells subsets were decreased after transplantation due to the effect of the immunosuppressive therapy, but not Th17 and IL-17-producing effector memory T-cells. One possible explanation for these discrepancies between both studies was the difference in PBMC sampling: in one study PBMC were sampled from patients exposed to tacrolimus for a long time and who showed a stable clinical course, while the second PBMC sampling was performed within 3 months after transplantation. More recently Merino *et al.*³⁸⁵ demonstrated in an *in vitro* study that tacrolimus reduced the production of IL-2 in memory T-cells, whereas it completely inhibited naïve T-cells, but the production of IL-17 did not change significantly. Therefore, tacrolimus seems to be more effective in controlling alloreactive memory T-cells responsible for potential rejection episodes.

In summary, the measurement of intracellular cytokines, such as IFN- γ and IL-2, may reflect the status of T-cell response and the immunomodulatory effect of tacrolimus in each transplant patient, whereas the role of IL-17 requires further investigation. To advance in the process of validation of these biomarkers as early predictive biomarkers of the risk of rejection and graft clinical outcome it is crucial to improve some methodological aspects. Thus, commercial and common cellular reagent standards and panel of reactive T-cells (*e.g.* pool of donor antigens that

reflect the potential of organ donors) should be available to further standardize and harmonize these functional assays.

Donor-specific anti-HLA antibodies

With recent advances in the diagnostic armamentarium the understanding of the importance of anti-human leukocyte antigen (HLA) antibodies has increased.³⁸⁶⁻³⁸⁸ The development of standardized highly sensitive solid-phase assays for detecting anti-HLA antibodies has significantly improved the clinical utility of this biomarker to predict antibody-mediated rejection (ABMR), and allograft injury in kidney transplant recipients. However, current methods have their limitations, and are only semiquantitative.³⁸⁹ Today, donor-specific anti-HLA antibodies (DSA) and the subsequent development of ABMR are considered to be leading causes for graft loss. The negative impact of de novo DSA (dnDSA) on long-term outcome after kidney transplantation has been demonstrated in many studies³⁸⁶⁻³⁹² and it is estimated that 20-30% of kidney allograft recipients will develop dnDSA after transplantation. The detection of anti-HLA DSA is widely implemented in clinical practice as an important biomarker for the assessment of pre-and post-transplant risks of ABMR and allograft loss.³⁸⁶ However, predictive capabilities of this biomarker alone are limited in the individual.^{389, 390, 392} Outcome in patients with dnDSA is variable, with some patients rapidly developing acute ABMR, while others having an indolent clinical course for years.³⁸⁶⁻³⁹² It is thought that among other factors, differences between DSA with regard to the complement-fixing capability, IgG subclass, concentration, affinity, and avidity are responsible for the observed differences in outcome.^{386-389, 393} In addition, the presence of complement-fixing DSA may guide treatment³⁹⁴ and scoring systems with additional clinical data improving its utility.³⁹⁵ Although many questions on the predictive capabilities of

DSA are under investigation³⁹⁶, there is consensus that dnDSA constitute an important non-invasive biomarker after renal transplantation and regular testing is recommended.^{386, 388}

Despite the progress in diagnostics, there is an unmet medical need with respect to therapeutic approaches³⁹⁶ and data on immunosuppression and in particular data on effects of tacrolimus exposure on DSA are scarce. For two decades, tacrolimus is an integral part in immunosuppressive protocols for immunologically high-risk patients and in desensitization protocols.³⁹⁷ Despite lack of firm evidence, higher tacrolimus exposure is usually employed in high-risk patients despite potential overimmunosuppression and toxicity concerns. Several studies demonstrate, that poor adherence is an important risk factor for the development of dnDSA.^{386-388, 398, 399} Poor adherence may lead to “drug holidays”, to low and variable tacrolimus trough levels, which might result in high within-patient tacrolimus variability. Several retrospective studies demonstrate a negative impact on long-term outcome in patients with high within-patient tacrolimus variability^{137, 400, 401} (see Pharmacokinetics Section). Similar to non-adherence, physician-guided CNIs withdrawal may result in the development of dnDSA.^{376, 402} In this regard, it is interesting to note, that CNIs have no direct effect on B-cell proliferation and function, thus effective suppression of the T-cell interaction with B-cells seems important for the prevention of dnDSA.^{403, 404}

So far only very few studies have investigated tacrolimus levels with regard to the development of DSA.^{405, 406} Still, retrospective studies have to be interpreted with caution, as bias by indication may limit the conclusion: e.g. patients with low CNI levels may have been put on purpose on low exposure (e.g. due to CNIs toxicity, elderly marginal kidney); or low exposure is a consequence of non-adherence. Only one prospective study⁴⁰⁶ of a steroid-free cohort treated with 1.2-1.4g/d mycophenolic acid reported that patients with a 50% lower tacrolimus dose

starting at month 4 after transplantation developed more dnDSA (tacrolimus levels at month 6: mean 4.1 vs. 6.7ng/ml). Obviously, more data are needed to address the important question.

Donor-specific antibodies (DSA) after heart transplantation are integral to the development of ABMR⁴⁰⁷, which is, accompanied with graft failure, a major cause of mortality up to 40%⁴⁰⁸ or even higher in terms of a late onset after heart transplantation.⁴⁰⁹ Furthermore, DSA also evidently promote cardiac allograft vasculopathy.⁴¹⁰ ABMR rates of approximately 25-40% occur in desensitized patients after heart transplantation. Moreover, approximately 20-30% of non-sensitized heart transplant recipients develop dnDSA with associated ABMR in most cases. Although an ISHLT consensus report on the management of antibodies pre- and postoperatively in heart transplantation⁴¹¹, well-designed studies in heart transplantation are scarce, and published results are mainly about retrospective single-center experience as published recently.⁴¹² Thus, strategies of monitoring and treatment of DSA vary widely among heart transplant centers.

In general, DSAs develop as a result from inadequate immunosuppression in the long-term after heart transplantation or because of activation of established memory responses to allo-antigens in sensitized heart transplant recipients. Consequently, the first step after detection of DSA is to initiate or to intensify tacrolimus exposure as the CNI of choice,⁴¹³ because tacrolimus significantly decreases rejection compared to cyclosporine.⁴¹⁴

In summary, in kidney and heart transplantation DSAs are a biomarker of under-immunosuppression, which may happen if patients are non-adherent but may also occur in both CNI-free and CNI-minimization clinical protocols. Most physicians agree that tacrolimus (with trough blood levels > 5ng/ml) is the CNI of choice in case of dnDSA, although no data from prospective controlled multicentre studies are available.

Graft-derived cell-free DNA

Quantification of donor-derived cell-free DNA (dd-cfDNA) in recipient blood or urine has been evaluated as a potential diagnostic biomarker for graft injury⁴¹⁵⁻⁴¹⁷ and acute rejection.^{415, 418}

Results from Sigel *et al.* demonstrate that serial monitoring of urinary dd-cfDNA can be a sensitive surrogate biomarker of acute injury in the donor organ but lacks the specificity to distinguish between acute rejection and BK virus nephropathy injury.⁴¹⁹ More recently, plasma levels of dd-cfDNA, from 102 kidney transplant recipients, were correlated with allograft rejection and outcome. The results suggest that dd-cfDNA may be used to assess allograft rejection (T-cell mediated as well as antibody-mediated) and injury.⁴²⁰

In a study including 10 adult liver graft recipients Oellerich *et al.* investigated whether graft-derived cell-free DNA (GcfDNA or d-cfDNA) quantification could be used to assess the minimally effective trough concentrations of tacrolimus, they observed an increase in GcfDNA of more than 10% at a tacrolimus cut-off of 6.8 ng/mL.⁴²¹ The authors concluded that measuring GcfDNA could be useful to establish effective tacrolimus concentrations in liver transplant patients and to individualize immunosuppressive drug regimens. Later a prospective, observational multicentric study including 107 adult liver transplant recipients⁴²² showed that monitoring GcfDNA in plasma by droplet digital PCR (ddPCR) based on a limited number of predefined single nucleotide polymorphisms allowed for earlier and more sensitive discrimination of acute rejection as compared with conventional liver function tests.

Although dcfDNA seems to be a promising biomarker for monitoring graft health after transplantation,⁴²³ multicenter, prospective, observational and interventional studies will be required to better define how it can be used and evaluate its clinical utility before considering it a valid biomarker in solid organ transplantation.

Executive summary and practical recommendations

- Determination of residual NFAT-regulated gene expression supports the identification of renal transplant recipients at higher risk of acute rejection, opportunistic infections, malignancy, and cardiovascular risk (B II).
- Monitoring residual NFAT-regulated gene expression complements CNI pharmacokinetics as an adjunct to guiding CNI therapy (B III).
- Monitoring intracellular T-cell IFN- γ production (particularly by the enzyme-linked immune-spot, ELISPOT, assay) before and early after transplantation can help to identify kidney and liver transplant recipients at high risk of acute rejection (B II) and select good candidates for immunosuppression minimization (B II).

Pharmacodynamic monitoring of tacrolimus therapy has not entered routine monitoring yet. To advance the validation of pharmacodynamic and immunologic biomarkers, it is crucial to improve and standardize some methodological aspects. The clinical implementation of these biomarkers as a complement of tacrolimus-TDM may have a tremendous impact in patient and graft care.

PHARMACOKINETIC/PHARMACOGENETIC MODELING AND

PHARMACOKINETIC/ PHARMACODYNAMIC MODELING FOR TACROLIMUS

Population pharmacokinetic modeling of tacrolimus

The pharmacokinetics of tacrolimus have been described extensively in the literature using one- and two-compartmental disposition models with first order elimination in 61% and 39% of PopPK studies, respectively.¹² About a fifth of models incorporated a lag time to describe delayed drug absorption, while a few studies attempted to describe a more complex absorption

process using a gamma distribution to describe the absorption rate and then to convolute it with a single or multi-exponential impulse response.⁴²⁴ The integral of this function represents an asymmetrical, S-shape absorption phase, the asymmetry of which increases when the absorption rate decreases, followed by drug distribution in one or two compartments and elimination from the central compartment. An Erlang model with a range of transit compartments has also been proposed, which represent a special case of the gamma distribution, in which the exponent is an integer that represents the number of transit compartments that the drug has to cross to reach the central compartment.⁴²⁵ Most models have been based on oral pharmacokinetic curves of whole blood tacrolimus concentrations and most commonly tacrolimus whole blood apparent clearance (CL/F) was characterized.

Although the absolute bioavailability of tacrolimus has been reported to be on average 25-30%,⁴²⁶ in four studies in which both intravenous and oral pharmacokinetic data for bid tacrolimus were available, typical bioavailability (F) was estimated and reported to range from 7.3 to 19.7%.¹²

Variability in tacrolimus whole blood apparent clearance amongst transplant recipients in these models was most commonly related to *CYP3A5* genotype (rs776746), patient hematocrit, patient weight, corticosteroid dose, postoperative day and a significant reduction in hepatic function (aspartate aminotransferase). Although co-medication is also an important determinant of tacrolimus disposition, most datasets did not contain information about the use of strong *CYP3A* inhibitors or inducers.¹²

Trough concentrations are used in most transplant centers for the TDM of tacrolimus. Although much easier to obtain and convenient for the patient, C_0 monitoring seems far from the ideal biomarker. Indeed, it has been shown that rejection and toxicity could occur even if the C_0 was

within the proposed therapeutic window.^{10, 91} As explained previously in the Pharmacokinetic Section, there is some evidence that C_0 correlates poorly with AUC_{0-12} .^{427, 428}

An alternative to single time point measurements or full concentration-time profiling to calculate AUC is the use of a population PK model in a Maximum A Posteriori (MAP) Bayesian forecasting technique to estimate AUC based on a limited number of measurements, generally taken in the first few hours of the dosing interval. MAP Bayesian forecasting with use of this population PK models can be a beneficial tool for accurate TDM.¹¹

Bias in the prediction of tacrolimus AUC using PopPK models has ranged from 15 to 10% (assessed by mean prediction errors), imprecision ranging from 0.81 to 40% (measured as root mean squared error (RMSE) or mean absolute prediction error (MAPE)) and R^2 values ranged from 0.27 to 0.99. About two thirds of MAP Bayesian forecasting models that used two or more tacrolimus concentrations showed *bias* of 10% or less, but only 39% showed imprecision $\leq$ 10%.¹²

Currently five tacrolimus formulations have been described in the transplant population (intravenous, twice daily oral suspension, twice daily oral capsule, once daily oral capsule and once daily melting dose) all with slightly different models and optimal limited sampling models. The combination of sampling times at 0, 1 and 3 hours post dose consistently showed bias and imprecision values of less than 15% with one exception; the new prolonged tacrolimus melting dose formulation requires sampling times of 0, 8 and 12 hours after dose intake.^{12, 429} This difference suggests that an alternative blood sampling procedure is required, such as dried blood spot monitoring, in order to make AUC monitoring feasible for this formulation.

Pharmacokinetic/Pharmacogenetic modeling

It is now well accepted that *CYP3A5**3 (rs776746) genetic profiling is informative to guide initial tacrolimus dosing.^{258, 430} and several popPK models including *CYP3A5* genotype have been developed for tacrolimus, as summarized above. As outlined in the different previous sections, pharmacogenetics may influence a large part of the between-individual difference in the clearance of tacrolimus or its intracellular distribution. This influence might be quantified through popPK modeling strategies. There are several advantages of popPK modeling over other pharmacogenetic analyses: (i) the ability to quantify the effect of covariables of interest and, thereby, make quantitative assumptions about the magnitude of SNP effects on all pharmacokinetics; (ii) it facilitates routine dose adjustments using MAP-BE and (iii) it enables simulation studies, allowing dose recommendations.¹¹ This approach has given rise to numerous interesting studies but, except for *CYP3A* polymorphisms, no clear conclusions can be drawn at this stage, especially due to the ethnic diversity in allelic frequencies and the lack of large studies and/or unbiased data.

Multiple popPK models describing the pharmacokinetic effect of *CYP3A5**3 have been developed so far in different types of transplantation populations and, on average, they showed that introducing the *CYP3A5**3 genetic status of the patient in the model explains approximately 30% of the variability in the tacrolimus CL when using a parametric model approach.^{28, 33, 94, 292, 301, 431-447} Statistical considerations demonstrated that it also decreased the Akaike information criteria (AIC) and improved the population and individual predictions in non- parametric models.^{265, 447}

In addition, confirming results observed in simple candidate gene association studies, it seems that popPK models including *CYP3A4**22 (rs35599367) are more accurate than those not taking this SNP into consideration. However, this SNP seems relevant in Caucasians not expressing

CYP3A5 only as it has been demonstrated that *CYP3A4**22 alone does not significantly improve the performance of tacrolimus popPK models.^{292, 441} In contrast, two recent studies have shown that including *CYP3A4**22 genotype information beyond *CYP3A5**3 for clustering the patients into poor (PM), intermediate (IM) and extensive (EM) metabolizers improved the predictability performance of such models.^{265, 441} Indeed, almost 40% of the residual variability was explained by CYP3A clustering in a popPK study using a parametric approach⁴⁴¹ whereas this clustering strategy was associated with the highest reduction in -2 log-likelihood in a popPK study using a non-parametric approach.²⁶⁵

By performing dosage simulations with their popPK model, Andreu *et al.* defined that the highest percentage of patients with a C_0 within the target therapeutic range (5-10 ng/mL) occurred after 4, 3, and 2 mg every 12 hours for EMs, IMs, and PMs, respectively (for hematocrit fixed at 34%).⁴⁴¹ Consistently, Woillard *et al.* developed a double gamma absorption model using a non-parametric approach (Pmetrics) including *CYP3A4**22/*CYP3A5**3 to refine the initial dose requirement of tacrolimus. Monte Carlo simulations were performed leading to the recommended starting doses of 0.07 mg/kg bid for poor metabolizers, 0.13 mg/kg bid for intermediate metabolizers and 0.2 mg/kg bid for extensive metabolizers. These recommendations have been approved recently and discussed and refined in a discriminant analysis of principal component. These proposed revisions are summarized in **Figure 4** and are in line with the CPIC or Pharmacogenetics National French Network recommendations.⁴³⁰ The principal difference between the developed strategy based on popPK studies and CPIC recommendations consists of decreasing the dose for *CYP3A4**22 carriers-*CYP3A5* defectives, *i.e.* the so-called PM clusters, and to allow up to 0.4 mg/kg/day prescribed to the EM cluster. For these EM it is specifically proposed to start therapy at 0.35 mg/kg/day and to further fine-tune these doses using TDM.

Other SNPs of interest such as *POR*28* (rs1057868) or *CYP3A4*1G* (rs2242480), have also been investigated and some researchers have even tried to model their impact on tacrolimus pharmacokinetics variability using popPK models. However, in comparison to *CYP3A5*3* or *CYP3A4*22*, their effect on tacrolimus systemic exposure appears to be clinically non-significant, at least in the Caucasian population. In contrast, in the African population in which *CYP3A4*22* has not yet been described and *CYP3A5*1* carriers are the majority, other SNPs might still be important for explaining the residual pharmacokinetic variability. In this particular case, *POR*28* status might be of interest to individualize the tacrolimus dose among *CYP3A5* expressors as the *POR*28* allele has been noted to influence tacrolimus pharmacokinetics but only in *CYP3A5* expressors. To our knowledge, none of the popPK studies reported to date has explored that possibility in the African population. In addition, in Asian patients, in whom the number of *CYP3A5* expressors is between those of Caucasians and Africans, it has been demonstrated that the combined genotype of *CYP3A5*-*POR* was the only covariant significantly related to the apparent clearance of tacrolimus. The situation is less clear for *CYP3A4*1G*, found exclusively in the Asian population. While this SNP has been associated with increased *CYP3A4* activity and linked with tacrolimus pharmacokinetics in simple association studies in renal,⁴⁴⁸ and hepatic transplantation,⁴⁴⁹ this effect has not yet been observed in popPK studies,⁴⁵⁰ limiting the relevance of these associations. Many other SNPs (*e.g.* *ABCB1*, *NR1I2*, *IL10*, *PPARa*) have also been investigated in popPK models, but mostly their inclusion failed to demonstrate any significant improvement of the model predictability and/or applicability. Concerning *ABCB1* SNPs, the popPK studies investigating the influence of *ABCB1* SNPs, such as the coding but synonymous 3435C>T or even the nonsynonymous 1199G>A, suggest a limited impact of these SNPs on tacrolimus blood exposure or bioavailability. Thus, it is generally accepted that *ABCB1*

genotype is not likely to have a clinical value when considering systemic pharmacokinetic.

However, it seems that *ABCB1* variants (associated with a decrease in its transport) may explain differences in tacrolimus tissue distribution and might influence the effective fraction of the drug that is available to exert its immunosuppressive activity in lymphocytes^{246, 272} or its toxic effect in the kidneys.⁴⁵¹⁻⁴⁵³ Unfortunately, none of the reported studies has used a popPK modeling approach to analyze those intracellular pharmacokinetic data. Hopefully, with the improvement of analytical techniques, this domain will be more extensively explored in the near future.

Pharmacokinetic/Pharmacodynamic modeling

The number of studies addressing tacrolimus pharmacokinetic-pharmacodynamic relationships using modeling approaches is still very few compared to those related with pure PK modeling. Similar to other therapeutic areas,^{454, 455} modeling and simulation methods for immunosuppressive drugs in transplantation are crucial for the quantitation and prediction for new clinical scenarios. This has already been outlined in the last biomarker consensus document¹⁵ but very few advances have occurred since then. Improved analytical techniques have enhanced our ability to measure various biomarkers that could be related to CNI use. The increasing knowledge of the underlying physiological mechanisms involved in CNI pharmacodynamics could allow the transition from an empirical to a quantitative framework. Development of pharmacokinetic-pharmacodynamic models could help to confirm the underlying physiological mechanisms and to facilitate the expansion and improvement of immunosuppressive treatments.

The **Supplementary Table 2**, <http://links.lww.com/TDM/A321> gives an overview of some of the most relevant studies that have attempted to use mathematical or statistical modeling approaches in transplantation. Some of the so-called pharmacokinetic-pharmacodynamic studies

found in the literature are based on correlations between pharmacodynamic-effects and drug exposure⁴⁵⁶⁻⁴⁵⁸ (and additional references of interest that are shown in **Supplementary Table 2**, <http://links.lww.com/TDM/A321>),^{321, 340, 348, 355, 359, 375, 380, 381, 459-461} while others have considered the use of pharmacodynamic models, the most widely applied being the direct inhibitory Emax models.^{319, 320, 322} None of these cases applied the indirect response models proposed by Jusko *et al.*⁴⁶² or disease progression models⁴⁶³ to account for changes in disease unrelated to drug action. Most of the models were developed for descriptive purposes, without the evaluation of their predictive capability being reported. Lately, some new pharmacokinetic-pharmacodynamic models based on relationships between longitudinal measurements of drug exposure and clinical outcomes have appeared, but still efforts should be made to move forward from the current scenario to modeling discrete data.⁴⁶⁴⁻⁴⁶⁶

In conclusion, more pharmacokinetic-pharmacodynamic and PB/PK modeling activities are still required to enhance the understanding of factors influencing clinical outcomes in transplantation. In spite of possible inconveniences for routine clinical practice, optimal sampling study designs are essential to allow robust conclusions.

Executive summary and practical recommendations

-The utilization of popPK model based Bayesian estimators has shown improved target achievement compared to standard TDM.⁴⁶⁷ While trough concentration is used in most transplant centers for TDM of tacrolimus there is some evidence that C_0 correlates poorly with AUC_{0-12} . The use of popPK model-derived Bayesian estimators based on limited sampling strategies (LSS), however, provides AUC predictions with bias <5% and an imprecision <20%. This seems to be an applicable way to improve future tacrolimus TDM as compared to continue

with standard trough concentration based TDM, especially when considering home sampling using microsampling devices that are currently under validation (as presented above).

-We strongly recommend the integration of *CYP3A5**3 and *CYP3A4**22 genotype information, when available, in future tacrolimus popPK models, primarily for the opportunity to optimize initial dosing.

-More pharmacokinetic-pharmacodynamic and PB/PK modeling activities are required to enhance the understanding of factors influencing clinical outcomes in transplantation.

CONCLUSIONS

In this Consensus Report we have assessed the evolution of best practice for the TDM of tacrolimus to allow for personalized treatment. We have taken into consideration the influence of standardized and harmonized analytical methods, as well as pharmacogenetic, pharmacodynamic and immunologic biomarkers, and their ability to act as early predictors of clinical events, such as rejection or drug-related adverse events.

The first Consensus Report on optimization of tacrolimus therapy¹⁰ confirmed that the TDM of tacrolimus has a significant impact on patient management. However, it was concluded that there was the need to concentrate efforts on developing and establishing new standardized and harmonized analytical strategies to fine-tune the target concentrations to be achieved in adult and pediatric populations, considering risk factors, comedication drug-interactions, and validated biomarkers.

One decade later, the evolution of graft and patient clinical outcomes in transplantation remains insufficiently studied in the context of personalized immunosuppressive treatment early and long-term after transplantation. Tacrolimus, in its different formulations, remains and is

considered the cornerstone of immunosuppressive therapy. Tacrolimus, mycophenolic acid and steroids are the most commonly used treatment combinations in solid organ transplantation. However, our understanding of immunosuppression to achieve personalized therapies is still evolving.

For some time now, tacrolimus-related nephrotoxicity has been considered to be a major risk factor, and dose minimization was readily applied in an attempt to prevent kidney damage. Currently, the histologic graft lesions are also known to be attributed to other factors, one of the main causes being an actively maintained allo-immunity. Several studies have demonstrated that it is essential to ensure consistent tacrolimus exposure over-time and instead of aiming for very low tacrolimus trough concentrations clinicians have to put more emphasis on the prevention of under-immunosuppression and a lower limit of 4 ng/mL or greater is suggested on most indications. In the present Consensus Report, whenever possible, the recommendations for achieving specific target concentrations of tacrolimus are based on the results obtained from multicenter prospective clinical trials for different types of solid organ transplantation in specific cohorts of low or high immunological risk patients, also taking the combination with other immunosuppressive drugs into consideration. With the recent developments of novel sampling techniques and improved dosing methods (*e.g.* popPK model-based Bayesian estimators), future focus on finding optimal AUC target should be emphasized. Few studies have evaluated the optimal tacrolimus target concentrations in children undergoing different types of clinical transplantation or in adult and pediatric populations when tacrolimus has been administered for other clinical indications. So, there is still room to better determine and adjust the optimal tacrolimus target concentrations for each patient group.

When looking back on the last ten years of tacrolimus TDM, there has been a continuous and notable improvement of analytical assay performance. Several FDA approved and IVD-CE certified tacrolimus measurement systems have been introduced, but only two standardized calibrator materials are available. Tacrolimus assay inconsistencies may have a negative impact on clinical decisions, drug adjustment, and patient outcomes, demonstrating the need for traceability, the generation of standardized reference materials as well as the placement of appropriate reference procedures for tacrolimus monitoring.

When interpreting whole blood drug exposure (C_0 target concentrations, AUC ranges) and clinical trial outcomes, clinicians should keep in mind the analytical aspects (*i.e.* the assay used and the between-method bias) as well as pharmacogenetic characteristics associated with tacrolimus disposition and effects. Furthermore, it is well-known that immunosuppressive drugs modulate the immune system of each patient differently. As tacrolimus is a narrow therapeutic index drug, small variations in systemic exposure can lead to substantial differences in the pharmacodynamic response influencing graft and patient clinical outcomes. The combined knowledge of pharmacokinetics, with pharmacogenetics together with pharmacodynamic biomarkers could provide further prognostic and diagnostic information regarding the risk of rejection and condition of the allograft at earlier time points and allow anti-rejection therapy to be adjusted at an early stage before severe graft injury ensues. Accordingly, the recommendations of the Consensus Report regarding pharmacogenetics, pharmacodynamics and immunological biomarkers are summarized as follows:

- The association between *CYP3A5* genotype and tacrolimus dose requirement is robust and has been observed among both adult and pediatric kidney, liver, heart and lung transplant recipients (grading of recommendation A I), but currently there is no convincing clinical evidence that a

pharmacogenetics-based approach to tacrolimus dose selection improves graft and patient clinical outcomes after solid organ transplantation. *CYP3A4* *22 genotype is associated with residual variability in tacrolimus pharmacokinetics, but further studies should investigate the clinical benefit of some pharmacogenetic clusters in tacrolimus disposition and effect.

- Pharmacodynamic monitoring of tacrolimus therapy has not entered routine monitoring yet, but NFAT-regulated gene expression is a candidate biomarker for personal response to tacrolimus and the identification of renal and liver transplant recipients at high risk of rejection and infection (B II).

- Monitoring intracellular T-cell IFN- γ production, (particularly by the ELISPOT-assay before and early after transplantation, can help to identify kidney and liver transplant recipients at high risk of acute rejection (B II) and select good candidates for immunosuppression minimization (B II).

The authors believe that future studies should continue to investigate the clinical benefit of PopPK models including pharmacogenetic phenotypes, as well as pharmacokinetic /pharmacodynamic modeling and the potential application of such models into clinical routine, in order to facilitate personalized tacrolimus dosing.

In conclusion, the Expert Committee emphasized that it is reasonable to expect that routine monitoring of tacrolimus pharmacokinetics, combined with pharmacogenetics and predictive pharmacodynamic and immunologic biomarkers will modify and control risk factors, improve long-term outcomes post-transplant as well as graft and patient survival. There is a need to harness the information we have generated, re-evaluate how we monitor tacrolimus exposure/effect and graft outcomes by incorporating early predictive biomarkers into

multidisciplinary designed prospective robust clinical trials to support evidence for patient stratification and immunosuppression guidance, and achieve timely regulatory approval.

References

1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336:924-926.
2. UpToDate. Grading guide [web site] 2019. Available at: <https://www.uptodate.com/home/grading-guide>. Accessed 19.3.2019.
3. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. *N Engl J Med*. 2007;357:2562-2575.
4. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant*. 2009;9 Suppl 3:S1-155.
5. Taylor DO, Barr ML, Meiser BM, et al. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. *J Heart Lung Transplant*. 2001;20:734-738.
6. Yano I, Masuda S, Egawa H, et al. Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation. *Eur J Clin Pharmacol*. 2012;68:259-266.
7. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. *Am J Transplant*. 2012;12:3008-3020.
8. Boudjema K, Camus C, Saliba F, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. *Am J Transplant*. 2011;11:965-976.
9. Ekberg H, Mamelok RD, Pearson TC, et al. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. *Transplantation*. 2009;87:1360-1366.
10. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. *Ther Drug Monit*. 2009;31:139-152.
11. Woillard JB, Saint-Marcoux F, Debord J, et al. Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose. *Pharmacol Res*. 2018;130:316-321.
12. Brooks E, Tett SE, Isabel NM, et al. Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet? *Clin Pharmacokinet*. 2016;55:1295-1335.
13. Pohanka A, Rosenberg S, Lindh JD, et al. Experiences from using LC-MS/MS for analysis of immunosuppressive drugs in a TDM service. *Clin Biochem*. 2016;49:1024-1031.
14. Seger C, Shipkova M, Christians U, et al. Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. *Ther Drug Monit*. 2016;38:170-189.
15. Brunet M, Shipkova M, van Gelder T, et al. Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. *Ther Drug Monit*. 2016;38 Suppl 1:S1-S20.
16. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. *Immunol Today*. 1992;13:136-142.

17. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. *Drugs*. 1997;54:925-975.
18. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. *Ther Drug Monit*. 1995;17:584-591.
19. Klintmalm GB. FK 506: an update. *Clin Transplant*. 1994;8:207-210.
20. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). *Ther Drug Monit*. 1995;17:606-614.
21. Venkataramanan R, Jain A, Warty VW, et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. *Transplant Proc*. 1991;23:931-933.
22. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. *Clin Pharmacokinet*. 1995;29:404-430.
23. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. *Clin Pharmacol Ther*. 1995;57:281-290.
24. Hesselink DA, Bouamar R, Elens L, et al. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. *Clin Pharmacokinet*. 2014;53:123-139.
25. Dubbelboer IR, Pohanka A, Said R, et al. Quantification of tacrolimus and three demethylated metabolites in human whole blood using LC-ESI-MS/MS. *Ther Drug Monit*. 2012;34:134-142.
26. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. *Drug Metab Pharmacokinet*. 2007;22:328-335.
27. Moller A, Iwasaki K, Kawamura A, et al. The disposition of ¹⁴C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. *Drug Metab Dispos*. 1999;27:633-636.
28. Bergmann TK, Hennig S, Barraclough KA, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. *Ther Drug Monit*. 2014;36:62-70.
29. Borra LC, Roodnat JJ, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. *Nephrol Dial Transplant*. 2010;25:2757-2763.
30. Park SI, Felipe CR, Pinheiro-Machado PG, et al. Circadian and time-dependent variability in tacrolimus pharmacokinetics. *Fundam Clin Pharmacol*. 2007;21:191-197.
31. Satoh S, Kagaya H, Saito M, et al. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. *Br J Clin Pharmacol*. 2008;66:207-214.
32. Wallemacq PE, Furlan V, Moller A, et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. *Eur J Drug Metab Pharmacokinet*. 1998;23:367-370.
33. Fukudo M, Yano I, Masuda S, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. *Clin Pharmacol Ther*. 2006;80:331-345.
34. Christiaans M, van Duijnhoven E, Beysens T, et al. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. *Transplant Proc*. 1998;30:1271-1273.
35. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. *Transplant Proc*. 1998;30:1261-1263.
36. Zheng S, Easterling TR, Umans JG, et al. Pharmacokinetics of tacrolimus during pregnancy. *Ther Drug Monit*. 2012;34:660-670.
37. Nakamura A, Amada N, Haga I, et al. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. *Transplant Proc*. 2014;46:592-594.

38. Maes BD, Lemahieu W, Kuypers D, et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. *Am J Transplant.* 2002;2:989-992.
39. Lemahieu W, Maes B, Verbeke K, et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. *Am J Transplant.* 2005;5:1383-1391.
40. Hesselink DA, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. *Br J Clin Pharmacol.* 2003;56:327-330.
41. Tang JT, Andrews LM, van Gelder T, et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. *Expert Opin Drug Metab Toxicol.* 2016;12:555-565.
42. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. *Clin Pharmacokinet.* 2002;41:813-851.
43. van Gelder T. Drug interactions with tacrolimus. *Drug Saf.* 2002;25:707-712.
44. Groll AH, Townsend R, Desai A, et al. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. *Transpl Infect Dis.* 2017;19.
45. Vanhove T, Bouwsma H, Hilbrands L, et al. Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients. *Am J Transplant.* 2017;17:2372-2380.
46. Kuypers DR, Claes K, Evenepoel P, et al. Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient. *Transplantation.* 2006;81:1750-1752.
47. van Maarseveen EM, Rogers CC, Trofe-Clark J, et al. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. *AIDS Patient Care STDS.* 2012;26:568-581.
48. Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT-450, Ombitasvir, and Dasabuvir. *Am J Transplant.* 2015;15:1313-1322.
49. Badri PS, Parikh A, Coakley EP, et al. Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. *Ther Drug Monit.* 2016;38:640-645.
50. Feng HP, Caro L, Fandozzi CM, et al. Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers. *J Clin Pharmacol.* 2018;58:666-673.
51. Kwo PY, Badshah MB. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. *Curr Opin Organ Transplant.* 2015;20:235-241.
52. Lam S, Partovi N, Ting LS, et al. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? *Ann Pharmacother.* 2008;42:1037-1047.
53. Stiff F, Undre N, van Hooff JP, et al. Effect of Breakfast on the Exposure of the Once-Daily Tacrolimus Formulation in Stable Kidney Transplant Recipients. *Ther Drug Monit.* 2016;38:456-462.
54. Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. *J Clin Pharmacol.* 2001;41:176-182.
55. Liu C, Shang YF, Zhang XF, et al. Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. *Eur J Clin Pharmacol.* 2009;65:881-885.

56. Liu MZ, Zhang YL, Zeng MZ, et al. Pharmacogenomics and herb-drug interactions: merge of future and tradition. *Evid Based Complement Alternat Med*. 2015;2015:321091.
57. Mai I, Stormer E, Bauer S, et al. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. *Nephrol Dial Transplant*. 2003;18:819-822.
58. Budde K, Bunnapradist S, Grinyo JM, et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. *Am J Transplant*. 2014;14:2796-2806.
59. Micromedex. IBM Micromedex [web site] 2019. Available at: <https://www.micromedexsolutions.com/micromedex2/librarian/>. Accessed 23.01.2019.
60. Christians U, Klawitter J, Clavijo CF. Bioequivalence testing of immunosuppressants: concepts and misconceptions. *Kidney Int*. 2010;115:s1.
61. Harrison JJ, Schiff JR, Coursol CJ, et al. Generic immunosuppression in solid organ transplantation: a Canadian perspective. *Transplantation*. 2012;93:657-665.
62. van Gelder T. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. *Transpl Int*. 2011;24:1135-1141.
63. Molnar AO, Fergusson D, Tsampalieros AK, et al. Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis. *BMJ*. 2015;350:h3163.
64. Alloway RR, Vinks AA, Fukuda T, et al. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. *PLoS Med*. 2017;14:e1002428.
65. Robertsen I, Asberg A, Ingero AO, et al. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. *Transplantation*. 2015;99:528-532.
66. Jacobo-Cabral CO, Garcia-Roca P, Reyes H, et al. Limustin(R), a non-innovator tacrolimus formulation, yields reduced drug exposure in pediatric renal transplant recipients. *Pediatr Transplant*. 2014;18:706-713.
67. van Gelder T. What Is the Future of Generics in Transplantation? *Transplantation*. 2015;99:2269-2273.
68. Marquet P, Albano L, Woillard JB, et al. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients. *Pharmacol Res*. 2018;129:84-94.
69. Saint-Marcoux F, Woillard JB, Jurado C, et al. Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. *Ther Drug Monit*. 2013;35:322-327.
70. Marquet P, Bedu A, Monchaud C, et al. Pharmacokinetic Therapeutic Drug Monitoring of Advagraf in More Than 500 Adult Renal Transplant Patients, Using an Expert System Online. *Ther Drug Monit*. 2018;40:285-291.
71. Israni AK, Riad SM, Leduc R, et al. Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics. *Transpl Int*. 2013;26:982-989.
72. Gatault P, Kamar N, Buchler M, et al. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. *Am J Transplant*. 2017;17:1370-1379.
73. Bouamar R, Shuker N, Hesselink DA, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(dagger). *Am J Transplant*. 2013;13:1253-1261.
74. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. *Transplant Proc*. 1999;31:296-298.

75. Kuypers DR, Claes K, Evenepoel P, et al. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. *Clin Pharmacol Ther.* 2004;75:434-447.
76. Larkins N, Matsell DG. Tacrolimus therapeutic drug monitoring and pediatric renal transplant graft outcomes. *Pediatr Transplant.* 2014.
77. Böttiger Y, Brattström C, Tyden G, et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. *Br J Clin Pharmacol.* 1999;48:445-448.
78. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. *Transplantation.* 1996;62:920-926.
79. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 Annual Data Report: kidney. *Am J Transplant.* 2015;15 Suppl 2:1-34.
80. Pascual J, Berger SP, Witzke O, et al. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. *J Am Soc Nephrol.* 2018;29:1979-1991.
81. Chapman WC, Brown RS, Jr., Chavin KD, et al. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. *Transplantation.* 2017;101:341-349.
82. Jia JJ, Lin BY, He JJ, et al. "Minimizing tacrolimus" strategy and long-term survival after liver transplantation. *World J Gastroenterol.* 2014;20:11363-11369.
83. Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. *Am J Transplant.* 2009;9:327-336.
84. Otero A, Varo E, de Urbina JO, et al. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. *Liver Transpl.* 2009;15:1542-1552.
85. Rodriguez-Peralvarez M, Germani G, Darius T, et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. *Am J Transplant.* 2012;12:2797-2814.
86. Rodriguez-Peralvarez M, Germani G, Papastergiou V, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. *J Hepatol.* 2013;58:262-270.
87. Becker T, Foltys D, Bilbao I, et al. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. *Transplantation.* 2008;86:1689-1694.
88. Hu AB, Wu LW, Tai Q, et al. Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center. *J Dig Dis.* 2013;14:38-44.
89. Lerut JP, Pinheiro RS, Lai Q, et al. Is minimal, [almost] steroid-free immunosuppression a safe approach in adult liver transplantation? Long-term outcome of a prospective, double blind, placebo-controlled, randomized, investigator-driven study. *Ann Surg.* 2014;260:886-891; discussion 891-882.
90. Margarit C, Bilbao I, Castells L, et al. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. *Transpl Int.* 2005;18:1336-1345.
91. Venkataramanan R, Shaw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. *J Clin Pharmacol.* 2001;41:542-551.
92. Riva N, Schaiquevich P, Caceres Guido P, et al. Pharmacoepidemiology of tacrolimus in pediatric liver transplantation. *Pediatr Transplant.* 2017;21.
93. Alloway R, Vanhaecke J, Yonan N, et al. Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. *J Heart Lung Transplant.* 2011;30:1003-1010.

94. Monchaud C, de Winter BC, Knoop C, et al. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. *Clin Pharmacokinet*. 2012;51:175-186.
95. Garrity ER, Jr., Hertz MI, Trulock EP, et al. Suggested guidelines for the use of tacrolimus in lung-transplant recipients. *J Heart Lung Transplant*. 1999;18:175-176.
96. Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. *Clin Pharmacokinet*. 2009;48:419-462.
97. Sikma MA, Hunault CC, Kirkels JH, et al. Association of Whole Blood Tacrolimus Concentrations with Kidney Injury in Heart Transplantation Patients. *Eur J Drug Metab Pharmacokinet*. 2018;43:311-320.
98. Sikma MA, Hunault CC, van de Graaf EA, et al. High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury. *Eur J Clin Pharmacol*. 2017;73:573-580.
99. Aumente Rubio MD, Arizon del Prado JM, Lopez Malo de Molina MD, et al. Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. *Transplant Proc*. 2003;35:1988-1991.
100. Sgroso JL, Araujo GL, Vazquez MC. Tacrolimus pharmacokinetics in heart transplant. *Transplant Proc*. 2002;34:142-143.
101. Undre NA, Stevenson PJ. Pharmacokinetics of tacrolimus in heart transplantation. *Transplant Proc*. 2002;34:1836-1838.
102. Wang CH, Ko WJ, Chou NK, et al. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. *Transplant Proc*. 2004;36:2386-2387.
103. Hiraoka A, Ohashi Y, Okamoto S, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. *Bone Marrow Transplant*. 2001;28:181-185.
104. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. *Blood*. 2000;96:2062-2068.
105. Oshima K, Sato M, Terasako K, et al. Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT. *Bone Marrow Transplant*. 2010;45:781-782.
106. Ram R, Gafter-Gvili A, Yeshurun M, et al. Prophylaxis regimens for GVHD: systematic review and meta-analysis. *Bone Marrow Transplant*. 2009;43:643-653.
107. Jacobson P, Ng J, Ratanatharathorn V, et al. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. *Bone Marrow Transplant*. 2001;28:753-758.
108. Kanda Y, Kobayashi T, Mori T, et al. A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. *Bone Marrow Transplant*. 2016;51:103-109.
109. Suetsugu K, Ikesue H, Miyamoto T, et al. Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. *Int J Hematol*. 2017;105:361-368.
110. Yano S, Mori S, Saito T, et al. Pharmacokinetics for once-daily modified release formulation of tacrolimus hydrate in unrelated hematopoietic stem cell transplantation. *Ann Hematol*. 2015;94:491-496.
111. Mori T, Kato J, Shimizu T, et al. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors. *Biol Blood Marrow Transplant*. 2012;18:229-234.

112. Ganetsky A, Shah A, Miano TA, et al. Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. *Bone Marrow Transplant.* 2016;51:568-572.
113. Wingard JR, Nash RA, Przepiorka D, et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. *Biol Blood Marrow Transplant.* 1998;4:157-163.
114. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. *Blood.* 1998;92:2303-2314.
115. Watanabe N, Matsumoto K, Muramatsu H, et al. Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children. *Bone Marrow Transplant.* 2010;45:1161-1166.
116. Offer K, Kolb M, Jin Z, et al. Efficacy of tacrolimus/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2015;21:496-502.
117. Cury Martins J, Martins C, Aoki V, et al. Topical tacrolimus for atopic dermatitis. *Cochrane Database Syst Rev.* 2015:Cd009864.
118. Undre NA, Moloney FJ, Ahmadi S, et al. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. *Br J Dermatol.* 2009;160:665-669.
119. McCollum AD, Paik A, Eichenfield LF. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. *Pediatr Dermatol.* 2010;27:425-436.
120. Mandelin JM, Rubins A, Remitz A, et al. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants: a two-year open-label study. *Int J Dermatol.* 2012;51:104-110.
121. Keaney TC, Bhutani T, Sivanesan P, et al. Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis. *J Am Acad Dermatol.* 2012;67:636-641.
122. Mele C, Salerno MP, Romagnoli J, et al. Complete clinical remission of psoriasis 6 months after renal transplantation. *Transplant Proc.* 2013;45:2788-2789.
123. Malecic N, Young H. Tacrolimus for the management of psoriasis: clinical utility and place in therapy. *Psoriasis (Auckl).* 2016;6:153-163.
124. Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. *J Cutan Med Surg.* 2014;18:8-14.
125. Hannah J, Casian A, D'Cruz D. Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. *Autoimmun Rev.* 2016;15:93-101.
126. Lee YH, Song GG. Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials. *Z Rheumatol.* 2017;76:904-912.
127. Chen W, Liu Q, Chen W, et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. *Lupus.* 2012;21:944-952.
128. Kamanamool N, Ingsathit A, Rattanasiri S, et al. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial. *Lupus.* 2018;27:647-656.
129. Tanaka H, Oki E, Tsuruga K, et al. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose. *Clin Nephrol.* 2009;72:430-436.
130. Kraaij T, Bredewold OW, Trompet S, et al. TAC-TIC use of tacrolimus-based regimens in lupus nephritis. *Lupus Sci Med.* 2016;3:e000169.

131. Mok CC. Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. *Expert Rev Clin Immunol*. 2017;13:35-41.
132. Takeuchi K, Shimoyama T, Yamamoto T. Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis. *Dig Dis*. 2018;36:106-112.
133. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. *Gut*. 2006;55:1255-1262.
134. Bruns T, Stallmach A. Drug monitoring in inflammatory bowel disease: helpful or dispensable? *Dig Dis*. 2009;27:394-403.
135. Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. *J Pediatr*. 2000;137:794-799.
136. Ziring DA, Wu SS, Mow WS, et al. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. *J Pediatr Gastroenterol Nutr*. 2007;45:306-311.
137. Whalen HR, Glen JA, Harkins V, et al. High Inpatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. *Transplantation*. 2017;101:430-436.
138. Del Bello A, Congy-Jolivet N, Danjoux M, et al. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. *World J Gastroenterol*. 2018;24:1795-1802.
139. Gueta I, Markovits N, Yarden-Bilavsky H, et al. High tacrolimus trough level variability is associated with rejections after heart transplantation. *Am J Transplant*. 2018.
140. Shuker N, Cadogan M, van Gelder T, et al. Conversion from twice-daily to once-daily tacrolimus does not reduce inpatient variability in tacrolimus exposure. *Ther Drug Monit*. 2015;37:262-269.
141. Lemaitre F, Tron C, Rayar M. Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View. *Am J Transplant*. 2017;17:1691-1692.
142. Vanhove T, Vermeulen T, Annaert P, et al. High Inpatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. *Am J Transplant*. 2016;16:2954-2963.
143. Rodrigo E, Segundo DS, Fernandez-Fresnedo G, et al. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development. *Transplantation*. 2016;100:2479-2485.
144. O'Regan JA, Canney M, Connaughton DM, et al. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation. *Journal of nephrology*. 2016;29:269-276.
145. Shuker N, Shuker L, van Rosmalen J, et al. A High intra-patient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. *Transpl Int*. 2016.
146. Sapir-Pichhadze R, Wang Y, Famure O, et al. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. *Kidney Int*. 2014;85:1404-1411.
147. Shemesh E, Bucuvalas JC, Anand R, et al. The Medication Level Variability Index (MLVI) Predicts Poor Liver Transplant Outcomes: A Prospective Multi-Site Study. *Am J Transplant*. 2017;17:2668-2678.
148. Rayar M, Tron C, Jezequel C, et al. High Inpatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes. *Transplantation*. 2018;102:e108-e114.
149. Christina S, Annunziato RA, Schiano TD, et al. Medication level variability index predicts rejection, possibly due to nonadherence, in adult liver transplant recipients. *Liver Transpl*. 2014;20:1168-1177.
150. Freeman DJ, Stawecki M, Howson B. Stability of FK 506 in whole blood samples. *Ther Drug Monit*. 1995;17:266-267.

151. Chen YL, Hirabayashi H, Akhtar S, et al. Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2006;830:330-341.
152. Stienstra NA, Sikma MA, van Dapperen A, et al. Development of a simple and rapid method to measure the free fraction of tacrolimus in plasma using ultrafiltration and LC-MS/MS. *Ther Drug Monit.* 2016.
153. Romano P, da Luz Fernandes M, de Almeida Rezende Ebner P, et al. UPLC-MS/MS assay validation for tacrolimus quantitative determination in peripheral blood T CD4+ and B CD19+ lymphocytes. *J Pharm Biomed Anal.* 2018;152:306-314.
154. Ghareeb M, Akhlaghi F. Development and validation of a sensitive and selective LC-MS/MS method for determination of tacrolimus in oral fluids. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2016;1038:136-141.
155. Tron C, Rayar M, Petitcollin A, et al. A high performance liquid chromatography tandem mass spectrometry for the quantification of tacrolimus in human bile in liver transplant recipients. *J Chromatogr A.* 2016;1475:55-63.
156. Koster RA, Alffenaar JW, Greijdanus B, et al. Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. *Talanta.* 2013;115:47-54.
157. Sadilkova K, Busby B, Dickerson JA, et al. Clinical validation and implementation of a multiplexed immunosuppressant assay in dried blood spots by LC-MS/MS. *Clin Chim Acta.* 2013;421:152-156.
158. Brandhorst G, Oellerich M, Maine G, et al. Liquid Chromatography-Tandem Mass Spectrometry or Automated Immunoassays: What Are the Future Trends in Therapeutic Drug Monitoring? *ClinChem.* 2012.
159. Christians U, Vinks AA, Langman LJ, et al. Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs. *Ther Drug Monit.* 2015;37:718-724.
160. Korecka M, Shaw LM. Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice. *Ann Transplant.* 2009;14:61-72.
161. Annesley TM, Clayton L. Simple extraction protocol for analysis of immunosuppressant drugs in whole blood. *Clin Chem.* 2004;50:1845-1848.
162. Seger C, Tentschert K, Stoggl W, et al. A rapid HPLC-MS/MS method for the simultaneous quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human blood samples. *Nat Protoc.* 2009;4:526-534.
163. Little JL, Wempe MF, Buchanan CM. Liquid chromatography-mass spectrometry/mass spectrometry method development for drug metabolism studies: Examining lipid matrix ionization effects in plasma. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2006;833:219-230.
164. Vethe NT, Gjerdalen LC, Bergan S. Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: assessment of matrix effects and assay performance. *ScandJClinLab Invest.* 2010;70:583-591.
165. Zhang Y, Zhang R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs. *Drug testing and analysis.* 2018;10:81-94.
166. Ansermot N, Fathi M, Veuthey JL, et al. Quantification of cyclosporine and tacrolimus in whole blood. Comparison of liquid chromatography-electrospray mass spectrometry with the enzyme multiplied immunoassay technique. *Clin Biochem.* 2008;41:910-913.
167. LeGatt DF, Shalapay CE, Cheng SB. The EMIT 2000 tacrolimus assay: an application protocol for the Beckman Synchron LX20 PRO analyzer. *Clin Biochem.* 2004;37:1022-1030.

168. Miura M, Masuda S, Egawa H, et al. Inter-laboratory Variability of Current Immunoassay Methods for Tacrolimus among Japanese Hospitals. *Biol Pharm Bull.* 2016;39:1331-1337.
169. Bazin C, Guinedor A, Barau C, et al. Evaluation of the Architect tacrolimus assay in kidney, liver, and heart transplant recipients. *J Pharm Biomed Anal.* 2010;53:997-1002.
170. Tempestilli M, Di Stasio E, Basile MR, et al. Low plasma concentrations of albumin influence the affinity column-mediated immunoassay method for the measurement of tacrolimus in blood during the early period after liver transplantation. *Ther Drug Monit.* 2013;35:96-100.
171. Wallemacq P, Goffinet JS, O'Morchoe S, et al. Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. *Ther Drug Monit.* 2009;31:198-204.
172. Cangemi G, Barco S, Bonifazio P, et al. Comparison of antibody-conjugated magnetic immunoassay and liquid chromatography-tandem mass spectrometry for the measurement of cyclosporine and tacrolimus in whole blood. *Int J Immunopathol Pharmacol.* 2013;26:419-426.
173. Ventura E, Bonardet A, Pageaux GP, et al. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring. *Transplant Proc.* 2009;41:707-709.
174. Griffey MA, Hock KG, Kilgore DC, et al. Performance of a no-pretreatment tacrolimus assay on the Dade Behring Dimension RxL clinical chemistry analyzer. *Clin Chim Acta.* 2007;384:48-51.
175. Doki K, Homma M, Hori T, et al. Difference in blood tacrolimus concentration between ACMIA and MEIA in samples with low haematocrit values. *J Pharm Pharmacol.* 2010;62:1185-1188.
176. Ju MK, Chang HK, Kim HJ, et al. Is the affinity column-mediated immunoassay method suitable as an alternative to the microparticle enzyme immunoassay method as a blood tacrolimus assay? *Transplant Proc.* 2008;40:3673-3678.
177. Moscato D, Nonnato A, Adamo R, et al. Therapeutic monitoring of tacrolimus: aberrant results by an immunoassay with automated pretreatment. *Clin Chim Acta.* 2010;411:77-80.
178. Bargnoux AS, Sutra T, Badiou S, et al. Evaluation of the New Siemens Tacrolimus Assay on the Dimension EXL Integrated Chemistry System Analyzer: Comparison With an Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method. *Ther Drug Monit.* 2016;38:808-812.
179. Kaneko T, Fujioka T, Suzuki Y, et al. Comparison of whole-blood tacrolimus concentrations measured by different immunoassay systems. *J Clin Lab Anal.* 2018;32:e22587.
180. Dasgupta A, Khalil SA, Johnson-Davis KL. Analytical Performance Evaluation of a New Cobas Tacrolimus Assay on Cobas e411 Analyzer: Comparison of Values Obtained by the CMA Tacrolimus Assay and a Liquid Chromatography Combined with Tandem Mass Spectrometric Method. *Ann Clin Lab Sci.* 2016;46:204-208.
181. De BK, Jimenez E, De S, et al. Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Abbott IMx methods. *Clin Chim Acta.* 2009;410:25-30.
182. Marubashi S, Nagano H, Kobayashi S, et al. Evaluation of a new immunoassay for therapeutic drug monitoring of tacrolimus in adult liver transplant recipients. *J Clin Pharmacol.* 2010;50:705-709.
183. Li ZY, Yan CL, Yan R, et al. Analytical performance of the Abbott Architect i2000 tacrolimus assay in Chinese patients after renal transplantation. *Transplant Proc.* 2010;42:4534-4537.
184. Saint-Marcoux F, Debord J, Parant F, et al. Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimus. *Ther Drug Monit.* 2011;33:171-177.
185. Shipkova M, Vogeser M, Ramos PA, et al. Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. *Clin Biochem.* 2014.

186. Qin X, Rui J, Xia Y, et al. Multi-center Performance Evaluations of Tacrolimus and Cyclosporine Electrochemiluminescence Immunoassays in the Asia-Pacific Region. *Ann Lab Med*. 2018;38:85-94.
187. Fung AWS, Knauer MJ, Blasutig IM, et al. Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer. *F1000Research*. 2017;6:1832.
188. Sasano M, Kimura S, Maeda I, et al. Analytical performance evaluation of the Elecsys(R) Cyclosporine and Elecsys(R) Tacrolimus assays on the cobas e411 analyzer. *Practical laboratory medicine*. 2017;8:10-17.
189. Leung EK, Yi X, Gloria C, et al. Clinical evaluation of the QMS(R) Tacrolimus immunoassay. *Clin Chim Acta*. 2014;431:270-275.
190. Akamine Y, Kagaya H, Ohkubo T, et al. A comparison of the effects of CYP3A5 polymorphism on tacrolimus blood concentrations measured by 4 immunoassay methods in renal transplant patients. *J Clin Pharm Ther*. 2018;43:181-188.
191. Agrawal YP, Cid M, Westgard S, et al. Transplant patient classification and tacrolimus assays: more evidence of the need for assay standardization. *Ther Drug Monit*. 2014;36:706-709.
192. Annesley TM, McKeown DA, Holt DW, et al. Standardization of LC-MS for therapeutic drug monitoring of tacrolimus. *Clin Chem*. 2013;59:1630-1637.
193. Levine DM, Maine GT, Armbruster DA, et al. The need for standardization of tacrolimus assays. *Clin Chem*. 2011;57:1739-1747.
194. Haeckel R, Wosniok W, Gurr E, et al. Permissible limits for uncertainty of measurement in laboratory medicine. *Clin Chem Lab Med*. 2015;53:1161-1171.
195. Steele BW, Wang E, Soldin SJ, et al. A longitudinal replicate study of immunosuppressive drugs: a College of American Pathologists study. *Arch Pathol Lab Med*. 2003;127:283-288.
196. Vesper HW, Myers GL, Miller WG. Current practices and challenges in the standardization and harmonization of clinical laboratory tests. *Am J Clin Nutr*. 2016;104 Suppl 3:907s-912s.
197. Siekmann L. Metrological traceability - a concept for standardization in laboratory medicine. *Clin Chem Lab Med*. 2013;51:953-957.
198. Jones GR, Jackson C. The Joint Committee for Traceability in Laboratory Medicine (JCTLM) - its history and operation. *Clin Chim Acta*. 2016;453:86-94.
199. Westgard JO. Error Methods Are More Practical, But Uncertainty Methods May Still Be Preferred. *Clin Chem*. 2018;64:636-638.
200. Westgard JO, Westgard SA. Measuring Analytical Quality: Total Analytical Error Versus Measurement Uncertainty. *Clin Lab Med*. 2017;37:1-13.
201. Theodorsson E. Uncertainty in Measurement and Total Error: Tools for Coping with Diagnostic Uncertainty. *Clin Lab Med*. 2017;37:15-34.
202. Menditto A, Patriarca M, Magnusson B. Understanding the meaning of accuracy, trueness and precision. *Accreditation and Quality Assurance*. 2007;12:45-47.
203. Rigo-Bonnin R, Blanco-Font A, Canalias F. Different top-down approaches to estimate measurement uncertainty of whole blood tacrolimus mass concentration values. *Clin Biochem*. 2018;57:56-61.
204. Vogeser M, Seger C. Irregular analytical errors in diagnostic testing - a novel concept. *Clin Chem Lab Med*. 2018;56:386-396.
205. Vogeser M, Seger C. Quality management in clinical application of mass spectrometry measurement systems. *Clin Biochem*. 2016;49:947-954.
206. Yates AM, Bowron A, Calton L, et al. Interlaboratory variation in 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 is significantly improved if common calibration material is used. *Clin Chem*. 2008;54:2082-2084.

207. Botelho JC, Shacklady C, Cooper HC, et al. Isotope-dilution liquid chromatography-tandem mass spectrometry candidate reference method for total testosterone in human serum. *Clin Chem*. 2013;59:372-380.
208. Botelho JC, Ribera A, Cooper HC, et al. Evaluation of an Isotope Dilution HPLC Tandem Mass Spectrometry Candidate Reference Measurement Procedure for Total 17-beta Estradiol in Human Serum. *Anal Chem*. 2016;88:11123-11129.
209. The International Bureau of Weights and Measures. JCTLM database: Laboratory medicine and in vitro diagnostics [web site]. Available at: <https://www.bipm.org/jctlm/>. Accessed 20.03.2019.
210. Grote-Koska D, Czajkowski S, Klauke R, et al. A candidate reference measurement procedure for cyclosporine A in whole blood. *Accreditation and Quality Assurance*. 2014;19:147-157.
211. IFCC. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC); Scientific Division; SD Working Groups; Immunosuppressive Drugs (WG-ID) [web site] 2018. Available at: <http://www.ifcc.org/ifcc-scientific-division/sd-working-groups/wg-id/>.
212. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. *Ther Drug Monit*. 2009;31:327-336.
213. Mei JV, Zobel SD, Hall EM, et al. Performance properties of filter paper devices for whole blood collection. *Bioanalysis*. 2010;2:1397-1403.
214. Enderle Y, Foerster K, Burhenne J. Clinical feasibility of dried blood spots: Analytics, validation, and applications. *J Pharm Biomed Anal*. 2016;130:231-243.
215. Kita K, Mano Y. Application of volumetric absorptive microsampling device for quantification of tacrolimus in human blood as a model drug of high blood cell partition. *J Pharm Biomed Anal*. 2017;143:168-175.
216. Martial LC, Hoogtanders KEJ, Schreuder MF, et al. Dried Blood Spot Sampling for Tacrolimus and Mycophenolic Acid in Children: Analytical and Clinical Validation. *Ther Drug Monit*. 2017;39:412-421.
217. Koster RA, Greijdanus B, Alffenaar JW, et al. Dried blood spot analysis of creatinine with LC-MS/MS in addition to immunosuppressants analysis. *Anal Bioanal Chem*. 2015;407:1585-1594.
218. Koster RA, Veenhof H, Botma R, et al. Dried blood spot validation of five immunosuppressants, without hematocrit correction, on two LC-MS/MS systems. *Bioanalysis*. 2017;9:553-563.
219. US Department of Health and Human Services Food and Drug Administration. Bioanalytical Method Validation; Guidance for Industry [web site]. Available at: <https://www.fda.gov/downloads/drugs/guidances/ucm070107.pdf>. Accessed 20.3.2019.
220. Capiou S, Veenhof H, Koster R, et al. Official International Association for Therapeutic Drug Monitoring and Toxicology guideline: Development and Validation of Dried Blood Spot-based Methods for Therapeutic Drug Monitoring. *TherDrug Monit*. 2019; (accepted for publication).
221. Al-Uzri A, Freeman KA, Wade J, et al. Longitudinal study on the use of dried blood spots for home monitoring in children after kidney transplantation. *Pediatr Transplant*. 2017;21.
222. Pensi D, De Nicolo A, Pinon M, et al. An UPLC-MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in peripheral blood mononuclear cells. *J Pharm Biomed Anal*. 2015;107:512-517.
223. Krogstad V, Vethe NT, Robertsen I, et al. Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies. *Ther Drug Monit*. 2018;40:292-300.
224. Ghareeb M, Akhlaghi F. Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS. *Bioanalysis*. 2015;7:1037-1058.

225. Lemaitre F, Antignac M, Fernandez C. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients. *Clin Biochem*. 2013;46:1538-1541.
226. Capron A, Lerut J, Latinne D, et al. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. *Transpl Int*. 2012;25:41-47.
227. Lemaitre F, Antignac M, Verdier MC, et al. Opportunity to monitor immunosuppressive drugs in peripheral blood mononuclear cells: where are we and where are we going? *Pharmacol Res*. 2013;74:109-112.
228. Capron A, Haufroid V, Wallemacq P. Intra-cellular immunosuppressive drugs monitoring: A step forward towards better therapeutic efficacy after organ transplantation? *Pharmacol Res*. 2016;111:610-618.
229. Bahmany S, de Wit LEA, Hesselink DA, et al. Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry. *Biomed Chromatogr*. 2018:e4416.
230. Klaasen RA, Bergan S, Bremer S, et al. A Longitudinal Study of Tacrolimus in Lymphocytes during the First Year after Kidney Transplantation. *Ther Drug Monit*. 2018.
231. Han SS, Yang SH, Kim MC, et al. Monitoring the Intracellular Tacrolimus Concentration in Kidney Transplant Recipients with Stable Graft Function. *PLoS One*. 2016;11:e0153491.
232. Lemaitre F, Blanchet B, Latournerie M, et al. Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells. *Clin Biochem*. 2015.
233. Bittersohl H, Schniedewind B, Christians U, et al. A simple and highly sensitive on-line column extraction liquid chromatography-tandem mass spectrometry method for the determination of protein-unbound tacrolimus in human plasma samples. *J Chromatogr A*. 2018;1547:45-52.
234. Belostotsky V, Adaway J, Keevil BG, et al. Measurement of saliva tacrolimus levels in pediatric renal transplant recipients. *Pediatr Nephrol*. 2011;26:133-138.
235. Ghareeb M, Gohh RY, Akhlaghi F. Tacrolimus Concentration in Saliva of Kidney Transplant Recipients: Factors Influencing the Relationship with Whole Blood Concentrations. *Clin Pharmacokinet*. 2018;57:1199-1210.
236. Kamdem LK, Streit F, Zanger UM, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. *ClinChem*. 2005;51:1374-1381.
237. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. *NatGenet*. 2001;27:383-391.
238. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. *Pharmacogenetics*. 2001;11:773-779.
239. Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. *Pharmacogenomics J*. 2011;11:274-286.
240. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. *Advanced drug delivery reviews*. 1997;27:201-214.
241. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. *J Biol Chem*. 1993;268:6077-6080.
242. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. *Annu Rev Pharmacol Toxicol*. 2003;43:285-307.
243. Cascorbi I, Gerloff T, John A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. *Clin Pharmacol Ther*. 2001;69:169-174.

244. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proc Natl Acad Sci U S A*. 2000;97:3473-3478.
245. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. *Clin Pharmacol Ther*. 2001;70:189-199.
246. Dessilly G, Elens L, Panin N, et al. ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. *PLoS One*. 2014;9:e91555.
247. Oneda B, Crettol S, Jaquenoud Sirot E, et al. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. *Pharmacogenet Genomics*. 2009;19:877-883.
248. Klein K, Thomas M, Winter S, et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. *Clin Pharmacol Ther*. 2012;91:1044-1052.
249. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. *Pharmacogenetics*. 2004;14:147-154.
250. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. *Transplantation*. 2003;76:1233-1235.
251. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. *Clin Pharmacol Ther*. 2003;74:245-254.
252. Picard N, Bergan S, Marquet P, et al. Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs. *Ther Drug Monit*. 2015;38 Suppl 1:S57-S61.
253. Zong YP, Wang ZJ, Zhou WL, et al. Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies. *World J Pediatr*. 2017;13:421-426.
254. Rojas L, Neumann I, Herrero MJ, et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. *Pharmacogenomics J*. 2015;15:38-48.
255. Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. *Am J Transplant*. 2006;6:2706-2713.
256. Thervet E, Lorient MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. *Clin Pharmacol Ther*. 2010;87:721-726.
257. De Meyer M, Haufroid V, Kanaan N, et al. Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study. *Pharmacogenomics*. 2016;17:1019-1027.
258. Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. *Clin Pharmacol Ther*. 2015;98:19-24.
259. Shuker N, Bouamar R, van Schaik RH, et al. A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. *Am J Transplant*. 2016;16:2085-2096.
260. H. dJ, de LH, Verbeke K, et al. In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients. *ClinPharmacolTher*. 2012.
261. Elens L, van Schaik RH, Panin N, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. *Pharmacogenomics*. 2011;12:1383-1396.

262. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. *ClinChem*. 2011;57:1574-1583.
263. Elens L, Capron A, van Schaik RH, et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. *Ther Drug Monit*. 2013;35:608-616.
264. Elens L, Haufroid V. Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22? *Pharmacogenomics*. 2017;18:1473-1480.
265. Woillard JB, Mourad M, Neely M, et al. Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. *Front Pharmacol*. 2017;8:358.
266. Kurzawski M, Dabrowska J, Dziwanowski K, et al. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. *Pharmacogenomics*. 2014;15:179-188.
267. Yoon SH, Cho JH, Kwon O, et al. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). *Transplantation*. 2013;95:828-834.
268. Li Y, Hu X, Cai B, et al. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. *Transpl Immunol*. 2012;27:12-18.
269. Singh R, Srivastava A, Kapoor R, et al. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period? *J Clin Pharmacol*. 2011;51:603-615.
270. Terrazzino S, Quaglia M, Stratta P, et al. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. *Pharmacogenet Genomics*. 2012;22:642-645.
271. Metalidis C, Lerut E, Naesens M, et al. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. *Transplantation*. 2011;91:1098-1102.
272. Capron A, Mourad M, De Meyer M, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. *Pharmacogenomics*. 2010;11:703-714.
273. Vafadari R, Bouamar R, Hesselink DA, et al. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. *Ther Drug Monit*. 2013;35:459-465.
274. Lunde I, Bremer S, Midtvedt K, et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. *Eur J Clin Pharmacol*. 2014;70:685-693.
275. Gijsen VM, van Schaik RH, Soldin OP, et al. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study. *Ther Drug Monit*. 2014;36:152-158.
276. de Jonge H, Metalidis C, Naesens M, et al. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. *Pharmacogenomics*. 2011;12:1281-1291.
277. Pulk RA, Schladt DS, Oetting WS, et al. Multigene predictors of tacrolimus exposure in kidney transplant recipients. *Pharmacogenomics*. 2015;16:841-854.
278. Kurzawski M, Malinowski D, Dziwanowski K, et al. Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients. *Pharmacogenet Genomics*. 2014;24:397-400.
279. Elens L, Hesselink DA, Bouamar R, et al. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. *Ther Drug Monit*. 2014;36:71-79.

280. Pouche L, Stojanova J, Marquet P, et al. New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs. *Pharmacogenomics*. 2016;17:277-296.
281. Noceti O, Pouche L, Esperon P, et al. Activity of the Calcineurin Pathway in Patients on the Liver Transplantation Waiting List: Factors of Variability and Response to Tacrolimus Inhibition. *Clin Chem*. 2017;63:1734-1744.
282. Pouche L, Koitka M, Stojanova J, et al. A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation. *Pharmacogenomics*. 2016;17:375-391.
283. Buendia JA, Otamendi E, Kravetz MC, et al. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients. *Exp Clin Transplant*. 2015;13:441-448.
284. Gomez-Bravo MA, Salcedo M, Fondevila C, et al. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. *J Clin Pharmacol*. 2013;53:1146-1154.
285. Uesugi M, Masuda S, Katsura T, et al. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. *Pharmacogenet Genomics*. 2006;16:119-127.
286. Provenzani A, Notarbartolo M, Labbozzetta M, et al. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. *Int J Mol Med*. 2011;28:1093-1102.
287. Yu S, Wu L, Jin J, et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. *Transplantation*. 2006;81:46-51.
288. Goto M, Masuda S, Kiuchi T, et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. *Pharmacogenetics*. 2004;14:471-478.
289. Debette-Gratien M, Woillard JB, Picard N, et al. Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. *Transplantation*. 2016;100:2129-2137.
290. Buendia JA, Bramuglia G, Staats CE. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis. *Ther Drug Monit*. 2014;36:442-447.
291. Uesugi M, Kikuchi M, Shinke H, et al. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation. *Pharmacogenet Genomics*. 2014;24:356-366.
292. Moes DJ, van der Bent SA, Swen JJ, et al. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. *Eur J Clin Pharmacol*. 2016;72:163-174.
293. de Denus S, Zakrzewski M, Barhdadi A, et al. Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. *J Heart Lung Transplant*. 2011;30:326-331.
294. Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. *Clin Pharmacol Ther*. 2007;82:711-725.
295. Fukudo M, Yano I, Yoshimura A, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. *Pharmacogenet Genomics*. 2008;18:413-423.
296. Hosohata K, Uesugi M, Hashi S, et al. Association between CYP3A5 genotypes in graft liver and increase in tacrolimus biotransformation from steroid treatment in living-donor liver transplant patients. *Drug Metab Pharmacokinet*. 2014;29:83-89.

297. Muraki Y, Usui M, Isaji S, et al. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. *Ann Transplant*. 2011;16:55-62.
298. Shi Y, Li Y, Tang J, et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. *Gene*. 2013;512:226-231.
299. Gomez-Bravo MA, Apellaniz-Ruiz M, Salcedo M, et al. Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients. *Pharmacogenet Genomics*. 2018;28:41-48.
300. Monostory K, Toth K, Kiss A, et al. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients. *Br J Clin Pharmacol*. 2015;80:1429-1437.
301. Guy-Viterbo V, Baudet H, Elens L, et al. Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. *Pharmacogenomics*. 2014;15:1207-1221.
302. Hosohata K, Masuda S, Katsura T, et al. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. *Drug Metab Dispos*. 2009;37:821-826.
303. Masuda S, Goto M, Fukatsu S, et al. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. *Clin Pharmacol Ther*. 2006;79:90-102.
304. Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. *Am J Transplant*. 2003;3:477-483.
305. Kniepeiss D, Renner W, Trummer O, et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. *Clin Transplant*. 2011;25:146-150.
306. Diaz-Molina B, Tavira B, Lambert JL, et al. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. *Transplant Proc*. 2012;44:2635-2638.
307. Gijsen VM, van Schaik RH, Elens L, et al. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. *Pharmacogenomics*. 2013;14:1027-1036.
308. Deininger KM, Vu A, Page RL, 2nd, et al. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients. *Clin Transplant*. 2016;30:1074-1081.
309. Gijsen V, Mital S, van Schaik RH, et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. *J Heart Lung Transplant*. 2011;30:1352-1359.
310. Lesche D, Sigurdardottir V, Setoud R, et al. CYP3A5*3 and POR*28 Genetic Variants Influence the Required Dose of Tacrolimus in Heart Transplant Recipients. *Ther Drug Monit*. 2014;36:710-715.
311. Sanchez-Lazaro I, Herrero MJ, Jordan-De Luna C, et al. Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation. *Pharmacogenomics*. 2015;16:971-979.
312. Zheng H, Zeevi A, Schuetz E, et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. *J Clin Pharmacol*. 2004;44:135-140.
313. Ruiz J, Herrero MJ, Boso V, et al. Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation. *Int J Mol Sci*. 2015;16:20168-20182.
314. Shipkova M, Wieland E. Editorial: Immune monitoring in solid organ transplantation. *Clin Biochem*. 2016;49:317-319.

315. Fruman DA, Klee CB, Bierer BE, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. *Proc Natl Acad Sci U S A*. 1992;89:3686-3690.
316. Blanchet B, Hulin A, Duvoux C, et al. Determination of serine/threonine protein phosphatase type 2B PP2B in lymphocytes by HPLC. *Anal Biochem*. 2003;312:1-6.
317. Carr L, Gagez AL, Essig M, et al. Calcineurin activity assay measurement by liquid chromatography-tandem mass spectrometry in the multiple reaction monitoring mode. *Clin Chem*. 2014;60:353-360.
318. Sommerer C, Giese T. Nuclear Factor of Activated T Cells-Regulated Gene Expression as Predictive Biomarker of Personal Response to Calcineurin Inhibitors. *Ther Drug Monit*. 2016;38 Suppl 1:S50-56.
319. Blanchet B, Duvoux C, Costentin CE, et al. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period. *Ther Drug Monit*. 2008;30:412-418.
320. Fukudo M, Yano I, Masuda S, et al. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. *Clin Pharmacol Ther*. 2005;78:168-181.
321. Koefoed-Nielsen PB, Karamperis N, Hojskov C, et al. The calcineurin activity profiles of cyclosporin and tacrolimus are different in stable renal transplant patients. *Transpl Int*. 2006;19:821-827.
322. Fukudo M, Yano I, Katsura T, et al. A transient increase of calcineurin phosphatase activity in living-donor kidney transplant recipients with acute rejection. *Drug Metab Pharmacokinet*. 2010;25:411-417.
323. Hogan PG, Chen L, Nardone J, et al. Transcriptional regulation by calcium, calcineurin, and NFAT. *Genes Dev*. 2003;17:2205-2232.
324. George T, Harmon I, Peterson EJ, et al. Measurement of nuclear translocation in primary cells using correlation analysis of images obtained on the ImageStream imaging flow cytometer (87.13). *The Journal of Immunology*. 2007;178:S130-S130.
325. Maguire O, Tornatore KM, O'Loughlin KL, et al. Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. *Cytometry Part A : the journal of the International Society for Analytical Cytology*. 2013;83:1096-1104.
326. Noceti OM, Woillard JB, Boumediene A, et al. Tacrolimus pharmacodynamics and pharmacogenetics along the calcineurin pathway in human lymphocytes. *Clin Chem*. 2014;60:1336-1345.
327. Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription: NFAT and AP-1. *Oncogene*. 2001;20:2476-2489.
328. Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. *Transplantation*. 2006;82:1280-1285.
329. Zahn A, Schott N, Hinz U, et al. Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: the first clinical trial in liver allograft recipients. *Liver Transpl*. 2011;17:466-473.
330. Hartel C, Schumacher N, Fricke L, et al. Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect. *Clin Chem*. 2004;50:141-151.
331. Giese T, Sommerer C, Zeier M, et al. Approaches towards individualized immune intervention. *Dig Dis*. 2010;28:45-50.
332. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. *Clin Chem*. 1999;45:1477-1484.

333. Sommerer C, Meuer S, Zeier M, et al. Calcineurin inhibitors and NFAT-regulated gene expression. *Clin Chim Acta*. 2012;413:1379-1386.
334. Hartel C, Fricke L, Schumacher N, et al. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. *Clin Chem*. 2002;48:2225-2231.
335. Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. *Transplantation*. 1999;68:1356-1361.
336. Sommerer C, Giese T, Meuer S, et al. Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit? *Nephrol Dial Transplant*. 2009;24:21-27.
337. Giese T, Zeier M, Meuer S. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. *Nephrol Dial Transplant*. 2004;19 Suppl 4:iv55-60.
338. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. *Transplantation*. 2004;77:339-344.
339. Abdel-Kahaar E, Giese T, Sommerer C, et al. Analytical validation and cross-validation of a NFAT-regulated gene expression assay for pharmacodynamic monitoring of therapy with calcineurin inhibitors. *Ther Drug Monit*. 2016.
340. Bremer S, Vethe NT, Skauby M, et al. NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation. *Br J Clin Pharmacol*. 2017.
341. Greenland JR, Chong T, Wang AS, et al. Suppressed calcineurin-dependent gene expression identifies lung allograft recipients at increased risk of infection. *Am J Transplant*. 2018;18:2043-2049.
342. Sommerer C, Zeier M, Meuer S, et al. Monitoring of calcineurin inhibitors by NFAT-regulated gene expression in de novo renal allograft recipients on cyclosporine A. *Clin Nephrol*. 2015;84:165-172.
343. Keller F, Sommerer C, Giese T, et al. Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients. *Clin Nephrol*. 2016.
344. Sommerer C, Schaefer M, Morath C, et al. The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial. *Trials*. 2014;15:489.
345. Steinebrunner N, Sandig C, Sommerer C, et al. Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation. *Transpl Infect Dis*. 2014;16:379-386.
346. Konstandin MH, Sommerer C, Doesch A, et al. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. *Transpl Int*. 2007;20:1036-1043.
347. Sommerer C, Schnitzler P, Meuer S, et al. Pharmacodynamic monitoring of cyclosporin a reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older. *Ther Drug Monit*. 2011;33:694-698.
348. Sommerer C, Zeier M, Meuer S, et al. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. *Transplantation*. 2010;89:1417-1423.
349. Sommerer C, Zeier M, Czock D, et al. Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia. *Ther Drug Monit*. 2011;33:373-379.
350. Sommerer C, Hartschuh W, Enk A, et al. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. *Clin Transplant*. 2008;22:549-554.

351. Sommerer C, Brocke J, Bruckner T, et al. Improved Pulse Wave Velocity and Renal Function in Individualized Calcineurin Inhibitor Treatment by Immunomonitoring: The Randomized Controlled Calcineurin Inhibitor-Sparing Trial. *Transplantation*. 2018;102:510-520.
352. Kannegieter NM, Hesselink DA, Dieterich M, et al. Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial. *Sci Rep*. 2017;7:15135.
353. Kannegieter NM, Hesselink DA, Dieterich M, et al. Pharmacodynamic Monitoring of Tacrolimus-based Immunosuppression in CD14+ Monocytes after Kidney Transplantation. *Ther Drug Monit*. 2017.
354. Kannegieter NM, Shuker N, Vafadari R, et al. Conversion to Once-Daily Tacrolimus Results in Increased p38MAPK Phosphorylation in T Lymphocytes of Kidney Transplant Recipients. *Ther Drug Monit*. 2016;38:280-284.
355. Albring A, Wendt L, Harz N, et al. Relationship between pharmacokinetics and pharmacodynamics of calcineurin inhibitors in renal transplant patients. *Clin Transplant*. 2015;29:294-300.
356. Cattral M, Luke S, Knauer MJ, et al. Randomized open-label crossover assessment of Prograf vs Advagraf on immunosuppressant pharmacokinetics and pharmacodynamics in simultaneous pancreas-kidney patients. *Clin Transplant*. 2018;32.
357. Tanaka T, Takatsuki M, Soyama A, et al. Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation. *Ann Transplant*. 2013;18:293-298.
358. Ravaioli M, Neri F, Lazzarotto T, et al. Immunosuppression Modifications Based on an Immune Response Assay: Results of a Randomized, Controlled Trial. *Transplantation*. 2015;99:1625-1632.
359. Barten MJ, Tarnok A, Garbade J, et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. *Cell Prolif*. 2007;40:50-63.
360. Kurata Y, Kato M, Kuzuya T, et al. Pretransplant pharmacodynamic analysis of immunosuppressive agents using CFSE-based T-cell proliferation assay. *Clin Pharmacol Ther*. 2009;86:285-289.
361. Weimer R, Melk A, Daniel V, et al. Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses. *Hum Immunol*. 2000;61:884-897.
362. Ashokkumar C, Talukdar A, Sun Q, et al. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. *Am J Transplant*. 2009;9:179-191.
363. Barten MJ, Rahmel A, Garbade J, et al. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients. *Transplant Proc*. 2005;37:4532-4534.
364. Bai YJ, Wang LL, Cai B, et al. [Regulatory function of tacrolimus and CsA on CD4/CD8 T lymphocyte subgroups and costimulators on them in allo-liver recipients]. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi*. 2008;24:989-992.
365. Shi G, Zeng Q, Zhao Z, et al. Variation of CD4(+)CD25(+)Foxp3(+) Regulatory T Cells and Th17 Cells in the Peripheral Blood of Human Liver Allograft Patients With Long-term Survival. *Transplant Proc*. 2017;49:1834-1840.
366. Laskin BL, Jiao J, Baluarte HJ, et al. The Effects of Tacrolimus on T-Cell Proliferation Are Short-Lived: A Pilot Analysis of Immune Function Testing. *Transplant Direct*. 2017;3:e199.
367. Gong N, Chen Z, Wang J, et al. Immunoregulatory effects of sirolimus vs. tacrolimus treatment in kidney allograft recipients. *Cell Immunol*. 2015;297:87-93.
368. Kim TJ, Kim N, Kang HJ, et al. FK506 causes cellular and functional defects in human natural killer cells. *J Leukoc Biol*. 2010;88:1089-1097.

369. Nakamura Y, Hama K, Katayama H, et al. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients. *Transplant Proc.* 2012;44:124-127.
370. Bohler T, Canivet C, Galvani S, et al. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients. *Int Immunopharmacol.* 2008;8:769-773.
371. Boix F, Mrowiec A, Muro M. Cytokine Expression Profile as Predictive Surrogate Biomarkers for Clinical Events in the Field of Solid Organ Transplantation. *Current protein & peptide science.* 2017;18:240-249.
372. Millan O, Brunet M. Cytokine-based immune monitoring. *Clin Biochem.* 2016;49:338-346.
373. Brunet M, Millan Lopez O, Lopez-Hoyos M. T-Cell Cytokines as Predictive Markers of the Risk of Allograft Rejection. *Ther Drug Monit.* 2016;38 Suppl 1:S21-28.
374. Hricik DE, Rodriguez V, Riley J, et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. *Am J Transplant.* 2003;3:878-884.
375. Millan O, Rafael-Valdivia L, San Segundo D, et al. Should IFN-gamma, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study. *Clin Immunol.* 2014;154:141-154.
376. Hricik DE, Formica RN, Nickerson P, et al. Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. *J Am Soc Nephrol.* 2015;26:3114-3122.
377. Boleslawski E, Conti F, Sanquer S, et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. *Transplantation.* 2004;77:1815-1820.
378. Akoglu B, Kriener S, Martens S, et al. Interleukin-2 in CD8+ T cells correlates with Banff score during organ rejection in liver transplant recipients. *Clin Exp Med.* 2009;9:259-262.
379. Ahmed M, Venkataraman R, Logar AJ, et al. Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. *Ther Drug Monit.* 2001;23:354-362.
380. Millan O, Benitez C, Guillen D, et al. Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. *Clin Immunol.* 2010;137:337-346.
381. Millan O, Rafael-Valdivia L, Torrademe E, et al. Intracellular IFN-gamma and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients. *Cytokine.* 2013;61:556-564.
382. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. *Annu Rev Immunol.* 2009;27:485-517.
383. Abadja F, Atemkeng S, Alamartine E, et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. *Transplantation.* 2011;92:396-403.
384. Chung BH, Kim KW, Kim BM, et al. Dysregulation of Th17 cells during the early post-transplant period in patients under calcineurin inhibitor based immunosuppression. *PLoS One.* 2012;7:e42011.
385. Merino D, San Segundo D, Medina JM, et al. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment. *Immunology.* 2016;148:206-215.
386. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. *Transplantation.* 2013;95:19-47.
387. Lefaucheur C, Viglietti D, Mangiola M, et al. From Humoral Theory to Performant Risk Stratification in Kidney Transplantation. *Journal of immunology research.* 2017;2017:5201098.

388. Loupy A, Lefaucheur C. Antibody-Mediated Rejection of Solid-Organ Allografts. *N Engl J Med*. 2018;379:1150-1160.
389. Karahan GE, Claas FHJ, Heidt S. Technical challenges and clinical relevance of single antigen bead C1q/C3d testing and IgG subclass analysis of human leukocyte antigen antibodies. *Transpl Int*. 2018;31:1189-1197.
390. Bamoulid J, Roodenburg A, Staeck O, et al. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation. *Transplantation*. 2017;101:2165-2174.
391. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. *Transplantation*. 2009;87:1505-1513.
392. Wiebe C, Gareau AJ, Pochinco D, et al. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. *Am J Transplant*. 2017;17:703-711.
393. Bouquegneau A, Loheac C, Aubert O, et al. Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. *PLoS Med*. 2018;15:e1002572.
394. Viglietti D, Bouatou Y, Kheav VD, et al. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. *Kidney Int*. 2018;94:773-787.
395. Viglietti D, Loupy A, Aubert O, et al. Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection. *J Am Soc Nephrol*. 2018;29:606-619.
396. Budde K, Durr M. Any Progress in the Treatment of Antibody-Mediated Rejection? *J Am Soc Nephrol*. 2018;29:350-352.
397. Malvezzi P, Jouve T, Noble J, et al. Desensitization in the Setting of HLA-Incompatible Kidney Transplant. *Exp Clin Transplant*. 2018;16:367-375.
398. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. *Am J Transplant*. 2012;12:388-399.
399. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. *Am J Transplant*. 2015;15:2921-2930.
400. Sablik KA, Clahsen-van Groningen MC, Hesselink DA, et al. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. *PLoS One*. 2018;13:e0196552.
401. Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. *Transplant Rev (Orlando)*. 2015;29:78-84.
402. Dugast E, Souillou JP, Foucher Y, et al. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. *Am J Transplant*. 2016;16:3255-3261.
403. Heidt S, Roelen DL, Eijssink C, et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. *Clin Exp Immunol*. 2010;159:199-207.
404. Matz M, Lehnert M, Lorkowski C, et al. Combined standard and novel immunosuppressive substances affect B-lymphocyte function. *Int Immunopharmacol*. 2013;15:718-725.
405. O'Leary JG, Samaniego M, Barrio MC, et al. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. *Transplantation*. 2016;100:39-53.

406. Wiebe C, Rush DN, Nevins TE, et al. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. *J Am Soc Nephrol*. 2017;28:3353-3362.
407. Nath DS, Angaswamy N, Basha HI, et al. Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation. *Hum Immunol*. 2010;71:1191-1196.
408. Lund LH, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. 2016;35:1158-1169.
409. Hodges AM, Lyster H, McDermott A, et al. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. *Transplantation*. 2012;93:650-656.
410. Frank R, Molina MR, Goldberg LR, et al. Circulating donor-specific anti-human leukocyte antigen antibodies and complement C4d deposition are associated with the development of cardiac allograft vasculopathy. *Am J Clin Pathol*. 2014;142:809-815.
411. Kobashigawa J, Colvin M, Potena L, et al. The management of antibodies in heart transplantation: An ISHLT consensus document. *J Heart Lung Transplant*. 2018;37:537-547.
412. Coutance G, d'Orio V, Belin L, et al. Favorable outcome of an exclusively posttransplant prophylactic strategy after heart transplantation in recipients with high immunological risk. *Transplantation*. 2018.
413. Barten MJ, Schulz U, Beiras-Fernandez A, et al. The clinical impact of donor-specific antibodies in heart transplantation. *Transplant Rev (Orlando)*. 2018;32:207-217.
414. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. *Am J Transplant*. 2006;6:1377-1386.
415. Garcia Moreira V, Prieto Garcia B, Baltar Martin JM, et al. Cell-free DNA as a noninvasive acute rejection marker in renal transplantation. *Clin Chem*. 2009;55:1958-1966.
416. Beck J, Bierau S, Balzer S, et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. *Clin Chem*. 2013;59:1732-1741.
417. Gielis EM, Ledeganck KJ, De Winter BY, et al. Cell-Free DNA: An Upcoming Biomarker in Transplantation. *Am J Transplant*. 2015;15:2541-2551.
418. Verhoeven J, Boer K, Van Schaik RHN, et al. Liquid Biopsies to Monitor Solid Organ Transplant Function: A Review of New Biomarkers. *Ther Drug Monit*. 2018;40:515-525.
419. Sigdel TK, Vitalone MJ, Tran TQ, et al. A rapid noninvasive assay for the detection of renal transplant injury. *Transplantation*. 2013;96:97-101.
420. Bloom RD, Bromberg JS, Poggio ED, et al. Cell-Free DNA and Active Rejection in Kidney Allografts. *J Am Soc Nephrol*. 2017;28:2221-2232.
421. Oellerich M, Schutz E, Kanzow P, et al. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. *Ther Drug Monit*. 2014;36:136-140.
422. Schutz E, Fischer A, Beck J, et al. Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. *PLoS Med*. 2017;14:e1002286.
423. Knight SR, Thorne A, Faro MLL. Donor-specific Cell-Free DNA as a Biomarker in Solid Organ Transplantation. A Systematic Review. *Transplantation*. 2018.
424. Debord J, Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporin. *Clin Pharmacokinet*. 2001;40:375-382.

425. Savic RM, Jonker DM, Kerbusch T, et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. *J Pharmacokinet Pharmacodyn*. 2007;34:711-726.
426. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. *Clin Pharmacokinet*. 2004;43:623-653.
427. Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. *Am J Kidney Dis*. 2000;35:660-666.
428. Knoop C, Thiry P, Saint-Marcoux F, et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. *Am J Transplant*. 2005;5:1477-1482.
429. Woillard JB, Debord J, Monchaud C, et al. Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients. *Clin Pharmacokinet*. 2017;56:1491-1498.
430. Woillard JB, Chouchana L, Picard N, et al. Pharmacogenetics of immunosuppressants: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics (RNPGx). *Therapie*. 2017;72:285-299.
431. Chen B, Shi HQ, Liu XX, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. *J Clin Pharm Ther*. 2017;42:679-688.
432. Zhu L, Yang J, Zhang Y, et al. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. *Xenobiotica*. 2015;45:840-846.
433. Jacobo-Cabral CO, Garcia-Roca P, Romero-Tejeda EM, et al. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation. *Br J Clin Pharmacol*. 2015;80:630-641.
434. Zhao W, Fakhoury M, Baudouin V, et al. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. *Eur J Clin Pharmacol*. 2013;69:189-195.
435. Storset E, Holford N, Midtvedt K, et al. Importance of hematocrit for a tacrolimus target concentration strategy. *Eur J Clin Pharmacol*. 2014;70:65-77.
436. Musuamba FT, Mourad M, Haufroid V, et al. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation. *J Clin Pharmacol*. 2012;52:1833-1843.
437. Zuo XC, Ng CM, Barrett JS, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. *Pharmacogenet Genomics*. 2013;23:251-261.
438. Han N, Yun HY, Hong JY, et al. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. *Eur J Clin Pharmacol*. 2013;69:53-63.
439. Woillard JB, de Winter BC, Kamar N, et al. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. *Br J Clin Pharmacol*. 2011;71:391-402.
440. Benkali K, Rostaing L, Premaud A, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. *Clin Pharmacokinet*. 2010;49:683-692.
441. Andreu F, Colom H, Elens L, et al. A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. *Clin Pharmacokinet*. 2017;56:963-975.
442. Jalil MH, Hawwa AF, McKiernan PJ, et al. Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. *Br J Clin Pharmacol*. 2014;77:130-140.

443. Zhao W, Elie V, Roussey G, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. *Clin Pharmacol Ther.* 2009;86:609-618.
444. Andrews LM, Hesselink DA, van Gelder T, et al. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. *Clin Pharmacokinet.* 2018;57:475-489.
445. Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. *Ther Drug Monit.* 2009;31:187-197.
446. Ogasawara K, Chitnis SD, Gohh RY, et al. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. *Clin Pharmacokinet.* 2013;52:751-762.
447. Asberg A, Midtvedt K, van Guilder M, et al. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. *Transpl Int.* 2013;26:1198-1207.
448. Zhou LY, Zuo XC, Chen K, et al. Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. *J Clin Pharm Ther.* 2016;41:341-347.
449. Liu Y, Zhang T, Zhang X, et al. A new donors' CYP3A5 and recipients' CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients. *Oncotarget.* 2017;8:70250-70261.
450. Zhang JJ, Liu SB, Xue L, et al. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. *Int J Clin Pharmacol Ther.* 2015;53:728-736.
451. Knops N, van den Heuvel LP, Masereeuw R, et al. The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells. *Mol Pharm.* 2015;12:758-768.
452. Naesens M, Lerut E, de Jonge H, et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. *J Am Soc Nephrol.* 2009;20:2468-2480.
453. Woillard JB, Gatault P, Picard N, et al. A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus-based regimen. *Am J Transplant.* 2018.
454. Lon HK, Liu D, Jusko WJ. Pharmacokinetic/pharmacodynamic modeling in inflammation. *Crit Rev Biomed Eng.* 2012;40:295-312.
455. Lovern M, Sargentini-Maier ML, Otoul C, et al. Population pharmacokinetic and pharmacodynamic analysis in allergic diseases. *Drug Metab Rev.* 2009;41:475-485.
456. Koefoed-Nielsen PB, Karamperis N, Jorgensen KA. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients. *Transplant Proc.* 2005;37:1736-1738.
457. Koefoed-Nielsen PB, Jorgensen KA. Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients. *Transplant Proc.* 2002;34:1743-1744.
458. Millan O, Brunet M, Campistol JM, et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. *Clin Chem.* 2003;49:1891-1899.
459. Millan O, Budde K, Sommerer C, et al. Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. *Br J Clin Pharmacol.* 2017;83:2636-2650.
460. Billing H, Breil T, Schmidt J, et al. Pharmacodynamic monitoring by residual NFAT-regulated gene expression in stable pediatric liver transplant recipients. *Pediatr Transplant.* 2012;16:187-194.

461. Steinebrunner N, Sandig C, Sommerer C, et al. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study. *Ann Transplant*. 2014;19:32-40.
462. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. *Clin Pharmacol Ther*. 1994;56:406-419.
463. Holford N. Clinical pharmacology = disease progression + drug action. *Br J Clin Pharmacol*. 2015;79:18-27.
464. Holford N. A time to event tutorial for pharmacometricians. *CPT: pharmacometrics & systems pharmacology*. 2013;2:e43.
465. Plan EL. Modeling and simulation of count data. *CPT: pharmacometrics & systems pharmacology*. 2014;3:e129.
466. Paule I, Girard P, Freyer G, et al. Pharmacodynamic models for discrete data. *Clin Pharmacokinet*. 2012;51:767-786.
467. Storset E, Asberg A, Skauby M, et al. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients-A Prospective, Randomized Study. *Transplantation*. 2015;99:2158-2166.

Figure Legends

Figure 1. Data from the Analytical Services International (ASI) proficiency testing (PT) program showing:

(A): Between-laboratory and between-method variability of the bias of reported to target tacrolimus concentrations (4 ng/mL, 8 ng/mL and 12 ng/mL).

(B): Between-laboratory and between-method imprecision observed with whole blood samples spiked with tacrolimus to concentrations of 4 ng/mL, 8 ng/mL or 12 ng/mL.

Included are 5-6 separate distributions of whole blood samples spiked with tacrolimus and sent to the PT participants between 2014 and 2017. The methods compared include liquid chromatography-tandem mass spectrometry (LC-MS/MS, 171-200 participants), chemiluminescent microparticle immunoassay (CMIA, 131-160 participants), electrochemiluminescence immunoassay (ECLIA, 16-49 participants), antibody conjugated magnetic immunoassay (ACMIA, 28-34 participants), enzyme multiplied immunoassay

technique (EMIT2000, 10-27 participants), and quantitative microsphere system (QMS, 8-13 participants).

Figure 2. Data from the Analytical Services International (ASI) proficiency testing (PT) program collected between 2014 and 2017 and demonstrating the method-dependent between-laboratory bias (A) and imprecision (B) using pooled samples from transplant patients on therapy with tacrolimus. Included are 31 separate PT distributions with a median tacrolimus concentration (based on the results reported by the LC-MS/MS group) of 8.7 ng/mL (range: 7.5 – 16.5 ng/mL). The methods compared include liquid chromatography-tandem mass spectrometry (LC-MS/MS, 171-200 participants), chemiluminescent microparticle immunoassay (CMIA, 131-160 participants), electrochemiluminescence immunoassay (ECLIA, 14-49 participants), antibody conjugated magnetic immunoassay (ACMIA, 28-36 participants), enzyme multiplied immunoassay technique (EMIT2000, 10-27 participants), and quantitative microsphere system (QMS, 7-13 participants).

Figure 3. Pharmacodynamic targets of tacrolimus

PI3K=Phosphoinositide 3-kinase; PIP3=phosphatidylinositol (3,4) triphosphate; AKT=protein kinase B; IKK=IkB kinase; NFkB=nuclear factor kappa-light-chain enhancer of activated B cells; ZAP70=zeta chain associated protein kinase 70); DAG=diacyl glycerol; RAS=rat sarcoma protein; RAC=GTPase; MEK=mitogen activated protein kinase kinase; MKK=dual specificity mitogen-activated protein kinase kinase; p38MAPK=p38 mitogen activated protein kinase 3; IP3=inositol-1,4,5-triphosphate; NFAT=nuclear factor of activated T cells; C-RAF=RAF proto-

oncogene serine/threonine-protein kinase; ERK=extracellular signal-regulated kinase;
FKBP12=FK binding protein 12; IFN γ =interferon gamma; GM-CSF= granulocyte macrophage
colony-stimulating factor.

Figure 4. Recommendations for initial tacrolimus dose according to CYP-genotype.

ACCEPTED

Table 1. Grading system for recommendations and evidence level used in the consensus document

Category, grade	Definition
Strength of recommendation	
A	Good evidence to support a recommendation for: -Specific target concentrations -Biomarker (BM) monitoring
B	Moderate evidence to support a recommendation for: -Specific target concentrations -BM monitoring
C1	Regardless of poor evidence, recommendation for: -Specific target concentrations -BM monitoring
C2	Poor evidence to support a recommendation for: -Specific target concentrations -BM monitoring
Quality of evidence	
I	Evidence from ≥ 1 properly randomized, controlled multicenter clinical trial using validated methodology
II	Evidence from ≥ 1 well-designed cohort or case-controlled non-randomized clinical trial, multiple time series, standardized methodologies.

III	Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports from expert committees
-----	---

- Grading Guide. UpToDate® - Wolters Kluwer Health [web site] 2015. Available at: <http://www.uptodate.com/home/grading-guide>. Accessed July 2015.
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336:924

Table 2: Drug interactions with tacrolimus^{41, 42}

Drug	Clinical Effect (Risk)
Aminoglycosides Amphotericin B Cisplatin Cyclosporine Ibuprofen Kanamycin	Additive or synergistic nephrotoxicity
Antacids Carbamazepine Dexamethasone HIV antivirals Modafinil Phenobarbital Phenytoin Pioglitazone Rifabutin Rifampin Troglitazone	Reduce tacrolimus concentrations (Transplant rejection)
Bromocriptine Chloramphenicol Cimetidine Cisapride Clarithromycin Clotrimazole Cyclosporine Danazol Diltiazem Elbasvir Erythromycin	Increase tacrolimus concentrations (Toxicity)

Esomeprazole	
Ethinylestradiol	
Fluconazole	
Grazeoprevir	
Itraconazole	
Ketoconazole	
Omeprazole	
Methylprednisolone	
Metoclopramide	
Miberfradil	
Nafazodone	
Nicardipine	
HIV Protease Inhibitors	
Theophylline	
Troleandomycin	
Verapamil	
Voriconazole	

Table 3: Minor allele frequencies (by ethnic group) for relevant tacrolimus biotransformation enzymes and transporters

	EUR	AFR	AMR	EAS	SAS
<i>CYP3A5*3, rs776746</i>	0.94	0.18	0.80	0.71	0.68
<i>CYP3A5*6, rs10264272</i>	<0.01	0.15	0.02	<0.01	<0.01
<i>CYP3A4*22, rs35599367</i>	0.05	<0.01	0.03	<0.01	<0.01
<i>ABCB1 3435T, rs1045642</i>	0.52	0.15	0.43	0.40	0.57
<i>ABCB1 1199A, rs2229109</i>	0.03	<0.01	0.02	<0.01	0.01
<i>POR*28, rs1057868</i>	0.30	0.17	0.28	0.37	0.35
<i>PPAR, rs4253728</i>	0.28	0.03	0.16	<0.01	0.10
<i>PPAR, rs4823613</i>	0.29	0.40	0.28	0.20	0.16

From 1000 Genomes Project data (<http://www.internationalgenome.org/>), all populations have been divided into 5 super populations according **EUR**, European; **AFR**, African; **AMR**, Ad Mixed American (Mexican, Puerto Ricans, Colombians and Peruvians); **EAS**, East Asian; **SAS**, South Asian

Table 4: CYP3A combined genotype classification according to ²⁵⁸

	<i>CYP3A4</i> *22 carriers (<i>CYP3A4</i> *1/*22 or *22/*22)	<i>CYP3A4</i> *22 non carriers
<i>CYP3A5</i> *1 non carriers or <i>CYP3A5</i> non expressers (e.g. <i>CYP3A5</i> *3/*3)	CYP3A poor metabolizers PM	CYP3A intermediate metabolizers IM
<i>CYP3A5</i> *1 carriers or <i>CYP3A5</i> expressers (e.g. <i>CYP3A5</i> *1/*3 or *1/*1)	CYP3A intermediate metabolizers IM *	CYP3A normal metabolizers NM

*This category of CYP3A is very rare according to the relative MAF of *CYP3A5**3 and *CYP3A4**22 in different ethnicities (see table 3)

Table 5. Pharmacodynamic biomarkers and assay platforms to assess the effect of tacrolimus

Biomarker	Assay
CaN activity	³² P release from a synthetic phosphorylated peptide
	Dephosphorylation of a synthetic peptide by HPLC
	Dephosphorylation of synthetic peptide by LC-MS/MS
Dephosphorylated proteins in signal transduction pathways	Phosphoflow cytometry
Nuclear translocation of NFAT	Flow cytometry
NFAT regulated gene expression	Real-time PCR
Intracellular cytokines and chemokines	Flow cytometry
Cytokine production by T-cells	ELISPOT
T-cell subsets (regulatory T-cells)	Flow cytometry, qPCR.
T-cell surface marker expression	Flow cytometry
T-cell proliferation	PCNA expression by qPCR, CFSE staining by flow cytometry
Graft derived cell-free DNA	Digital droplet PCR
ATP release from CD4 ⁺ T-cells	Luminescence

ATP, adenosine triphosphate; CaN, calcineurin; CFSE, carboxylfluorescein diacetate succinimidyl ester; DNA, deoxyribonucleic acid; ELISPOT, enzyme-linked immunospot; HPLC, High-Performance Liquid Chromatography; NFAT, nuclear factor of activated T-cells; LC-MS/MS, Liquid Chromatography-Mass Spectrometry and Tandem Mass Spectrometry; PCNA, proliferating cell nuclear antigen; Real-time PCR, real-time quantitative polymerase chain reaction; qPCR, quantitative polymerase chain reaction.











